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  Abstract  
Abstract 
 
Quorum sensing signalling molecules (QSSMs) are important to Pseudomonas 
aeruginosa virulence and biofilm development which aid establishment and 
persistence of these bacteria in the host.  Recent progress in quorum sensing (QS) 
research has demonstrated that the two QSSMs, 3-oxo-C12-HSL and PQS interact 
with eukaryotic cells and modulate immune responses.  Early research has indicated 
these two QSSMs are immunosuppressive, and because T cells play an important 
role in defending the host against the attack of P. aeruginosa (Stevenson et al., 
1995), this warrants investigations into the interactions between QSSMs and T cells. 
 
Previous studies have shown 3-oxo-C12-HSL and PQS can exert differential 
immune-modulatory effects on mammalian immune responses, however, no studies 
have confirmed these activities using pure human T cells.  The purpose of my PhD 
was to investigate for the first time, the effects of these two QSSMs on pure human 
T cells in a staged manner, beginning with mouse splenocytes, human peripheral 
blood mononuclear cells (hPBMCs) and finally pure T cells, then if successful, 
paving the way for gene array technology. 
 
This present work confirms inhibitory effects by QSSMs on mouse splenocytes 
stimulated to proliferate using the lectin concanavalin (ConA) or anti-CD3 antibody, 
and hPBMCs stimulated to proliferate using anti-CD3 and anti-CD28 antibody.  In 
order to further understand interactions between QSSMs and the immune system, the 
effects of 3-oxo-C12-HSL and PQS on pure human T cell proliferation and cytokine 
production following stimulation of T cells with monoclonal antibodies directed 
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against CD3 and CD28 were compared, using CsA as the positive control.  All three 
compounds inhibited pure T cell proliferation.  CsA and PQS were the more potent 
anti-proliferative compounds with IC50 values of 3.2±0.31 µM and 3.8±0.15 µM 
respectively compared to 19±1.62 µM for 3-oxo-C12-HSL, indicating the QSSMs 
ability to suppress T cell activity and therefore advantageous to P. aeruginosa. 
 
To further comprehend the mechanism of action of these two QSSMs, the effects of 
QSSMs on cytokine production were assessed.  3-oxo-C12-HSL significantly 
inhibited IL-2 release while PQS enhanced the production of IL-2 even though 
suppression of T cell proliferation was observed, suggesting a cytostatic effect and 
demonstrating PQS may in fact act proximally to the IL-2 receptor (IL-2R) or 
downstream of the T cell signalling pathway, whereas 3-oxo-C12-HSL acts on early 
T cell signalling events.  3-oxo-C12-HSL also inhibited production of IFNȖ in pure 
T cells and although results were inconclusive for PQS in pure T cell assays, both 
QSSMs were shown to have an inhibitory effect on IFNȖ in mouse splenocytes, 
suggesting suppression of T cell proliferation is via Th1.  Furthermore, 
3-oxo-C12-HSL suppressed IL-4, IL-5, IL-10 and TNFĮ while PQS suppressed 
IL-10 release at 3.12 ȝM and enhanced TNFĮ release, indicating these QSSMs may 
inhibit T cell proliferation by eliminating both Th1 and Th2 response.   
 
The immune suppressive properties of 3-oxo-C12-HSL and PQS show potential as 
future therapeutic entities.  Immunosuppressive drugs such as CsA and rapamycin 
are routinely used to maintain transplants and treat auto-immune disorders.  
However, they can be non-selective and are limited by their side effects including 
nephrotoxicity and neurotoxicity.  Despite recent developments of new 
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immunosuppressants, there remains an unmet need for less toxic and more widely 
applicable immunosuppressive agents.  3-oxo-C12-HSL and PQS are worthy of 
attention as possible future immunosuppressive agents used in conjunction with or in 
place of present immunosuppressants. 
 
In summary, this study clearly demonstrates for the first time that the two structurally 
diverse QSSMs, 3-oxo-C12-HSL and PQS, can exert differential modulatory effects 
on pure T cells, opening a path for further study into their mode of actions within the 
T cell signalling pathways and their effects at an RNA level.  
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1. Introduction 
 
The ultimate purpose of this study is to investigate for the first time the effect of two 
P. aeruginosa quorum sensing signalling molecules (QSSMs)  3-oxo-C12-HSL and 
PQS  on the function of purified human T cells.  The introduction will include 
information on the human immune system and more specifically for this research, 
T cell subsets and their signalling pathways.  This introduction will also cover 
P. aeruginosa infections and the purpose of its quorum sensing systems and QSSMs, 
and how they have been shown to interact with eukaryotic cells. 
 
1.1. The human immune system 
 
The immune system is composed of many interdependent cell types that collectively 
protect the body from bacterial, parasitic, fungal and viral infections, and from the 
growth of tumour cells.  The immune system protects organisms from infection with 
layered defences of increasing specificity.  Most simply, physical barriers prevent 
pathogens from entering the body.  If these barriers are breached, the innate immune 
system provides an immediate, but non-specific response.  If the innate immune 
system is evaded by the pathogen, the innate response activates the adaptive immune 
system, to provide a more specific means of defence and increased protection against 
subsequent re-infection with the same pathogen (Lydyard et al., 2004).  Thus, the 
innate and adaptive immune systems frequently work together. 
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1.1.1. The innate immune system 
 
Most infectious agent induces inflammatory responses by activating innate 
immunity.  Microorganisms such as bacteria that penetrate the epithelial surfaces of 
the body for the first time are met immediately by cells and molecules that can mount 
an innate immune response.  Phagocytic macrophages and neutrophils conduct the 
defence against bacteria by means of surface receptors that are able to recognise and 
bind common constituents of many bacterial surfaces.  A number of cell surface 
receptors have been identified that not only act as a first line of defence against many 
infectious organisms, but also are important to the development of an adaptive 
immune response (Medzhitov and Janeway, 1997).  These surface receptors are 
called pattern recognition receptors and recognise pathogen-associated molecular 
patterns (PAMPs) generated by microbes.  PAMPs are essential for microbial 
survival and are conserved structures among many pathogens, which allow innate 
immunity to recognise microorganisms.  Among pattern recognition receptors, 
Toll-like receptors (TLRs) were highlighted as the key recognition structures of the 
innate immune system (Akira et al., 2006).   
 
Lipopolysaccharide (LPS) is a cell wall component of gram-negative bacteria.  LPS 
is composed of lipid A, which is recognised by TLR4.  LPS recognition by TLR4 
requires the formation of a protein complex containing accessory molecules:  LPS is 
generally bound to LPS-binding protein present in the serum, this complex is firstly 
recognised by CD14 receptor, strongly expressed in peripheral blood monocytes and 
macrophages (Shimazu et al., 1999, Correia et al., 2001).  Once bound to CD14, LPS 
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comes in close proximity with TLR4 to trigger an inflammatory response (Correia et 
al., 2001). 
 
Macrophages encountering bacteria in the tissues are triggered to release cytokines 
that increase the permeability of blood vessels, allowing fluid and proteins to pass 
into the tissues.  Chemokines are also released to direct the migration of neutrophils 
and monocytes to the site of infection to aid microbial killing.  The release of 
cytokines and chemokines initiate the process of inflammation.  Inflammation and 
the phagocytosis of invading bacteria may also be triggered as a result of the action 
of complement on the bacterial cell surface.  Complement is a system of plasma 
proteins that activates a cascade of proteolytic reactions on microbial surfaces, 
coating these surfaces with fragments that are recognised and bound by phagocytic 
receptors on macrophages (Janeway et al., 2001, Alberts et al., 1994).   
 
Other cells of the innate immune system include natural killer cells, mast cells and 
basophils.  Natural killer cells are important for the protection against viruses and 
some tumours.  Changes in the surface molecules of cells as the result of virus 
infection allow natural killer cells to bind to and kill infected cells by releasing 
perforins and inducing apoptosis.  In addition, on binding to virus-infected cells, 
natural killer cells secrete interferon-gamma (IFNȖ) which protects adjacent cells 
from infection by viruses and helps to activate T cell mediated immunity.  Mast cells 
and basophils, when activated, degranulate, releasing pharmacological mediators that 
cause vasodilation, increased vascular permeability and leukocyte migration. 
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Also recruited at the site of infection are immature dendritic cells.  Dendritic cells 
(DCs) are important as they represent a primary interface between the innate and 
adaptive immune systems.  Dendritic cells also carries pattern recognition receptors 
on its surface (Akira et al., 2006, Shimazu et al., 1999).  As with macrophages and 
neutrophils, binding of a bacterium to these receptors stimulates the dendritic cell to 
engulf the pathogen and degrade it intracellularly.  Immature dendritic cells are also 
continually taking up extracellular material, including any pathogens that maybe 
present, by the receptor-independent mechanism of macropinocytosis.   
 
The function of dendritic cells, however, is not only primarily to destroy pathogens 
but also to carry pathogen antigens to peripheral lymphoid organs, and there, present 
them to T lymphocytes.  Immature dendritic cells have immature phenotype that is 
associated with low levels of major histocompatibility complex (MHC) proteins, and 
they lack co-stimulatory B7 molecules.  Activation of TLRs on DCs by binding to 
PAMPs on invading microbes forms an important bridge between innate and 
adaptive immunity.  On activation, the dendritic cells matures into highly effective 
antigen presenting cells (APCs), and through TLRs and antigen presentation, 
regulates the expression of co-stimulatory molecules on APCs to drive T cell 
activation, by creating a cytokine milieu to conduct the differentiation of T cells into 
the desired subset (Re et al., 2001).   TLR4 and TLR9 are generally thought to 
induce a Th1 response by driving IL-12 production by DCs (Krieg, 2002, Trinchieri, 
2003), while TLR2 activation might induce a Th2-biased immune response, through 
production of IL-10 and IL-13 (Dillon et al., 2004).   
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1.1.2. The acquired immune system  
 
Activated dendritic cells synthesise new MHC class I and II molecules that present 
peptides of the pathogens at a high level, and express B7 molecules which can 
co-ordinate naïve T cells and large numbers of adhesion molecules (ICAM-1, 
ICAM-2, LFA-1 and LFA-3) which enable them to interact with antigen-specific 
T cells.  In addition, activated dendritic cells secrete cytokines that influence both 
innate and adaptive immune response, making these cell essential gatekeepers that 
determine whether and how the immune system responds to the presence of 
infectious agents (Alberts et al., 1994, Janeway et al., 2001).   
 
MHC class I and MHC class II molecules have a distinct distribution among cells 
that reflects the different effector functions of the T cells that recognise them.  MHC 
class I molecules present peptides from pathogens, commonly viruses, to CD8 
cytotoxic T cells, which are specialised to kill cell that they specifically recognise.  
As viruses can infect any nucleated cell, almost all such cells express MHC class I 
molecules, although the level of constitutive expression varies from one cell type to 
the next, e.g. cells of the immune system express abundant MHC class I  on their 
surface, whereas hepatocytes express relatively low levels.  In contrast, the main 
function of the CD4 T cells that recognise MHC class II molecules is to activate 
other effector cells of the immune system.  Thus MHC class II molecules are 
normally found on B lymphocytes, dendritic cells, and macrophages  cells that 
participate in immune responses  but not on other tissue cells (Janeway et al., 2001, 
Alberts et al., 1994). 
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Naïve T cells recirculate through the secondary lymphoid organs looking for 
appropriately processed antigen.  Initial recognition of processed antigen by T cells is 
via the T cell receptor (TCR).  Accessory molecules provide additional linkages 
between the APC and the T cell to strengthen their cellular association (Fig. 1.1).  
CD4 binds to the constant region domain of class II MHC molecules thereby 
strengthening the association of the TCR with peptide-class II MHC molecules.  In 
contrast, CD8 binds to class I MHC molecules to strengthen the association of the 
TCR with class I MHC molecules.  In addition to engagement of these ligand-
receptor pairs, additional adhesion molecules, integrins, become engaged (fig. 1.1).  
These include intercellular adhesion molecules (ICAMs) and lymphocyte function-
associated antigens (LFAs) (Alberts et al., 1994, Janeway et al., 2001).   
   
Ligation of the TCR on its own does not stimulate T cell clonal expression or 
lymphokine production.  The full activation of antigen-specific T cells requires two 
signals.  A first signal, the cluster of differentiation 3 (CD3) antigen is provided 
through the TCR that interacts with MHC molecules on the membrane of APCs, and 
signal two is provided by engagement of a co-stimulatory molecule.  One of the best 
characterised co-stimulatory molecules expressed by T cells is CD28, which interacts 
with CD80 and CD86 on the membrane of APC (fig. 1.1) (AlberolaIla et al., 1997).    
Co-stimulation allows T cells to become functionally activated, and the outcomes are 
proliferation and generation of effector populations.  CD28 is one important 
co-receptor that regulates T cell proliferation and survival.  T cell activation that 
culminates in cytokine production, cellular proliferation, and the acquisition of 
effector functions is initiated by the combination of intracellular
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Figure 1.1 
 
 
 
Figure 1.1.  Pairs of molecules that strengthen the association of T cells with 
antigen presenting and target cells.  Dendritic cells in lymphoid tissue express high 
levels of MHC class I and class II molecules, as well as high levels of the adhesion 
molecules ICAM-1, V-CAM and LFA-3 for efficient T cell binding.  Engagement of 
the TCR/CD3 complex are involved in T cell activation and signal transduction 
(Clevers et al., 1988), and engagement of the CD28 receptor leads to potent 
enhancement of lymphokine production (Thompson et al., 1989).  Co-stimulation of 
CD3 and CD28 with anti-CD3 and anti-CD28 leads to complete activation of T cells 
and a dramatic up-regulation of IL-2 expression (Fraser et al., 1991, Lindsten et al., 
1989). 
 
 
T cell APC/target cell 
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MHC TCR/CD3 
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CD2 LFA-3 
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 signals emanating from the TCR/CD3 complex and from co-stimulatory molecules 
such as CD28 (Cantrell, 2002) . 
 
Precursors of CD8
+
 cytotoxic T cells also need to be activated to develop into mature 
CD8 effector T cells containing granzymes and perforin.  This requires attachment of 
their TCR to MHC class I-peptide complexes on APCs (signal 1).  In addition, a 
second co-stimulatory signal involving binding of B7 to CD28 on the cytotoxic 
T lymphocyte (CTL) is required.  This activation step also induces the expression of 
FasL on the cytotoxic T cell, which can interact with Fas expressed on the surface of 
the virus infected cell (Janeway et al., 2001, Alberts et al., 1994, Lydyard et al., 
2004). 
 
B lymphocytes are also involved in adaptive immunity.  B cells develop from 
hemopoietic stem cells primarily in the bone marrow.  The two main functions of the 
bone marrow as a primary lymphoid organ are to (a) produce large numbers of 
B cells, each with unique antigen receptors such that, overall, there is sufficient 
B cell diversity to recognise the entire antigen are our environment; (b) eliminate 
B cells with antigen receptors for self molecules.  Mature B cells migrate via the 
bloodstream to the secondary lymphoid organs/tissues.  B cells make and use 
antibodies as their specific antigen receptor.  They have molecules similar to CD3 of 
T cells, i.e. CD79, which are important in their activation, and B cells can mature 
into plasma cells that produce and secrete large amounts of antibody (Alberts et al., 
1994). 
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Activation of Th cells results in expression of CD40 ligand, the ligand for B cell 
surface molecule CD40.  Th cells now triggers the activation of the B cell via the 
CD40 surface receptor and as a result, activated B cells reciprocally co-stimulates the 
Th cell via CD28.  Production of IL-4 and IL-5 from Th2 cells act as growth and 
differentiation factors for B cells promoting IgE and IgA production.  IgE plays a 
significant role in enhancing acute inflammation, in protection from infection by 
worms, and in allergic reactions (Erb, 2007, Gould et al., 2003).  After stimulation of 
the development of IgE-producing plasma cells by antigen, the IgE produced binds to 
receptors on mast cells.  When antigen is reintroduced into an individual, it binds to 
the antigen-binding site of the IgE molecule on the mast cell, and as a result of this 
interaction, the mast cell is triggered to release pharmacologically active agents 
e.g. histamine (Gould et al., 2003).  IgA is synthesised locally by plasma cells in 
mammary and salivary glands, and along the respiratory, gastrointestinal and 
genitourinary tracts.  IgA is then transported through epithelial cells to the lumen.  
This antibody is the first line of defence against microbial invaders at mucosal 
surfaces and in the blood, interacts with immune effector cells to initiate 
inflammatory reactions. IgA causes antibody-dependent cell-mediated cytotoxicity, 
degranulation of eosinophils and basophils, phagocytosis by monocytes, 
macrophages, neutrophils and eosinophils, and triggering of respiratory burst activity 
by polymorphonuclear leukocytes (Snoeck et al., 2006, Kaetzel et al., 1991). 
 
In addition, IFNȖ and TNFĮ from Th1 cells help promote the development of B cells 
that produce primarily IgG antibodies, which provides the bulk of immunity to most 
blood borne infectious agents.  IgG can bind to many kinds of pathogens e.g. viruses, 
bacteria, and fungi, and protects the body against them by complement activation, 
Chapter 1           Introduction  
 - 10 -
opsonisation for phagocytosis and neutralisation of their toxins (Alberts et al., 1994, 
Janeway et al., 2001, Lydyard et al., 2004).  
 
1.1.3. T cells and their subsets 
 
There are two classes of T lymphocytes, cytotoxic T cells and T helper (Th) cells.   
 
Mature cytotoxic T cells, generated with the help of Th1 cells, contain the cytotoxic 
machinery required to kill virus-infected cells.  These cytotoxic T cells are able to 
induce apoptosis of the virus-infected cells through two distinct pathways:  
 
a. Release of lytic granules containing perforin that polymerise in the membrane of 
infected cell creating pores that allow entry of granzymes.  These enzymes cleave 
cellular proteins, the products that initiate induction of apoptosis (Alberts et al., 
1994, Janeway et al., 2001). 
 
b. Fas-mediated apoptosis.  Viruses up-regulate expression of Fas (CD95) in 
nucleated cells.  Cytotoxic T cells activated to release granules by their first 
encounter with antigen presented by MHC class I molecules are induced to up-
regulate FasL, which then also allows them to kill specific virus-infected cells by an 
additional mechanism through interaction with surface CD95 (Janeway et al., 2001). 
 
The second T cell subset involves production of cytokines and their receptors 
following activation of Th cells.  These are involved in the expansion and further 
differentiation of the T cells into memory and effector cells.  On stimulation, T cells 
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produce interleukin 2 (IL-2), an autocrine growth factor important to T cell 
proliferation, and express IL-2 receptors (IL-2R).  Other surface molecules induced 
by activation of T cells include CD40L, which interacts with CD40 on dendritic 
cells.  Binding of CD40 induces dendritic cells to produce cytokines required for 
T cell proliferation and differentiation (Janeway et al., 2001). 
 
Helper T (Th) cells have two important functions: to stimulate cellular immunity and 
inflammation and to stimulate B cells to produce antibodies.  Two functionally 
distinct subsets of Th cells secrete cytokines that promote these different activities.  
Th1 cells predominantly produce IL-2, interferon gamma (IFNȖ) and tumour necrosis 
beta (TNFȕ) which activates cytotoxic T cells and macrophages to stimulate cellular 
immunity and inflammation.  Th1 cells also secrete IL-3 and GM-CSF (granulocyte 
macrophage-colony stimulating factor) to stimulate the bone marrow to produce 
more leukocytes.  Th2 cells predominantly secrete IL-4, IL-5, IL-6 and IL-10 which 
stimulate antibody production by B cells (Janeway et al., 2001).   
 
T cells are initially activated as Th0 cells, which produce IL-2, IL-4 and IFNȖ.  The 
nearby cytokine environment then influences differentiation into Th1 or Th2 cells.  
IL-4 stimulates Th2 activity via the signal transducer and activator of transcription 6 
(STAT6) and suppresses Th1 activity, while IL-12 promotes Th1 activities through 
STAT1.  Th1 and Th2 cytokines are antagonistic in activity.  Th1 cytokine IFNȖ 
inhibits proliferation of Th2 cells, while Th2 cytokine IL-10 inhibits Th1 secretion of 
IFNȖ and IL-2.  Even though there are a number of caveats concerning the 
differentiation of type 1 versus type 2 Th lymphocytes, one of the most critical 
elements in determining Th differentiation is the cytokine milieu in which the 
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T lymphocyte is activated (Borish and Rosenwasser, 1996).  Thus, the balance 
between Th1 and Th2 activity may steer the immune response in the direction of 
cell-mediated or humoral immunity (fig. 1.2).   
 
Th1/Th2 regulation is exceedingly complex, but its importance is unquestionable, 
particularly in the study of such diverse disease as allergies and asthma, as well as 
type 1 diabetes and other autoimmune disorders.  For example, rheumatoid arthritis 
is a dysregulation in Th1/Th2 cell balance, as defined by the production of their 
specific cytokines, IFNȖ and IL-4, respectively, is suggested, leading to eventual 
destruction of joint tissues.   Recently, it has been realized that Th1/Th2 cytokine 
production offer the unique possibility to predict drug efficacy.  For example, IL-5 
plays an essential role in orchestrating the eosinophilic inflammation of asthma 
(Greenfeder et al., 2001).  Blocking antibodies to IL-5 inhibit eosinophilic 
inflammation and airway hyper responsiveness (AHR) in animal models of asthma, 
including primates (Egan et al., 1996).  Humanised monoclonal antibodies to IL-5 
have been developed and a single intravenous infusion of one of these antibodies 
(mepolizulab) markedly reduces blood eosinophils and prevents eosinophil 
recruitment into the airways after allergen challenge in patients with mild asthma 
(Leckie et al., 2000).  However, this treatment has no significant effect in the early or 
late response to allergen challenge or baseline AHR, suggesting that eosinophils may 
not be of critical importance for these responses in humans (Leckie et al., 2000).  In 
addition, Flood-Page et al. demonstrated that anti-IL-5 antibody, while profoundly 
reducing eosinophils in the circulation (by over 95%), is less effective at reducing 
eosinophils in bronchial biopsies (by approximately 50%), which may explain
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Figure 1.2 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2.  Cytokines involved in clonal expansion and development of T cells.  Upon antigenic stimulation, naïve CD4
+
 T cells activate, 
expand and differentiate into different effector subsets and are characterised by the production of distinct cytokines and effector functions. 
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why this treatment is not clinically effective (Flood-Page et al., 2003).  Nevertheless, 
this suggests that blocking IL-5 is not likely to be useful approach to asthma therapy.  
 
1.1.4. Th17 lineage 
 
In addition to the Th1/Th2 lineages, recent studies have suggested a greater 
diversification of the CD4 T cell effector repertoire than that encompassed by the 
Th1/Th2 paradigm.  A new lineage was proposed, characterised by production of 
members of the IL-17 cytokine group, including IL-17A, B, C, D, IL-17E (also 
called IL-25) and IL-17F (Kolls and Linden, 2004, Fort et al., 2001) whose 
development involved mechanisms that are independent of the STAT pathways 
required for Th1 and Th2 cells (Harrington et al., 2005), and dubbed the Th17 
lineage.  While IL-25 is mainly produced by Th2 cells (Fort et al., 2001) different 
cell types including T cells, NK cells and neutrophils produce IL-17A and F (Kolls 
and Linden, 2004).  In CD4
+
 T cells, IL-17A is specifically expressed in a subset of 
T cells called Th17 for which it became the hallmark cytokine (Langrish et al., 2005) 
(fig. 1.2).   
 
The majority of studies have focused on the role of IL-17A, IL-17E and IL-17F, with 
the key function of these three members is to chemoattract different cell types 
through the induction of other cytokines and chemokines (Kolls and Linden, 2004).  
IL-25 (IL-17E) induces the expression of Th2-type cytokines and chemokines such 
as RNATES and Eotaxin-1 and plays a role in Th2-type allergic responses (Fort et 
al., 2001).  IL-17A and IL-17F have pro-inflammatory properties and act on a broad 
range of cell types to induce the expression of cytokines (IL-6, IL-8, GM-CSF, and 
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G-CSF) and chemokines (CXCL1, CXCL10).  IL-17A and F are also key cytokines 
for the recruitment, activation and migration of neutrophils (Kolls and Linden, 2004).  
The production of IL-17 and the recruitment of neutrophils seem important in host 
protection against gram-negative bacteria and fungal infections.  The preferential 
production of IL-17 by T cells during infections with Klebsiella pneumonia (Ye et 
al., 2001), Bacteroides fragilis (Chung et al., 2003), Mycobacterium tuberculosis 
(Infante-Duarte et al., 2000), and fungal species (LeibundGut-Landmann et al., 
2007) suggests that Th17 responses are triggered by specific pathogens, probably 
through TLR4 (Pirhonen et al., 2007, Eijnden et al., 2006) and are required for their 
clearance.  In addition to neutrophils, IL-17 might also dictate the migration of other 
important effector cell types during infection, for example, pathogen-specific Th17 
cells generated during mycobacterial infection induce the expression of CXCL9, 
CXCL10 and CXCL11, which attract IFNȖ-producing CD4+ Th1 cells to the lung in 
order to control the infection (Khader et al., 2007).   
 
Furthermore, Th17 cells might potentially play an important role in asthma, 
autoimmune diseases such as rheumatoid arthritis (RA) and allograft rejection.  The 
recruitment of neutrophils which are prominent in acute, severe exacerbations of 
asthma (Jatakanon et al., 1999), IL-17 is expressed in bronchial biopsies, 
bronchoalveolar lavage fluid and sputum of patients with asthma (Molet et al., 2001, 
Sun et al., 2005, Barczyk et al., 2003).  Levels of IL-17 are elevated in the synovium 
of patients with RA (Kotake et al., 1999), and synovial cultures from patients with 
RA spontaneously secrete IL-17 (Chabaud et al., 1999); the source of this IL-17 is 
local production by T cells (Chabaud et al., 1999) and juxta-articular bone 
lymphocytes (Chabaud et al., 2001).  Pathologically, this cytokine can activate and 
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enhance mechanisms involved in RA such as up-regulate and/or synergise with local 
inflammatory mediator such as IL-6, IL-1ȕ and TNFĮ (Chabaud et al., 1998, Katz et 
al., 2001, LeGrand et al., 2001).  In human lung organ transplantation, IL-17 has 
been reported as being elevated during acute rejection (Vanaudenaerde et al., 2006), 
while rat models have demonstrated that collagen type V-specific lymphocytes can 
mediate lung allograft rejection and express IL-17 locally at the site of rejection 
(Yoshida et al., 2006).  In cardiac allograft models, antagonism of the IL-17 network 
(via expression of an IL-17R-immunoglobin fusion protein) can reduce intragraft 
production of inflammatory cytokines (namely IFNȖ) and prolong graft survival (Li 
et al., 2006). 
 
Recently, it has been recognised that a combination of two cytokines, namely IL-6 
and transforming growth factor beta (TGFȕ) is necessary for the differentiation of 
naïve T cells to Th17 cells (Veldhoen et al., 2006, Bettelli et al., 2006, Mangan et 
al., 2006).  Veldhoen et al. determined naïve precursor T cells could be skewed 
towards a Th17 phenotype in the presence of dendritic cells and Tregs in an 
inflammatory milieu (lipopolysaccharide stimulation) (Veldhoen et al., 2006).  In the 
presence of Tregs and DC, the important drivers of Th17 differentiation were Treg-
derived TGFȕ and DC-derived IL-6, although both TNFĮ and IL-1ȕ (both DC-
derived) also augmented the commitment to Th17.  These data were corroborated by 
Bettelli et al., who demonstrated using cells from a Foxp3-GFP knock-in mice strain 
that differentiation towards Treg and Th17 phenotypes were mutually exclusive.  
Activation of naïve precursor cells using anti-CD3 in the presence of TGFȕ lead to 
production of Tregs, but activation in the presence of IL-6 in addition to TGFȕ 
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completely abrogated this and led to development of Th17 cells (Bettelli et al., 
2006). 
 
1.1.5. Regulatory T cells 
 
Regulatory T cells are a specialized subpopulation of T cells that act to suppress 
activation of the immune system and thereby maintain immune system homeostasis 
and tolerance to self-antigens.  Given that both human and murine knock-outs for 
CD4
+
 CD25
+
 T cells (Tregs) develop severe autoimmune diseases (Sakaguchi et al., 
1996, Sakaguchi et al., 1995), the focus of attention in the literature has been mainly 
on these Tregs.  Naturally arising CD4
+
 CD25
+
 Tregs, which constitute 5-10% of 
peripheral CD4
+
 T cells in normal rodents and humans, are produced at least in part 
by the normal thymus as functionally mature and distinct subpopulation of T cells 
(Sakaguchi, 2004).  In vitro, Tregs have the ability to inhibit proliferation and 
production of cytokines by responder (CD4
+
 CD25
-
 and CD8
+
) T cells (Jonuleit et 
al., 2001, Dieckmann et al., 2001, Thornton and Shevach, 1998) to polyclonal 
stimuli, as well as to down-modulate the responses of CD8
+
 T cells, NK cells and 
CD4
+
 cells to specific antigens (Dieckmann et al., 2001, Wing et al., 2003).  These 
predicates translate in vivo to a greater number of functions other than the 
maintenance of tolerance to self-components (i.e. prevention of autoimmune disease) 
(Baecher-Allan and Hafler, 2006), and include control of allergic diseases (Umetsu 
and DeKruyff, 2006) and regulation of responses to microbial pathogens (Rouse et 
al., 2006), as well as the ability to prevent transplant rejection (Waldmann et al., 
2006).   
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The latest research suggests that Tregs are defined by expression of the forkhead 
family transcription factor Foxp3 (Fontenot et al., 2005, Sakaguchi, 2005).  The large 
majority of Foxp3-expressing regulatory T cells are found within the MHC class II 
restricted CD4
+
 T cell population and express high levels of the IL-2 receptor 
(IL-2R) alpha chain (CD25) (Fontenot and Rudensky, 2005, Sakaguchi, 2005).  
Setoguchi et al. showed that IL-2 is essential for physiological expansion and 
survival of natural of natural CD4
+
 CD25
+
 Tregs in the periphery, and that 
neutralisation of IL-2 in normal mice inhibited the physiological proliferation of 
peripheral CD4
+
 CD25
+
 Tregs.  IL-2 neutralisation in normal mice for a limited 
period also induced autoimmune disease similar to the one produced by depletion of 
CD4
+
 CD25
+
 Tregs (Setoguchi et al., 2005).  In addition to the Foxp3-expressing 
CD4
+
 CD25
+
, there also appears to be a minor population of MHC class I restricted 
CD8
+
 Foxp3-expressing regulatory T cells (Belkaid and Rouse, 2005). 
 
1.2. Cytokine signalling pathways 
 
Cross-linking of the TCR through the binding of peptide-MHC complexes on the 
membrane of APC or with antibodies to CD3 initiates cytokine production.  
Cytokines initiate intracellular signals through the binding and oligomerisation of 
receptor subunits.  The common outcome of each receptor oligomerisation event 
causes the rapid stimulation of associated protein tyrosine kinases (PTK) such as the 
JAK and the Src family kinases (AlberolaIla et al., 1997, Cantrell, 2002), this 
triggers activation of a plethora of downstream signalling molecules (AlberolaIla et 
al., 1997, Cantrell, 2002).  In contrast to JAK kinases that function specifically in 
cytokine receptor signalling, Src kinases has been implicated in numerous cellular 
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processes.  However, several members of the Src family including Src, Lck, Fyn and 
Lyn have also been implicated in cytokine signalling (Miyajima et al., 1992, 
AlberolaIla et al., 1997, Cantrell, 2002).  Cellular responses induced by cytokine 
stimulation may be categorised into several general types  cellular proliferation, 
activation of specific genes and in some cases cell death. 
 
Important components of these intracellular mediators are the Ras/mitogen-activated 
protein kinases (MAPKs), most often associated with cellular proliferation.  The 
Ras/MAPK pathway was one of the first pathways in which extracellular signals 
were biochemically and genetically linked to activation of gene expression in the 
nucleus (Marshall, 1994).  The central components of this pathway are a series of 
related small (21 KDa) GTPases, the best characterised of which are the p21 Ras 
proteins.  Ras proteins undergo post translational modification which localises the 
Ras proteins to the plasma membrane (Hancock et al., 1990). Membrane associated 
Ras binds GTP, which is then hydrolysed to GDP by the GTPase activity of Ras.  
Cytokine stimulation results in a rapid increase in the amount of Ras-GTP, the 
biologically active form that initiates downstream cascade of kinase reactions termed 
the MAPK pathway (Hall and Self, 1986).  In the Ras/MAPK cascade, two specific 
isoforms of MAPK kinases (MAPKK) have been identified and are termed MEK1 
and MEK2 (MAP/Erk kinases) (Denhardt, 1996).  Activation of the MEKs results in 
the phosphorylation and activation of MAPK.  As with MAPKK, two isoforms of 
MAPK have been identified and are referred to as extracellular signal-regulated 
kinase 1 and 2 (Erk1/2) (fig. 1.3) (Denhardt, 1996).  In turn, these kinases activate 
specific T cell factors (TCF)/transcription factors and early immune response genes 
such as the IL-2 and IL-2 receptor (IL-2R) genes (Garrington and Johnson, 1999).   
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Figure 1.3. Early biochemical events leading to T cell activation.  Activation of 
cytokines leads to initiation of intracellular signals through the binding and 
oligomerisation of receptor subunits.  The outcome of this is the activation of 
tyrosine kinases followed by phosphorylation of cellular substrates.  Cytokine 
activation of the Ras/MAPK is most often associated with cellular proliferation.  
Activation of PI-3 kinase is also clearly important in the stimulation of cellular 
proliferation by numerous cytokines including IL-2.  Currently employed 
immunosuppressive drugs include cyclosporin A (CsA), FK506 and rapamycin.  CsA 
and FK506 inhibit calcineurin, preventing the activation of NFAT.  Rapamycin 
inhibits the serine-threonine kinase mTOR, the key regulator of translation.   
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ERKs in particular catalyse the phosphorylation of the transcription factor Elk-1, 
resulting in the activation of the cFos proto-oncogene (Davis, 1995).  Disruption of 
the MAPK kinase (MEK) 1/Erk pathway with specific inhibitors suppresses the 
proliferative response and the production of several cytokines by T cells (fig. 1.3) 
(Dumont et al., 1998). 
 
Distinct kinases with functions similar to the ERKs can be activated through kinase 
cascades initiated by Ras as well as other small GTPases.  These kinases include Jun 
nuclear kinases (JNK, which phosphorylate the transcription factor Jun, p38 kinase, 
which phosphorylates the transcription factor ATF2, and p90rsk, which 
phosphorylates Fos (Denhardt, 1996, Davis, 1995).  Signals leading to the activation 
of these different transcription factors are often co-ordinated.  The activation of the 
cFos gene by ERK-activated Elk-1 and the activation of Jun by JNK phosphorylation 
leads to the formation of AP-1, a transcription activator composed of cFos and Jun 
heterodimers that is involved in the transcription of numerous genes (Davis, 1995).  
Ultimately, this induction of gene expression leads to many of the cellular responses 
attributed to the activation of the Ras/MAPK pathway.  
 
Many aspects of the phosphoinositide 3-kinase (PI3-kinase) pathway, a second 
signalling pathway activated by cytokines, have proven to differ from the 
Ras/MAPK pathway.  The activation of PI3-kinase is clearly important in the 
stimulation of cellular proliferation by numerous cytokines including IL-2, IL-3, 
IL-4, IL-5 and GM-CSF (Gold et al., 1994, Merida et al., 1991).  PI-3-kinase is 
composed of a p110 catalytic subunit and a p85 regulatory subunit.  The p85 subunit 
contains an N-terminal SH3 domain and two praline-rich regions that interact with 
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SH3 domains in other signalling molecules (Kapeller et al., 1994).  The C-terminal 
SH2 domain links the p85/p110 heterodimer to tyrosine phosphorylated proteins and 
activated receptor molecules, resulting in bringing PI3-kinase to the membrane near 
activated receptor complexes (Kapeller and Cantley, 1994, Kapeller et al., 1994).  
Once recruited to activated receptor complexes, PI3-kinase is activated by several 
mechanism.  Direct interaction of the SH2 domains with phosphorylated receptors or 
adaptor molecules induce conformational change resulting in the increased catalytic 
activity of the p110 subunit (Shoelson et al., 1993).  It is also likely that JAK kinase 
activation leads to p85 phosphorylation since engagement of different cytokine 
receptors that associate with JAK kinases induce the tyrosine phosphorylation of the 
p85 subunit (Ruizlarrea et al., 1993).  Activation of PI3-kinase also may occur from 
its interaction with activated Ras-GTP molecules in a situation analogous to the 
activation of Raf-1 by Ras-GTP (Rodriguezviciana et al., 1994). 
 
The phosphorylated lipids resulting from the activation of PI3-kinase act as second 
messengers that activate a number of cellular kinases by interacting directly with 
these proteins.  In particular, PtdIns(3,4,5)P3 and PtdIns(3,4)P2 have been shown to 
act as potent activators of Ca
2+
-independent forms of protein kinase C, which 
phosphorylate and alter the activity of numerous cellular substrates (Toker et al., 
1994) (fig. 1.3). 
 
Analysis of cytokine production and the subsequent T cell signalling pathways is 
increasingly important in defining the course of an immune response and in 
evaluating specific therapies of immune diseases as well as playing a pivotal role in 
the immune response to allograft rejection.   
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1.2.1. The effect of immunosuppressive agents on the T cell signalling 
pathways 
 
The development of effective and safe immunosuppressive procedures for the 
treatment of organ transplant rejection and autoimmune allergic and inflammatory 
diseases represents a major goal in contemporary medicine.  Because T cell 
activation plays a central role in the regulation of immune responses, its 
pharmacologic inhibition has provided a powerful approach towards this goal.  The 
currently employed immunosuppressive drugs such as CsA, FK506 and rapamycin, 
which have a degree of selective action on cells of the immune system, has led to a 
dramatic increase in the success rate of transplant surgery despite their side effects.  
CsA can be nephrotoxic and rapamycin can cause immune-mediated toxicity 
(Allison, 2000), indicating the importance of further immunosuppressive products to 
clinical medicine and also an understanding of molecular mechanisms involved 
(Allison, 2000).   
 
Rapamycin treatment has been shown to cause Gap 1 (G1) arrest in a variety of cell 
types including T cells (Schmelzle and Hall, 2000).  In proliferating cells, the cell 
cycle consists of four phases and the G1 phase is the interval between mitosis and 
DNA replication that is characterised by cell growth.  The transition that occurs at 
the restriction point in G1 commits the cell to the proliferative cycle.  If the 
conditions that signal this transition are not present or blocked, the cell exits the cell 
cycle and enters Go, a non-proliferative phase.  The inhibition of T cell proliferation 
is primarily due to the blockage of IL-2 signalling (Powell et al., 1998, Brennan et 
al., 1999) (fig. 1.3).  It has been well established that rapamycin inhibits the 
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serine-threonine kinase mTOR (mammalian target of rapamycin)/FRAP 
(FKBP12-rapamycin-associated protein) (Brown et al., 1994, Chiu et al., 1994, 
Sabatini et al., 1994, Almawi et al., 1999, Gingras et al., 2001) and that mTOR is a 
key regulator of translation (Gingras et al., 2001) (fig. 1.3).  Two of the most 
important components in the translational process that are regulated by mTOR are 
4EBP-1 and p70
s6k
 (Gingras et al., 2001).  4EBP-1 is a repressor of eukaryotic 
initiation factor (eIF4E) and the availability of eIF4E is critical for translation, thus 
rapamycin has been suggested to affect translation of polypyrimidine-tract containing 
mRNAs (Jefferies et al., 1994).   
 
CsA inhibits T cell growth factor gene expression at the level of mRNA transcription 
(Kronke et al., 1984).  Liu et al. (1991) found that CsA inhibits the phosphatase 
activity   of   calcineurin (fig. 1.3).      By   preventing   their    calcineurin-mediated 
dephosphorylation, CsA inhibits the translocation of the NFAT family of 
transcription factors from the cytoplasm to the nucleus of activated T cells (Liu et al., 
1991).  The NFAT group is involved in the transcriptional activation of the genes 
encoding IL-2, IL-12 and the CD40L.  In addition, CsA has recently been found to 
block the JNK and p38 signalling pathways triggered by antigen recognition in 
T cells (Matsuda and Koyasu, 2000).  The presence of two target pathways for CsA 
in T cells could explain the high specificity of its immunosuppressive effects. 
 
In addition, as rapamycin and CsA are widely used to prevent allograft rejection, and 
the development of an alloimmune response into rejection or stable allograft 
tolerance is strongly determined by the balance between alloreactive effector cells 
and CD4+CD25
+
 Tregs (Coenen et al., 2005, Zheng et al., 2003), it remains to be 
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elucidated whether these drugs have an effect on CD4
+
CD25+ Tregs.  Recently, Qu 
et al. observed that rapamycin significantly enhanced the relative levels of 
CD4
+
CD25
+
 Tregs in the spleen and thymi of mice while most of T cell subsets were 
decreased.  Although rapamycin inhibited the immune response of CD4
+
 T cells to 
allogenic antigen or mitogens, the immunosuppressive function of CD4
+
CD25
+
 Treg 
cells was not impacted by the treatment of rapamycin in in vitro and in vivo 
functional assays (Qu et al., 2007).  This may suggest that the treatment with 
rapamycin may selectively inhibit the host immune rejection against grafts while still 
keep the host with the potential ability to induce immune tolerance.  This may be 
beneficial to patients who have transplant grafts or autoimmune diseases, as they 
have the tendency to achieve immune tolerance.  In contrast to rapamycin, Zeiser et 
al. determined that CsA did not abrogate but significantly reduced the function of 
allostimulated Treg cells in vitro (Zeiser et al., 2006).  Reduced FoxP3 gene 
transcription of murine Treg cells when exposed to CsA, but not to rapamycin, is 
consistent with a recent study showing that calcineurin inhibitors reduced FoxP3 
expression in human Treg cells, whereas mTOR inhibitors have little or no impact 
(Baan et al., 2005). 
 
Furthermore, Coenen et al. reported that allogenic expansion of human naturally 
occurring CD4
+
CD25
+
 Tregs leads to the emergence of a distinct, highly suppressive 
CD27
+
 Treg subset next to a CD27
-
 Treg subset which has modest suppressive 
potency (Coenen et al., 2005, Koenen et al., 2005).  The CD27+ Treg subset was 
shown to suppress not only naïve and antigen-experience memory T cells but also 
ongoing T cell responses.  Coenen et al. demonstrated that rapamycin and CsA act 
differently with regard to the preservation of the high CD27
+
 Treg/CD27
-
 Treg 
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ration.  In contrast to CsA, rapamycin preserved the dominance of CD27
+
 Tregs over 
CD27
-
 Tregs on allogenic stimulation, resulting in strong suppressive capacity of the 
expanded CD4
+
CD25
+
 Treg pool as a whole (Coenen et al., 2006).  It can therefore 
be envisaged that a predominance of CD27
+
 Tregs, which is supported by treatment 
with rapamycin, can add to the development of stable tolerance and prevention of 
rejection in solid-organ transplantation. 
 
Cross-linking of CD27 has been shown to induce proliferation following the 
mobilisation of intracellular free Ca
2+
 (Croft, 2003, Dejong et al., 1991).  As CsA 
specifically targets Ca
2+
-dependent activation pathways, CsA may thus inhibit 
CD27
+
 Treg proliferation, however, preliminary data from Coenen et al. do not 
support an inhibition of proliferation. 
 
It has been proposed that signalling by the growth factor IL-2 is crucial for the 
functionally activity of Tregs (Malek and Bayer, 2004, Thornton et al., 2004).  As 
mentioned earlier, CsA inhibits TCR-induced activation and IL-2 production, 
whereas rapamycin blocks signalling in response to T cell growth factors.  In theory, 
both drugs could therefore interfere with Treg function.  However recent studies 
observed that in the presence of CsA or rapamycin freshly isolated CD4
+
CD25
+
 
Tregs were able to suppress CD4
+
CD25
-
 T cells indicating that CsA and rapamycin 
did not significantly interfere in the activation or suppressor function of these cells 
(Coenen et al., 2006). 
 
Immunomodulatory small molecules with new modes of action such as the 
compounds examined in this present study could therefore be extremely useful for 
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immunology research and crucially, are potential for the treatment of autoimmune 
diseases such as rheumatoid arthritis and multiple sclerosis, and for the maintenance 
of transplants. 
 
1.3. Pseudomonas aeruginosa  
 
1.3.1. Background on P. aeruginosa 
 
Pseudomonas aeruginosa is a gram negative bacterium capable of causing serious 
infections in insects, plants and animals (McGrath, 2003).  P. aeruginosa emerged as 
a human pathogen in the past century, probably because of the development of 
available niches after the eradication of the old pathogens by use of antibiotics and 
disinfectants.  As an opportunistic pathogen of humans, P. aeruginosa is a major 
cause of nosocomial infections and is responsible for the chronic lung infections that 
affect most cystic fibrosis (CF) patients (Van Delden and Iglewski, 1998, Smith et 
al., 2001, McGrath, 2003).  P. aeruginosa pneumonia is also an emerging problem 
and in many cases is fatal in patients with advanced HIV infections (Meynard et al., 
1999, Smith et al., 2001) and ventilator-associated pneumonia (Dunn and 
Wunderink, 1995, Brewer et al., 1996, Smith et al., 2001).   
 
Once acquired, P. aeruginosa infections are difficult to eradicate using current 
antimicrobial therapies due to its inherent antimicrobial resistance mechanisms 
(Wagner et al., 2004).  The ability of P. aeruginosa to colonise a wide variety of 
anatomical sites and produce such diverse and often overwhelming infections, is due 
to an arsenal of well-regulated virulence factors which are capable of causing 
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extensive tissue damage and bloodstream invasion consequently promoting systemic 
dissemination (Van Delden and Iglewski, 1998, Calfee et al., 2001).  Chronic 
infections such as CF lung infections and colonisation of indwelling medical devices 
(e.g. catheters), are characterised by biofilm formation, localised containment of the 
bacteria to a specific area of the body and persistence (Furukawa et al., 2006).  
During the course of CF, P. aeruginosa forms biofilms characterised by cellular 
aggregates embedded within the mucus layer present in the airways (Lam et al., 
1980).  After colonisation occurs, antibiotic therapy can never completely eradicate 
the bacteria even though high levels of antibiotics can be achieved in the airway 
secretions.  Colonisation of urinary tract catheters is another example of a 
P. aeruginosa chronic infection.  Stickler et al. demonstrated that acyl-homoserine 
lactone signals  were produced by P. aeruginosa biofilms growing on the surface of a 
catheter (Stickler et al., 1998).   
 
1.3.2. Bacterial pathogenicity factors 
 
The failure of the bacterium to infect a healthy individual means the human immune 
system and more importantly T cells play an essential role in defending the host 
against P. aeruginosa.  However, in immunocompromised patients, an array of 
virulence factors may work to prevent establishment of an immune response and aid 
maintenance of the bacteria in the host.  For example, exotoxin A is toxic to 
macrophages, is a T cell mitogen and inhibits granulocyte and macrophage 
progenitor cell proliferation (Pearson et al., 1997).  Exotoxin A is also responsible 
for local tissue damage, bacterial invasion (Woods and Iglewski, 1983), and 
immunosuppression (Vidal et al., 1993).  Purified exotoxin A is highly lethal for a 
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mouse which supports its role as a major systemic virulence factor of P. aeruginosa 
(Woods and Iglewski, 1983).  Exoenzyme S is responsible for direct tissue 
destruction in lung infections (Nicas et al., 1985b) and may be important for bacterial 
dissemination (Nicas et al., 1985a).  The two hemolysins, phospholipase C and 
rhamnolipid may act synergistically to break down lipids and lecithin.  Both may 
contribute to tissue invasion by their cytotoxic effects.  Rhamnolipid is believed to 
solubilise the phospholipids of lung surfactant making them more accessible to 
cleavage by phospholipase C (Liu, 1974) and also inhibits the mucoiliary transport 
and ciliary function of human respiratory epithelium (Read et al., 1992).   
 
P. aeruginosa also produces several proteases including Las B elastase and LasA 
elastase.  The ability of P. aeruginosa to destroy the protein elastin is a major 
virulence determinant during acute infection.  Elastin is a major part of human lung 
tissue and is responsible for lung expansion and contraction.  It is also an important 
component of blood vessels, which rely on it for their resilience.  The concerted 
activity of LasB elastase and LasA elastase is believed to be responsible for 
destroying elastin-containing human lung tissue and cause the pulmonary 
haemorrhages of invasive P. aeruginosa infections (Galloway, 1991).  LasA nicks 
elastin, rendering it sensitive to degradation by other proteases such as LasB elastase, 
alkaline protease and neutrophils elastase (Galloway, 1991).  LasB elastin also 
degrades fibrin and collagen (Heck et al., 1986), can inactivate substances such as 
human immunoglobulin G and A (Heck et al., 1990), airway lysozyme (Jacquot et 
al., 1985), complement components  (Hong and Ghebrehiwet, 1992), and substances 
involved in protecting the respiratory tract against proteases such as alpha-1-protease 
inhibitor and bronchial mucus proteinase inhibitor (Morihara et al., 1979, Johnson et 
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al., 1982).  Therefore, LasB elastase not only destroys tissue components but also 
interferes with host defence mechanisms.  Studies in animal models demonstrated 
that mutants defective in LasB elastase production were less virulent than their 
parent strains (Nicas and Iglewski, 1985, Tamura et al., 1992, Tang et al., 1996), 
which supports the role of LasB elastase as a virulence factor.  Pyocyanin inhibits 
lymphocyte proliferation and leukocidin is cytotoxic to neutrophils and lymphocytes 
(Pearson et al., 1997, Wilson and Dowling, 1998).   
 
Many of these extracellular virulence factors are crucial for the competence of 
P. aeruginosa to establish and maintain the infection and have been shown to be 
controlled by a complex regulatory circuit involving cell-to-cell signalling systems 
termed quorum sensing (QS) (Telford et al., 1998, Van Delden and Iglewski, 1998, 
McGrath, 2003, Smith and Iglewski, 2003a).  Mutants defective in quorum sensing 
are typically compromised in their ability to establish a successful infection, for 
example, mutants defective in quorum sensing were substantially less pathogenic 
than their parental strains in the burned mouse model, the mouse agar bead model or 
in the neonatal mouse model of pneumonia (Tang et al., 1996, Rumbaugh et al., 
1999, Wu et al., 2000).  Thus understanding this QS network and its mode of action 
within the host may prove important in combating P. aeruginosa infections, and its 
importance in T cells function is further discussed in the next sections. 
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1.4. P. aeruginosa quorum sensing systems and quorum sensing signalling 
molecules 
 
QS is a generic regulatory mechanism that allows bacteria to launch a unified, 
co-ordinated response in a population density-dependent manner to accomplish tasks 
that would be difficult, if not impossible to achieve for a single cell.  QS systems of 
gram positive bacteria involve peptide pheromones as signals (Kleerebezem et al., 
1997).  In contrast, QS systems in gram negative bacteria are composed of a small 
molecule called an autoinducer with the various types of autoinducers described in 
gram negative bacteria are homoserine lactose-based molecules (Fuqua et al., 1996).   
 
P. aeruginosa has one of the most extensively studied QS systems.  In this organism, 
QS is complex and enables the regulation of genes by the production of small 
diffusible N-acyl homoserine lactone signal molecules (AHLs) also termed quorum 
sensing signal molecules (QSSMs) (Finch et al., 1998, Smith et al., 2001).  At low 
cell density, autoinducers are synthesised at basal levels and is thought to diffuse into 
the surrounding media where it becomes diluted.  With increasing cell density, the 
intracellular concentration of autoinducer increases until it reaches a threshold 
concentration.  At this critical concentration, the autoinducer has been reported to 
bind to a LuxR-type transcriptional activator protein (R-protein) (Greenberg, 1997).  
The R-protein/autoinducer complex has been proposed to bind specific DNA 
sequences upstream of target genes enhancing their transcription (Stevens et al., 
1994, Stevens and Greenberg, 1997).  QSSMs therefore allow bacteria to express 
specific genes as a population. 
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P. aeruginosa produces at least three small compounds that function as intercellular 
communication signals.  The two AHL signal molecules, N-(3-oxododecanoyl) 
homoserine lactone (3-oxo-C12-HSL) and N-butyryl-L-homoserine lactone 
(C4-HSL), have been well studied and function in combination with the LuxR 
homologs LasR and RhlR, respectively (Gambello and Iglewski, 1991, Pearson et al., 
1994, Pearson et al., 1995, Calfee et al., 2001, Smith et al., 2001, McGrath, 2003).  
Together, these QS signals control 4-12% of the P. aeruginosa genome (Whiteley et 
al., 1999, Calfee et al., 2001, McGrath, 2003, Schuster et al., 2003, Wagner et al., 
2003).  The third P. aeruginosa intercellular signal, 2-heptyl-3-hydroxy-4-quinolone 
(the Pseudomonas quinolone signal [PQS]) (Pesci et al., 1999) controls multiple 
virulence factors and is intertwined in the QS cascade, where it appears to be a 
regulatory link between the las and rhl QS systems (McKnight et al., 2000, Diggle et 
al., 2003). 
 
To elaborate, in las QS , the 3-oxo-C12-HSL synthase, lasI, directs the synthesis of 
primarily 3-oxo-C12-HSL (Pearson et al., 1994), triggering the las R-encoded 
transcriptional activator, LasR (fig. 1.4) (Gambello and Iglewski, 1991, Pearson et 
al., 1997), to induce a number of virulence genes including lasB, lasA, apr, toxA, and 
lasI itself (Toder et al., 1991, Gambello et al., 1993, Passador et al., 1993).  The las 
system also auto-regulates lasI, leading to the production of more 3-oxo-C12-HSL 
(Seed et al., 1995).  In addition, the las system controls expression of the xcpP and 
xcpR genes that are involved in the regulation of the Type II general secretion 
pathway (Chapon-Herve et al., 1997) and has been implicated in the maturation of 
P. aeruginosa biofilms (Davies et al., 1998).  Although 3-oxo-C12-HSL is diffusible, 
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Figure 1.4 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Simplified model of the P. aeruginosa quorum sensing hierarchy.  As the bacterial population increases, AHLs accumulate, and 
once a maximum threshold is reached, these molecules bind to and activate their cognate transcriptional regulators, eventually leading to 
production of virulence factors and biofilm production.  The AHL molecule 3-oxo-C12-HSL and the quinolones molecule PQS has been 
suggested to inhibit immune cell proliferation (Hooi et al., 2004). 
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it appears to partition into cell membranes, and P. aeruginosa efflux pumps aid in the 
movement of this signal to the external environment (Pearson et al., 1999). 
 
The second cell-to-cell signalling system, rhl, directs the synthesis of C4-HSL 
(fig. 1.4) (Pearson et al., 1995, Winson et al., 1995).  This diffusible signal (Pearson 
et al., 1999) in conjunction with RhlR activates expression of the rhlAB rhamnolipid 
synthesis genes, rhamnolipid, and  to  some  extent  lasB,  which  encodes  the  major  
virulence factor LasB elastase  (Gambello and Iglewski, 1991, Ochsner et al., 1994, 
Latifi et al., 1995, Ochsner and Reiser, 1995, Latifi et al., 1996, Pearson et al., 1997).  
Other virulence factors and secondary metabolites, including pyocyanin, cyanide, 
and chitinase are positively regulated by the rhl system (Latifi et al., 1995, Ochsner 
and Reiser, 1995). 
  
Recent data have shown that the las and rhl QS systems of P. aeruginosa interact.  
Both systems are highly specific in that their respective autoinducers are unable to 
activate the transcriptional activator protein of the other system.  However, neither 
system is completely independent of the other.  The lasR/3-oxo-C12-HSL complex 
activates the expression of rhlR placing the las system in a cell-to-cell signalling 
hierarchy above the rhl system (Latifi et al., 1996, Pesci and Iglewski, 1997).  
Moreover, 3-oxo-C12-HSL can bind to RhlR, blocking the binding of C4-HSL to its 
transcriptional activator rhlR (Pesci and Iglewski, 1997).  The las system therefore 
controls the rhl system at both a transcriptional and post-translational level, and so 
genes controlled by the rhl system require a functional las system for full activation 
(fig. 1.4). 
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Studies have indicated that the production of PQS occurs only in the presence of an 
active form of lasR and the provision of exogenous PQS induces expression of lasB, 
rhl and rhlR which is important for PQS bioactivity (Pesci et al., 1999, McKnight et 
al., 2000).  The discovery that PQS regulates the expression of lasB and that the 
synthesis and bioactivity of PQS are mediated by both the las and rhl QS systems, 
respectively, suggests that PQS and AHL-dependent QS must be interlinked (Pesci et 
al., 1999, McKnight et al., 2000).  PQS strongly induces rhl in P. aeruginosa and has 
less positive effects on the transcription of lasR and rhlR.  Furthermore, data 
indicates that rhl and lasB are both cooperatively regulated by PQS and C4-HSL, and 
the combined addition of C4-HSL and PQS has synergistic effect on the expression 
of lasB when compared to C4-HSL or PQS alone (McKnight et al., 2000).  However, 
McKnight et al. (2000) suggested that PQS is not involved in sensing cell density as 
it was identified much later in the growth cycle than is typical for QS signal 
molecule.  It was speculated that the purpose of PQS in regulating rhl expression, 
might be to further up-regulate the rhl QS system in late stationary phase cultures 
i.e. at a time of increased cell stress (McKnight et al., 2000).  Conversely, studies 
have demonstrated that although PQS levels are indeed maximal in late stationary 
phase, they are already detectable in the logarithmic phase of growth, and that 
substantial levels of the molecule are present at the onset of stationary phase, 
indicating that PQS, apart from being important in late stationary phase may also 
have a function at a much earlier stage of growth (Diggle et al., 2003, Lepine et al., 
2003).   
 
More recently, the structural genes required for PQS have been identified 
(pqsABCDH) along with a transcriptional regulator (pqsR) and a response effector 
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(pqsE) (Gallagher et al., 2002).  The transcription of pqsH is regulated by the las QS 
system, linking QS and PQS regulation.  Taken together, these data demonstrate that 
the PQS molecule is a central component of the P. aeruginosa QS hierarchy 
(fig. 1.4).  Its addition was found to promote biofilm formation and to positively 
affect production of multiple quorum sensing-controlled virulence factors, including 
lectins, pyocyanin and proteases (Pesci et al., 1999, McKnight et al., 2000, Calfee et 
al., 2001, Diggle et al., 2003). 
 
Work in the past few years showed that QS is essential for the expression of 
virulence factors as well as for biofilm formation by P. aeruginosa and thus 
represents an attractive target for the design of novel drugs for the treatment of 
P. aeruginosa infections. 
 
1.5. Role of P. aeruginosa quorum sensing in pathogenesis 
 
Taking into account that QS regulates such a wide range of factors that play such 
diverse roles in the function of P. aeruginosa, examining the role of QS in bacterial 
infections is inevitable.  Studies confirm the importance of both the las and rhl QS 
systems for P. aeruginosa to disseminate from the initial site of infection which leads 
to septicaemia, induces both acute and chronic lung infections, and causes pathology 
and mortality (Rumbaugh et al., 1999, Pearson et al., 2000, Smith et al., 2002).  QS 
has also been shown to be functional during P. aeruginosa infections in humans.  
Sputum samples from CF patients chronically colonised with P. aeruginosa 
contained mRNA transcripts for the QS genes lasR and lasI (Storey et al., 1998, 
Erickson et al., 2002).  Accumulation of these transcripts in sputum correlated with 
Chapter 1           Introduction  
 - 38 -
the levels of transcripts for various QS-regulated genes.  The first study to address 
the production of AHLs in vivo used mice infected with P. aeruginosa together with 
an E. coli AHL reporter strain.  3-oxo-C12-HSL produced by P. aeruginosa was 
detected in these mice directly demonstrating that P. aeruginosa AHLs were 
produced in vivo (Wu et al., 2000).  The production of AHLs in vivo was 
corroborated by studies that showed sputum from P. aeruginosa colonised CF 
patients was able to produce both 3-oxo-C12-HSL and C4-HSL (Singh et al., 2000).  
In addition to these studies, AHLs were directly extracted and measured in the 
sputum of CF patients colonised with P. aeruginosa (Erickson et al., 2002).  
Erickson et al. demonstrated the sputum of these CF patients contained 
approximately 22 nM 3-oxo-C12-HSL and 5 nM C4-HSL; however they speculated 
that these levels may be significantly lower than local concentrations associated with 
the bacteria (Erickson et al., 2002).  In experiments where P. aeruginosa were grown 
in a biofilm, concentrations of 3-oxo-C12-HSL were measured in association with 
the bacteria (Charlton et al., 2000).  These studies demonstrate that QS is active 
during P. aeruginosa infections, it potentially regulates the expression of various 
genes in vivo and that both 3-oxo-C12-HSL and C4-HSL are actively produced.  The 
presence of the molecule in vivo may be a factor in allowing P. aeruginosa to 
develop or maintain a chronic state.   
 
Furthermore, Collier et al. demonstrated that PQS was present in three different 
types of samples from infected CF patients.  PQS production by P. aeruginosa 
cultured form chronically infected CF patients was observed where nine of the ten 
strains cultured form different patients produced varying amounts of PQS, leading to 
the conclusion that many P. aeruginosa CF strains are capable to producing PQS 
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when grown in vitro (Collier et al., 2002).  Coller et al. went onto analysing sputum 
from infected CF patients and showed the presence of PQS indicating that PQS is 
produced in vivo.  Moreover, the amount of PQS evident in each extract correlates 
with the relative density of P. aeruginosa in each sample with the concentration of 
P. aeruginosa in the sputum sample containing the highest amount of PQS was 
approximately 2 µM.  This concentration is on the edge of the physiologically active 
range but the authors speculated that this is an underestimate of the actual amount 
because of the inefficient PQS recovery achieved by organic extraction (Collier et 
al., 2002, Pesci et al., 1999).  Since sputum must pass through the oral cavity and 
consists of a mixture of lower and upper respirator tract secretions, Collier et al. also 
examined samples collected below the larynx from patients infected with 
P. aeruginosa.  Results indicated production of PQS in the bronchoalveolar space of 
CF patients as well as in mucopurulent airway fluid, providing additional evidence of 
PQS is produced inside the CF lung (Collier et al., 2002) 
 
The involvement of QS in P. aeruginosa biofilm formation has also been intensively 
studied where emphasis has been placed on PQS playing a major role in biofilm 
formation, protecting the bacterial cells from adverse environmental conditions 
including the host immune system and anti-microbial agents (Bjarnsholt and 
Givskov, 2006).  It is generally appreciated that when P. aeruginosa chronically 
infects patients, it adapts to the biofilm mode of growth.  The generally accepted 
definition of a biofilm is a community of cells attached to a surface or interface or 
to each other, imbedded in a self-made, protective matrix of extracellular polymeric 
substances (EPS).  The clinical implications of bacterial biofilms are particularly 
pronounced (Davies, 2003).  P. aeruginosa is capable of forming two general types 
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of biofilms in the laboratory based on their structure.  A flat biofilm is characterised 
by a relatively confluent, uniform community of bacteria on the surface.  A 
structured biofilm consists of cell aggregates or mushrooms separated by 
channels or spaces (Kirisits and Parsek, 2006).  The undifferentiated flat biofilms 
are less stable than the differentiated biofilms as they can easily be disrupted by the 
detergent sodium dodecyl sulphate (Davies et al., 1998).  The ability of 
P. aeruginosa to form biofilms has severe implications for infected patients, as cells 
grown in biofilms are much more resistant against host defence systems and exhibit 
increased resistance against a variety of antibodies (Greenberg, 2003).   
 
Davies et al. (1998) originally reported an involvement of the QS circuitry in the 
regulation of biofilm formation.  In this study it was shown that the wild-type and 
rhlI mutant strains formed structured biofilms, while the lasI and the lasI/rhlI mutant 
strains formed flat, undifferentiated biofilms (Davies et al., 1998).  Based on this 
observation, it has been suggested that the las system is required for the development 
of typical biofilm architecture.  Bjarnsholt et al. showed by viability staining and by 
determination of viable counts that a P. aeruginosa in vitro biofilm is much less 
tolerant of tobramycin treatment.  The QS-deficient biofilm was almost entirely 
eradicated, in contrast with the wild-type biofilm, in which only cells in the top layer 
were killed (Bjarnsholt et al., 2005a).  Shih and Huang obtained similar results by 
comparing wild-type and QS-deficient biofilms on treatment with kanamycin (Shih 
and Huang, 2002). 
 
Favre-Bonté et al. determined that QSSMs are produced in biofilms covering 
intubation devices (Favre-Bonte et al., 2007).  The 3-oxo-C12-HSL and C4-HSL can 
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be detected in situ in biofilms covering intubation devices retrieved from patients 
colonised by P. aeruginosa.  Moreover, all P. aeruginosa isolates collected either 
from these biofilms or from tracheal aspirates produced these QSSMs in vitro.  
Whereas 3-oxo-C12-HSL has been previously shown to play a role in the 
differentiation of P. aeruginosa biofilms (Davies et al., 1998, De Kievit et al., 2001), 
C4-HSL seems to be important during the maturation stage of biofilm development 
(Sauer et al., 2002), for the total amount of biofilm formed (Favre-Bonte et al., 
2003), and for the maintenance of biofilm architecture (Davey et al., 2003).  In 
addition, Favre-Bonté et al. also demonstrated isolates recovered from the biofilm of 
intubation devices produced higher levels of C4-HSL than 3-oxo-C12-HSL in vitro 
(Favre-Bonte et al., 2007) supporting previous observations where C4-HSL is 
produced in higher quantities than 3-oxo-C12-HSL in P. aeruginosa biofilms in the 
lungs of CF patients (Singh et al., 2000, Favre-Bonte et al., 2002). 
 
Furthermore, PQS signalling has been shown to promote P. aeruginosa biofilm 
formation.  Diggle et al. showed that P. aeruginosa biofilm development on stainless 
steel coupons was substantially enhanced in the presence of PQS.  The stimulating 
influence of PQS on both RhlR/C4-HSL may be responsible for the biofilm 
phenotype observed in the presence of synthetic PQS (Diggle et al., 2003). 
 
A growing number of reports also indicate that autoinducers may efficiently enter 
and modulate gene expression in cells of a host eukaryotic organism (Williams et al., 
2004).  Initial studies examining the effects of P. aeruginosa AHLs on eukaryotic 
cells used a strain containing a lasR deletion, which produces few AHLs.  It was 
found that when this strain was added to in vitro culture of human bronchial 
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epithelial cells, the amount of IL-8 produced was significantly less than that 
stimulated by wild-type P. aeruginosa (Tang et al., 1996).  High levels of 
chemotactic factors, such as IL-8 and neutrophils, have been associated with chronic 
P. aeruginosa infections in CF patients.  Neutrophils that enter the infection site 
secrete multiple mediators, such as reactive oxygen species and elastase.  P. 
aeruginosa tends to be resistant to their effects likely to be due in part to the growth 
of the bacteria in protective biofilms.  P. aeruginosa also produces catalases and 
superoxide dismutases that are able to neutralise the deleterious effects of hydrogen 
peroxide and oxidative stress (Hassett et al., 1999).  Therefore, instead of clearing 
the bacterial infection, the release of neutrophils mediators results in tissue 
destruction.  Wagner et al. found that supernatants of P. aeruginosa collected within 
2 to 24 hr after cultivating the bacteria under conditions leading to biofilm formation, 
contained a chemotactic activity for neutrophils (Wagner et al., 2007).  Chemotaxis 
and phagocytosis of bacteria is critically dependent on adhesion proteins.  Wagner et 
al. tested the effect of 3-oxo-C12-HSL on the surface expression of the ȕ2-integrin 
CD11b/CD18 on neutrophils and found that an up-regulation was seen, compatible 
with a transport to the membrane of performed molecules, as it occurs also in 
response to bona fide stimuli such as IL-8.  Furthermore, an up-regulation of 
immunoglobulin (IgG) receptor CD16 was seen as was induction of CD64, the later 
representing the high-affinity receptor for IgG.  Corresponding to the enhanced 
expression of the immunoglobulin receptors, an increased uptake of opsonised 
bacteria by 3-oxo-C12-HSL-pretreated neutrophils was seen (Wagner et al., 2007). 
 
It was also demonstrated that purified 3-oxo-C12-HSL at high concentrations 
(100 µM) activated p42/44 MAPK pathway and subsequently transcription factor 
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NFNB that stimulated the production of inflammatory cytokine IL-8 from human 
lung bronchial cells, but were unable to identify its binding target (Dimango et al., 
1995).  Additional experiments examining this activation demonstrated a specific 
signal pathway that was stimulated by 3-oxo-C12-HSL in bronchial epithelial cells.  
3-oxo-C12-HSL activated extracellular-signal-regulated kinases (ERKs) that 
subsequently induced the activation of the transcription factor NFțB.  Thus 
activation of NFțB is essential for maximal production of IL-8 with 3-oxo-C12-HSL 
stimulation (Smith et al., 2001).  3-oxo-C12-HSL was also found to induce the 
expression of several other chemokines that can stimulate the migration of 
monocytes, neutrophils and T cells (Smith et al., 2002).  These results were 
supported by in vivo experiments.  Smith et al. showed that direct injection of 
3-oxo-C12-HSL into the skin of C57BL/6 mice promoted the production of 
messenger RNA (mRNA) encoding cytokines IL-1Į and IL-6 and macrophage 
inflammatory protein-2 (MIP-2), the mouse analogue  of the human cytokine IL-8.  
This agrees with observation made by Bjarnoholt et al., who found the MIP-2 
concentration to be significantly higher in mice infected with QS active 
P. aeruginosa than those infected with the QS-deficient counterparts.  They also 
observed that the high concentration of MIP-2 was correlated with slow clearance of 
the bacteria (Bjarnsholt et al., 2005a, Bjarnsholt et al., 2005b). 
 
In addition, Vikström et al. investigated the influence of 3-oxo-C12-HSL on different 
functions of macrophages and specifically MAPK pathways in the cells (Vikstrom et 
al., 2005).  It was demonstrated that the level of phagocytic activity in macrophages 
was significantly higher after pre-treatment with 100 ȝM 3-oxo-C12-HSL for either 
30 min or 1 hr with the authors speculating that the concentration and time exposure 
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constraints may help the macrophages to both sense and block P. aeruginosa biofilm 
formation by being stimulated to phagocytose the bacteria.  Vikström et al. also 
provided evidence that 3-oxo-C12-HSL specifically activates the p38 MAPK 
pathway in human macrophages but failed to activate the p42/44 MAPK signalling 
cascade (Vikstrom et al., 2005).  Mitogenic stimuli, such as growth factors, activate 
the ERK or p42/44 cascades, whereas pro-inflammatory and stress stimuli activate 
the p38 and JNK pathway.  SB203580 is a specific inhibitor of p38 MAPK, and has 
thus been widely used to investigate the role of p38 MAPK in the function and 
differentiation of cells (Kurosaka et al., 2003, Pearson et al., 2001, Rao, 2001, Carter 
et al., 1999, Dziarski et al., 1996).  Vikström et al. also found that pre-treatment of 
cells with 10 ȝM SB203580 prevented 3-oxo-C12-HSL-induced phagocytic 
activation of human macrophages.  These findings demonstrate the notion that p38 
MAPK cascade is involved in 3-oxo-C12-HSL-induced increase of phagocytic 
capacity (Vikstrom et al., 2005).  In contrast to these observations, it was previously 
shown that 3-oxo-C12-HSL can induce rapid activation of p42/p44 and subsequently 
the NFțB pathway in human lung fibroblasts and epithelial cells but failing to 
activate the p38 MAPK pathway (Smith et al., 2001), speculating that 
3-oxo-C12-HSL can distinctly modulate MAPK signalling cascades in different cell 
types. 
 
In contrast to the findings that 10 ȝM and 100 ȝM of 3-oxo-C12-HSL did not induce 
cell death of neutrophils from human peripheral blood (Wagner et al., 2007), and 
enhancement of macrophage activity with 100 ȝM 3-oxo-C12-HSL (Vikstrom et al., 
2005), Tadeta et al. reported induction of apoptosis in mouse macrophages and in 
neutrophils with 50 ȝM of 3-oxo-C12-HSL (Tateda et al., 2003).  Species and 
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concentration differences apparently account for the discrepant finding, as apoptosis 
was not observed in human cells. 
 
Smith et al also reported that 3-oxo-C12-HSL can up-regulate the expression of 
cyclooxygenase-2 (cox-2), an enzyme important for the production of prostaglandins 
(Smith et al., 2002).  This induction of cox-2 and subsequent activation of 
prostaglandin E2 (PGE2) synthase resulted in the increased production of PGE2.  
Increased levels of PGE2 have been associated with P. aeruginosa infections in CF 
lungs an in burn wounds (Hahn et al., 1999, Konstan et al., 1993).  PGE2 has many 
functions, one of which is the induction of endothelial permeability.  Compounding 
this response is the inhibition of both coronary and pulmonary smooth muscle 
contractions with 3-oxo-C12-HSL stimulation (Lawrence et al., 1999).  This 
vasorelaxant activity might lead to increased local blood flow, oedema and cellular 
migration to the site of infection. 
 
Studies also demonstrated that relatively high concentrations of 3-oxo-C12-HSL (in 
the 1-100 PM range) (but not the short chain C6-HSL) could inhibit the production 
of IL-12 and TNFD from LPS-activated mouse peritoneal exudates cells or hPBMCs 
(Telford et al., 1998, Chhabra et al., 2003).  IL-12 is instrumental in the stimulation 
of IFNȖ production from T cells, which is important for the activation of 
macrophages and the induction of proinflammatory response.  Down-regulation of 
IL-12 may support the Th2-dominated adaptive immune response which is 
characteristic of CF patients with chronic P. aeruginosa lung infection (Moser et al., 
2000).  This inhibition of IL-12 could potentially alter the activation of T cells and 
the production of IFNȖ (Telford et al., 1998).  In contrast, Smith et al. demonstrated 
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3-oxo-C12-HSL can directly interact with T cells and stimulate the production of 
IFNȖ with little or no effect on IL-4 in transgenic murine splenic T cells (Smith et 
al., 2002), though both studies are not totally contradictory as the concentration of 
3-oxo-C12-HSL used by Telford et al. were high (~ 100 ȝM) compared to Smith et 
al. (< 10 ȝM).   
 
In 2003, Richie et al. showed that 3-oxo-C12-HSL alone promotes neither Th1 nor 
Th2 response when administered to mice (Ritchie et al., 2003).  The authors 
hypothesised that 3-oxo-C12-HSL interacts non-specifically with the host innate 
immune response, and this could be by direct interaction with the leukocytes and not 
by interfering directly with the cytokine profile and other processes in the 
inflammation cascade.  It was concluded that caution is required when extrapolating 
to in vivo scenarios the effects of 3-oxo-C12-HSL obtained in vitro, because the 
response is greatly affected by the immune status of the host. 
 
Additionally, Hooi et al. demonstrated that 3-oxo-C12-HSL and PQS can exert 
differential modulatory effects on mammalian immune responses in vitro (Hooi et 
al., 2004).  PQS and 3-oxo-C12-HSL significantly reduced the ability of human 
peripheral blood mononuclear cells (hPBMCs) to respond to ConA and to anti-CD3 
and anti-CD28.  PQS did so without any effect on cell viability while 
3-oxo-C12-HSL suppressed proliferation before viability was affected.  Furthermore, 
3-oxo-C12-HSL was shown to inhibit IL-2 and TNFĮ release while PQS stimulated 
the release of these cytokines (Hooi et al., 2004).  This paper described for the first 
time the immune-modulatory activity of PQS and demonstrated the different 
immunological activities of these QSSMs. 
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Given the documented immune modulatory activity of 3-oxo-C12-HSL, especially 
its ability to inhibit TNFĮ and IL-12 and so promoting Th2 responses (Telford et al., 
1998), Pritchard et al. investigated its effect on the development of insulitis and 
diabetes in non-obese diabetic (NOD) mouse (Pritchard et al., 2005).  NOD mouse is 
a well established model of type 1 insulin-dependent diabetes mellitus and studies 
have demonstrated the immune response leading to ȕ-cell destruction is characterised 
by a Th1 type CD4 T cell response and involves TNFĮ (Christen et al., 2001).  
ȕ-cells in the islets of Langerhans of the pancreas are required for insulin production.  
Blockage of IL-12 production has also been shown to inhibit the development of 
diabetes (Falcone et al., 1999).  Pritchard et al. demonstrated that 3-oxo-C12-HSL 
significantly reduced insulitis and NOD mice treated with 3-oxo-C12-HSL was 
shown to significantly retard the cumulative incidence of diabetes, suggesting 
3-oxo-C12-HSL treated mice would be protected from the development of diabetes 
(Pritchard et al., 2005).  This study indicates the potential for QSSMs to be used 
therapeutically. 
 
Additional studies characterising this response in leukocytes observed that the 
structure of the AHL molecule is important for the regulation of cytokine production.  
Work by Chhabra et al. (2003) showed that inhibition of ConA-stimulated murine 
spleen cell proliferation by a range of 3-oxo-C12-HSL-related compounds required 
an acyl side chain a minimum of 11 carbons in length and high lipophilicity of the 
molecule.  The homoserine ring was also shown to be essential for efficient 
suppression of lymphocyte proliferation (fig. 1.5a) (Chhabra et al., 2003).  Dimango 
et al. determined C6-HSL and C4-HSL  were unable to stimulate production of IL-8 
in human lung bronchial epithelial cell, indicating the structure of 3-oxo-C12-HSL  
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was important for this activation (Dimango et al., 1995).  In addition to AHLs, the 
activity of PQS also depends on the presence of the 3-hydroxy group as neither 
2-heptyl-4(1H)-quinolone nor 3-formyl-2-heptyl-4(1H)-quinolone exhibited any 
biological activity comparable with PQS (fig. 1.5b) (Diggle et al., 2003).  Thus, it 
seems likely that the PQS signal transduction pathway contains a sensor protein that 
recognises PQS with a high degree of structural specificity.   
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Figure 1.5. Structure of 3-oxo-C12-HSL (a) and PQS (b) 
 
In addition to gram-negative bacteria, a number of gram-positive bacteria are known 
to employ quorum-sensing systems.  No gram-positive bacteria have been shown to 
produce AHLs; gram-positive quorum sensing systems typically make use of small 
posttranslationally modified peptide-based signal molecules.  Quorum sensing is 
used to regulate the development of bacterial competence in Bacilllus subtilis and 
Streptococcus pneumoniae, conjugation in Enterococcus faecalis and virulence in 
Staphylococcus aureus and Enterococcus faecalis (Dunny and Leonard, 1997, 
Kleerebezem et al., 1997, Novick and Muir, 1999).   
 
The virulence of S. aureus is dependent on the temporal expression of a diverse array 
of virulence factors regulated by the agr locus (Novick and Muir, 1999).  During the 
early stages of S. aureus infection, surface proteins involved in attachment and 
defence e.g. protein A, coagulase and fibronectin-binding proteins predominate.  
However, once a high cell density is achieved at the infection site, expression of 
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S. aureus surface proteins is decreased and secreted protein are preferentially 
expressed e.g. proteases, hemolysins, toxic shock syndrome toxin-1 and enterotoxin 
B (Dunny and Leonard, 1997, Bronner et al., 2004, Novick and Muir, 1999).  In 
several experimental animal models of S. aureus infection, agr mutants exhibit 
significantly reduced virulence, highlighting the key role of this regulatory locus in 
staphylococcal pathogenicity (Cheung et al., 2004).   
 
The growing number of human pathogens found to contain QS systems highlights 
the importance of exploring further into this area and increasing our understanding of 
the mechanisms involved, allowing future exploitation of these regulatory systems 
for therapeutic interventions. 
 
1.6. Microarray technology 
 
As the human genome is gradually fully sequenced, and protein interaction maps 
become available, the scientific community is able to evaluate the complexity of the 
eukaryotic cellular network.  To take advantage of this knowledge, further studying 
the differential effects of 3-oxo-C12-HSL and PQS at the mRNA level would be 
valuable in assessing molecular targets within the immune system.  The examination 
of gene expression using microarrays holds tremendous promise for the identification 
of candidate genes involved in a variety of processes.  Gene expression is a central 
concept in molecular biology and forms part of our knowledge of the role of genes in 
human diseases.  Genome-wide monitoring of gene expression using DNA 
microarrays represents one of the latest break-through in experimental molecular 
biology and provides unprecedented opportunity to explore changes in cell signalling 
Chapter 1           Introduction  
 - 50 -
pathways when faced with bacterial infections by providing a comprehensive survey 
of a cells transcriptional landscape.  Gene microarray technology has become highly 
valuable for identifying complex global changes in gene expression patterns, by 
harvesting total cellular RNA and using it to generate probes through a variety of 
strategies including incorporating a label into the first strand cDNA made from total 
RNA or attaching a T7 RNA polymerase promoter during cDNA synthesis, then 
labelling of the resulting RNA (fig. 1.6).   
 
Microarray therefore allows simultaneous assessment of the transcription of tens of 
thousands of genes, and of their relative expression between treated cells and 
untreated cells.  Cristillo and Bierer used cDNA-based microarray analysis to 
obtain a more comprehensive view of CsA- and FK506-sensitive early genes in 
purified human peripheral blood T lymphocytes (Cristillo and Bierer, 2002).  
Cristillo and Bierer hypothesised that changes in gene expression common to both 
CsA and FK506 treatment would likely be secondary to inactivation of calcineurin 
phosphatase activity.  Additionally, perturbations in gene expression unique to one 
drug alone would potentially identify specific immunophilin (CyP or FKBP)-
dependent gene targets.  Although Cristillo and Bierer failed to identify transcripts 
specifically regulated by only one immunosuppressive agent, suggesting that 
immunophilin-dependent, calcineurin-independent gene expression was below the 
limits of detection of their analysis, they did identify a number of CsA- and FK506-
sensitive (and calcineurin-dependent) genes induced or inhibited following anti-CD3 
monoclonal antibody ligation relative to resting cells (Cristillo and Bierer, 2002).   
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Figure 1.6 
 
Figure 1.6. Schematic outline of a microarray analysis experiment.  RNA is 
isolated from reference (control) cells and test (experimental) cells.  cDNA is 
synthesised from each RNA population by a reverse transcription process.  The 
resulting two cDNA samples (control and experimental) are labelled with two 
different fluorescent dyes, mixed, and hybridized to the targets the microarray.  
Hybridization is monitored through measurement of the amount of fluorescence 
associated with individual target molecules on the array.  Since the two dyes 
fluoresce at different wavelengths, it is possible to distinguish hybridization due to 
the control cDNA population from that due to the experimental cDNA population 
(adapted from http://www.microarray.lu/en/MICROARRAY_Overview.shtml, 
http://www.genome.gov/10000533). 
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Microarray analysis was also used by Grolleau et al. to identify global and specific 
effects of rapamycin on translation.  Translation of a large number of ribosomal 
proteins and elongation factors were found to be strongly repressed by rapamycin 
and a large number of additional genes uncovered.  Part of the regulated genes has 
functions related to RNA processing and translation, for example, translation 
initiation factors 4A and 5A were strongly repressed and translation of prothymosin 
alpha was also strongly repressed by rapamycin (Grolleau et al., 2002).  Prothymosin 
alpha has been reported to enhance cell-mediated immunity as well as proliferative 
and cytotoxic responses of T cells (Cordero et al., 1992, Bustelo et al., 1991).   
 
Comparing differences in total RNA expression levels between treated T cells, 
subjected to known immunosuppressive agents or QSSMs, and control T cells 
stimulated to proliferate using anti-CD3 and anti-CD28 on a 30K human array, may 
therefore give greater insights to the effects QSSMs have at a genetic level and 
comparing these effects to currently used immunosuppressive drugs.   
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1.7. Summary 
 
In summary, quorum sensing is important for the regulation of multiple factors in 
P. aeruginosa that has a significant effect on the virulence of the bacteria.  
Moreover, the production of 3-oxo-C12-HSL and PQS by P. aeruginosa is not only 
important for cell-to-cell communication between the bacteria, but also directly acts 
as a virulence factor.  It is clear from previous studies that 3-oxo-C12-HSL can  
inhibit (at low doses) and activate as well as cause apoptosis (at high doses) in 
multiple cell types and thus potentially change the host response during 
P. aeruginosa infections (Telford et al., 1998, Smith and Iglewski, 2003a, Smith and 
Iglewski, 2003b).  It has also been recently demonstrated that PQS is also 
immunosuppressive in hPBMCs, and these two QSSMs engage different molecular 
targets within the cells, establishing differential effects  3-oxo-C12-HSL showing 
an inhibitory effect while PQS showing a stimulatory effect on IL-2 and TNFĮ 
production (Hooi et al., 2004, Pritchard, 2006).   
 
The clinical implications of these findings are potentially significant, as the 
differential activity reported for 3-oxo-C12-HSL and PQS suggest that QSSMs act 
immunologically in infected tissues and supports the concept that QSSMs are true 
virulence determinants (Collier et al., 2002).  Increasing the understanding of 
immune modulation by these two QSSMs is important.  Present studies have focused 
on their effects on murine splenocytes and hPBMCs.   
 
The purpose of my research was to study for the first time the effects of QSSMs on 
pure human T cells, shown to be important in immunity to P. aeruginosa (Stevenson 
et al., 1995).  This study confirms the differential effects of 3-oxo-C12-HSL and 
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PQS on IL-2 and TNFĮ release from pure T cells isolated from whole blood.  In 
addition, to further understand the mechanism of actions of these two QSSMs, the 
effect they have on IFNȖ and IL-4 was also tested, as they are markers of Th1 and 
Th2 responses respectively.  Further cytokine analysis was performed to confirm the 
effect the two QSSMs have on Th1 and Th2 responses.  The differential effects of 
3-oxo-C12-HSL and PQS observed in pure human T cells supports previous 
suggestions they may act in a similar manner to CsA and rapamycin.  Establishing 
the effects these two QSSMs have on pure T cells help to further understand their 
mechanisms of actions and possibly contributing to future development of novel 
therapeutics for a multitude of immunological diseases. 
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1.8. Aims and Objectives 
 
To further understand the interactions of QSSMs within the immune system by 
assessing: 
 
x The differential effects of 3-oxo-C12-HSL and PQS on mouse splenocyte 
proliferation and IL-4 and IFNȖ release. 
x The differential effects of 3-oxo-C12-HSL and PQS on human PBMC cell 
proliferation and IL-2 release. 
x The differential effects of 3-oxo-C12-HSL and PQS on pure human T cell 
proliferation and IL-2 release. 
x The effects P. aeruginosa QSSMs on an array of cytokine expression in pure 
human T cells using cytometric bead analysis technology. 
x The effect of PQS on total and phospho-Erk 1/2 activity in pure human 
T cells. 
 
Proceed to investigate at a gene array level the differential effects of Pseudomonas 
derived and classical immune suppressive chemicals on total RNA expression 
following engagement of the TCR: 
 
x Isolate total RNA from pure T cells stimulated to proliferate using anti-CD3 
and anti-CD28 and treated with either 3-oxo-C12-HSL, PQS or CsA using 
the IC50 concentration values obtained from the proliferation assays. 
x Assessment of total RNA quality and quantity using Agilent 2100 
Bioanalyzer in combination with Nanodrop spectrophotometer. 
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x RNA amplification and dye incorporation using Ambions MessageAmpTM 
aRNA Amplification kit followed by quality control. 
x Microarray hybridisation onto a MWG 30K human array, scanning is 
performed using an Axon GenePix 4000B scanner and the scanning output 
file imported into Genespring (Silicon genetics) to quality control and analyse 
data. 
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2. General Materials and Methods 
 
2.1. Preparation of QSSMs and CsA 
 
The 3-oxo-C12-HSL and PQS used for all the procedures were synthesised by the 
Medicinal Chemistry group, University of Nottingham, according to the method 
described by Chhabra et al. (1993).  The compounds were purified to homogenecity 
by semi-preparative high performance liquid chromatography and their structures 
confirmed by mass spectrometry and proton nuclear magnetic resonance 
spectroscopy (Chhabra et al., 1993, Winson et al., 1995).  3-oxo-C12-HSL and PQS 
were dissolved in 100% dimethyl sulphoxide (DMSO) at a concentration of 0.1 M 
and stored at 4
o
C. 
 
CsA (Sigma, Poole, UK) was solubilised in 100% ethanol at a concentration of 
0.05 M and stored at -20
o
C in 10 µl aliquots. 
 
2.2. Cell culture 
 
Mouse splenocytes, human PBMC and human T-lymphocytes were maintained in 
complete cell culture medium (CTCM) consisting of endotoxins-free RPMI 1640 
supplemented with 5% heat inactivated fetal calf serum (FCS, Sigma, Poole, UK), 
100 U/ml penicillin/100 ȝg/ml streptomycin (Sigma, Poole, UK), 2 mM L-glutamine 
(Sigma, Poole, UK) and 5x10
-5 
M 2-meracaptoethanol (ME, Sigma, Poole, UK). 
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2.3. Cell density determination 
 
Cell density and viability were determined by trypan blue (Sigma, Poole, UK) dye 
exclusion.  This method is based on the principle that viable cells are not permeable 
to certain dyes, whereas non-viable cells are.  Cell suspension was mixed thoroughly 
via pipetting before adding 5 ȝl of cell suspension to 20 ȝl of trypan blue solution 
(0.4% (w/v) trypan blue in PBS).  The trypan blue-cell suspension was transferred to 
both chambers of the haemocytometer without overfilling the chambers.  Viable cells 
were counted within the large middle square.  Cell concentration per ml and the total 
number of cells were determined using the following calculations: 
 
 Cells per ml =  Total cell count x 10
4
 x 5 (dilution factor) 
 Total cell no.  =  Cells per ml x original vol. of cell suspension 
 
2.4. Cytotoxicity assay 
 
Cell viability was determined using a colorimetric method, utilising solutions of a 
novel tetrazolium compound 3-(4,5-dimethylthiazol-2yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfonphenyl)-2H-tetrazolium, inner salt (MTS, 
Promega, Southampton, UK) and an electron-coupling reagent phenozine 
methosulphate (PMS, Promega, Southampton, UK).  The MTS-PMS mix is 
bio-reduced by viable cells into a formazan product that is soluble in tissue culture 
medium (Barltrop et al., 1991, Cory et al., 1991, Riss and Moravec, 1992).  The 
MTS-PMS mix is versatile and offers several advantages over MTT tetrazolium and 
other cytotoxicity assays due to the solubility of the MTS-PMS formazan product in 
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tissue culture medium and its specificity for living cells.  The production of the 
coloured formazan product is thus proportional to the number of viable cells in 
culture.   
 
Briefly, 100 ȝl cells suspension was added at a density of 105 cells per well of 
96-well flat-bottomed tissue culture plates (NUNC, Leicestershire, UK) with either 
3-oxo-C12-HSL, PQS or CsA at concentrations of 100 µM and subsequent half 
dilutions, and incubated for 48 hr at 37
o
C in a humidified, 5% CO2 atmosphere.  
40 µl MTS/PMS solution was then added per 200 µl cell culture for 4 hr at 37
o
C in 
5% CO2-air, protected from light.  The production of formazan was determined by 
measuring the absorbance of the compound at 490 nm with a spectrophotometric 
96-well plate reader (Dynex Technologies, Sussex, UK).  The viability of the cells 
was calculated as follows: 
 
    % viability = ([absorbance of treated cells]/[absorbance of untreated cells]) x 100 
 
2.5. Cytokine determination using ELSIA 
 
The levels of interferon-Ȗ (IFNȖ) and interleukin-4 (IL-4) (BD Pharmingen, UK) 
produced in the murine splenocyte culture supernatants, and the levels of IL-2 (BD 
Pharmingen, UK) produced in the hPBMC and pure T cell culture supernatants after 
24 hr were determined using sandwich Enzyme-Linked Immunosorbent Assay 
(ELISA).  Briefly, 96-well Nunc MaxiSorp (Life Technologies, Paisley, UK) plates 
were coated overnight at 4
o
C with 100 µl of purified anti-cytokine capture antibody 
per well (BD Pharmingen, UK) at 2 µg/ml diluted with binding solution (0.1 M 
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Na2HPO4, adjusted to pH 9 with 0.1 M NaH2PO4).  After washing the plates three 
times with PBS-Tween (Phosphate buffered saline, with 0.5% (v/v) Tween-20 
(Sigma, Poole, UK)), plates were blocked at room temperature (RT) for 2 hr with 
200 µl/well concentration of 1% (w/v) BSA (Sigma, Poole, UK) in PBS.  Following 
four washes with PBS-Tween, 50 µl of cell culture supernatants were added and 
incubated overnight (o/n) at 4
o
C; recombinant cytokines (BD Pharmingen, UK) were 
included as standards for each plate.  After washing the plates four times with 
PBS-Tween, 100 µl/well of biotinylated detection antibody (1:250 dilution) (BD 
Pharmingen, UK) were added at 1 µg/ml for 1 hr at room temperature then washed 
for a further 4 times.  The presence of biotinylated antibodies was detected by the 
addition of 100 µl/well of a 1:1000 dilution streptavidin-peroxidase (BD 
Pharmingen, UK) and 30 min incubation at RT.  After thorough washes the assay 
was developed using 100 µl of 0.1 mg/ml 3,3,5,5-tetramethylbenzidine substrate 
(Sigma, Poole, UK) in 0.05 M phosphate-citrate buffer (pH 5), containing 0.03% 
hydrogen peroxide.  The enzyme reaction was stopped with 50 µl of 2 M sulphuric 
acid (Fisher Scientific Ltd, UK) after an incubation of 15 min at RT, and the 
colorimetric development was read at 450 nm with a spectrophotometric 96-well 
plate reader (Dynex Technologies, Sussex, UK).  Cytokine levels were determined 
by interpolation from the reference standard curve obtained from recombinant 
cytokines. 
 
2.6. Statistical analysis 
 
Statistical analysis all data were performed by applying the parametric, ordinary 
analysis of variance (ANOVA) test, followed by Dunnetts test, comparing each of 
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the treatment groups with control groups.  Probability values (P-value) of <0.001, 
<0.01 or <0.05 were considered significant with 99.9 %, 99 % or 95 % of confidence 
respectively.   All calculations were performed with Sigmastat version 3.5. 
 
Values for 50% inhibitory concentration (IC50) were calculated from nonlinear 
regression analysis by using Graph-Pad Prism version 5 for Windows. 
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3. Assessment of the effect of 3-oxo-C12-HSL, PQS and CsA on 
mouse splenocyte proliferation and cytokine production 
 
3.1. Introduction 
 
The P. aeruginosa signalling molecules 3-oxo-C12-HSL and PQS are known to 
suppress mouse splenocyte proliferation (Chhabra et al., 2003).  In addition, 
3-oxo-C12-HSL is known to affect cell viability at high concentrations (Telford et 
al., 1998, Chhabra et al., 2003, Hooi et al., 2004).  The original report of 
immunomodulation by Telford et al. demonstrated an inhibition in production of the 
Th1 cytokines TNFĮ and IL-12 by murine peritoneal macrophages from BALB/c 
mice stimulated with LPS in vitro by 3-oxo-C12-HSL at concentrations > 70 ȝM 
(Telford et al., 1998).   In contrast, Smith et al. saw a significant induction in the 
production of IFNȖ by 5 ȝM 3-oxo-C12-HSL, at levels similar to those induced by 
the cytokine IL-12, but had no effect on IL-4 production, suggesting 3-oxo-C12-HSL 
induces an inflammatory Th1 phenotype in T cells (Smith et al., 2002).  Moreover, 
Ritchie et al. demonstrated that in vitro exposure to 3-oxo-C12-HSL had a 
suppressive effect on both IFNȖ and IL-4 protein secretion by mitogen and antigen 
stimulation of mouse splenocytes at concentrations ranging from 1-10 ȝM (Ritchie et 
al., 2003). 
 
The aim of this chapter was to confirm the effects of 3-oxo-C12-HSL and PQS on 
mouse splenocytes stimulated with ConA or anti-CD3.  Traditionally, mitogenic 
lectins such as ConA have been used for polyclonal T cell stimulation.  ConA 
activate T cells by binding to cell membrane glycoproteins, including the TCR-CD3 
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complex (Kay, 1991).  ConA is reported to stimulate cytotoxic T cells (Simon et al., 
1986), suppressor inducer T cells (Morimoto et al., 1985), or virgin T cells (Miller 
et al., 1991).  The effects of ConA on activation and proliferation of mature T cells 
are well known and similar to those induced by anti-CD3 antibody, mimicking the 
effects of high avidity of TCR ligation. (Powell and Leon, 1970, Novogrod.A and 
Katchals.E, 1971).  However, a more physiologically relevant approach uses 
anti-CD3 and anti-CD28 to stimulate T cells in a manner that partially mimics 
stimulation by antigen-presenting cells (Trickett and Kwan, 2003).  Anti-CD3 
provides an initial activation signal to T cells, but proliferation is dependent on co-
stimulatory signal, usually via the CD28 molecule (Acuto and Michel, 2003).  
Interestingly, anti-CD28 is not required to stimulate murine lymphocyte 
proliferation.  Studies have demonstrated T cells from CD28-deficient mice are still 
able to produce immune responses to pathogens (Shahinian et al., 1993, Green et al., 
1994) thus anti-CD28 was not used to stimulate murine proliferation in this study.  
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3.2. Methods 
 
To understand the effects of 3-oxo-C12-HSL and PQS on murine splenocytes, cell 
proliferation, viability and cytokine production were examined. 
 
3.2.1. Mouse splenocyte isolation and stimulation 
 
Eight-week-old female BALB/c mice were obtained from Harlan (Bicester, Oxon, 
UK) and given food and water ad libitum.  The ConA (Sigma, Poole, UK) or 
anti-CD3 (BD Pharmingen) proliferation assay was used to assess the effect of 
P. aeruginosa QSSMs (3-oxo-C12-HSL and PQS, provided by Prof. David 
Pritchard, University of Nottingham, UK) and CsA (Sigma, Poole, UK) on 
splenocyte activation and proliferation.  The concentration of ConA (Sigma, Poole, 
UK) and anti-CD3 (BD Pharmingen, UK) that induced optimal spleen cell 
proliferation was determined in preliminary dose response experiments with 
concentrations ranging from 0.03 µg/ml to 4 µg/ml and 0.04 µg/ml to 6 µg/ml 
respectively.  Proliferation was assessed by the incorporation of [
3
H]-thymidine 
(Amersham Biosciences) into DNA.   
 
Splenocyte suspensions were prepared by removing the spleens aseptically and 
placing them in cold RPMI 1640 (Roswell Park Memorial Institute, Sigma, Poole, 
UK).  Briefly, spleens were disrupted by forcing through a 70 ȝM nylon cell strainer 
(BD Biosciences, Europe) with a plunger from a 5 ml syringe to produce a single cell 
suspension in complete cell culture medium (CTCM).  Cells were pelleted by 
centrifugation at 600 x g for 10 min, re-suspended, and erythrocytes lysed by 
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treatment with lysis buffer (0.017 M Tris (Sigma, Poole, UK), 0.144 M ammonium 
chloride buffer (Sigma, Poole, UK), adjusted to pH 7.2) for 5 min at room 
temperature (RT).  Cells were washed in RPMI 1640 medium with 2% (v/v) FCS, 
pelleted by centrifugation and subjected to a second treatment with lysis buffer and 
washed twice before re-suspending in 10 ml CTCM.  Cell density and viability were 
determined using the trypan blue assay.  100 µl cell suspension (10
5
 cells) was added 
per well of 96-well round-bottom tissue culture plates. 
 
3-oxo-C12-HSL, PQS and CsA were tested at final concentrations of 100 µM and 
subsequent half dilutions with either 1 µg/ml ConA or 3 µg/ml anti-CD3.  
Experiments were performed in triplicate wells in a final volume of 200 µl per well.  
After 24 hr incubation at 37
o
C under 5% CO2, 100 µl of cell culture supernatants was 
removed and stored at -20
o
C until required for cytokine analysis.   
 
3.2.2. Proliferation assay 
 
[
3
H]-thymidine incorporation into cells is a convenient method for quantifying cell 
proliferation, reflecting DNA synthesis.  DNA synthesis is measured by 
incorporation of the radioactive exogenous precursor [
3
H]-thymidine into 
proliferating cells.  Briefly, following a further 24 hr incubation cultures were pulsed 
for 24 hr with 10 µl of 0.25 µCi/well 
3
H-thymidine (Amersham Pharmacia Biotech. 
Inc., UK).  Cells were then harvested onto 96-well glass fibre culture (G/F C) plates 
(Unifilter Filtermate Harvester
TM
, Packard Bioscience Ltd, UK) left to dry at 37
o
C, 
followed by the addition of 40 µl scintillant (MicroScint-O
TM
, Packard Bioscience 
Ltd, UK) to each well.  The radioactivity in the filters was measured for 2 min per 
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filter with a ȕ-scintillation counter (TopcountTM, Packard Bioscience Ltd, UK) 
according to manufacturers specification.  The results are expressed as the mean 
cpm of [
3
H]-thymidine incorporated in triplicate cultures ± SD (Appendix 2) and 
mean cpm of all individual data ± SE (main chapter).   
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3.3. Results 
 
3.3.1. Optimisation of assay condition 
 
The dose response of ConA and anti-CD3 were initially assessed stimulating mouse 
splenocytes with 4 ȝM ConA and subsequent half dilutions or 6 ȝM anti-CD3 and 
subsequent half dilutions.  Both ConA and anti-CD3 stimulated cellular proliferation 
in a dose dependent manner.  The optimal dose for ConA was 1 µg/ml (fig. 3.1a), 
while the optimal dose for anti-CD3 was 3 µg/ml (fig. 3.1b).   
 
3.3.2. Effects of QSSMs and CsA on ConA stimulated cell proliferation 
 
Both PQS and 3-oxo-C12-HSL significantly inhibited cell proliferation in a dose 
dependent manner when splenocytes isolated from BALB/c mice spleens were 
stimulated with 1 µg/ml ConA (fig. 3.2a).  PQS exhibited an IC50 value of 
2.3±0.06 µM compared to 6.3±0.4 µM for 3-oxo-C12-HSL. CsA also inhibited 
splenocyte proliferation giving an IC50 value of 2.8±0.7 µM.  DMSO and ethanol 
were used as diluents controls and did not exert any significant effect on the ConA 
stimulated cell proliferation.  
  
3.3.3.  Effects of QSSMs and CsA on anti-CD3 stimulated cell proliferation 
 
As with mouse splenocytes stimulated with ConA, both PQS and 3-oxo-C12-HSL 
inhibited cell proliferation in a dose dependent manner when spleen cells were 
stimulated with 3 µM anti-CD3 (fig. 3.2b).  Similar to the ConA proliferation assays, 
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PQS exhibited an IC50 value of 2.3±0.1 µM compared to that of 5.7±0.4 µM for 
3-oxo-C12-HSL.  CsA also significantly suppressed anti-CD3 driven splenocyte 
proliferation with an IC50 value of 2.1±0.3 µM, similar to the IC50 value of PQS.  
DMSO and ethanol did not exert any significant effect on the cell proliferation. 
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Figure 3.1 
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Figure 3.1.  Stimulatory effect of ConA (a) and anti-CD3 (b) on murine 
splenocyte.  ConA and anti-CD3 stimulated cellular proliferation in a dose 
dependent manner compared to the cell control (untreated cells) with an optimal dose 
of 1 ȝg/ml and 3 ȝg/ml respectively.  Bkg (background) represents readings for 
CTCM.  Data represents the mean of 6 and 4 independent experiments respectively; 
the results of the original experiments are individually plotted in A.2.1 for ConA and 
A.2.2 for anti-CD3.   
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Figure 3.2 
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Figure 3.2.  The effect of P. aeruginosa QSSMs and CsA on ConA (a) and 
anti-CD3 (b) driven splenocyte proliferation.  All three compounds inhibited cell 
proliferation.  (a) PQS gave an IC50 of 2.3±0.06 µM compared to 6.3±0.4 µM for 
3-oxo-C12-HSL and 2.8±0.7 µM for CsA.  (b) Similar to the ConA assay, PQS gave 
and IC50 value of 2.3±0.1 µM compared to 5.7±0.4 µM for 3-oxo-C12-HSL and 
2.1±0.3 µM for CsA.  DMSO and ethanol were used as diluent controls for the 
QSSMs and CsA respectively and had no effect on cell proliferation.  ***P<0.001 
and **P<0.01 compared with the ConA or anti-CD3 control (cells stimulated only 
with ConA (a) or anti-CD3 (b)).  Cell control represents untreated cells.  Data 
represents the mean of independent experiments (n = number of independent 
experiments); the results for the original experiments are individually plotted in 
A.2.3 and A.2.4 respectively.   
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3.3.4. Effect of QSSMs and CsA on murine splenocyte viability 
 
Cytotoxic effects of P. aeruginosa QSSMs on mouse splenocytes were assessed 
before further in vitro tests were carried out.  Concurrent MTS assay data (fig. 3.3) 
illustrated that for both 3-oxo-C12-HSL and PQS, suppression of proliferation was 
evident in the absence of cytotoxicity.  Over 92% of cell survival was seen when 
treated with the selected concentrations of 3-oxo-C12-HSL, over 96% cell survival 
when treated with the selected concentrations of PQS, and 100% cell survival when 
treated with the selected concentrations of CsA compared to the untreated cell 
control.  
 
3.3.5. Cytokine production by spleen cell cultures stimulated with ConA 
and P. aeruginosa QSSMs 
 
To determine whether P. aeruginosa QSSMs mediated suppression affects the 
production of cytokines, the levels of IFNȖ and IL-4 in cultures of splenocytes 
stimulated with ConA alone or in the presence of P. aeruginosa QSSMs were 
determined using the sandwich ELISA technique.  ConA stimulation of splenocytes 
resulted in increased production of IFNȖ and IL-4  423 pg/ml and 53 pg/ml 
respectively (fig. 3.4a and fig. 3.4b).  Both 3-oxo-C12-HSL and PQS significantly 
inhibited IFNȖ production in a dose dependent manner both having similar potency 
shown by the IC50 value obtained  3.5 ȝM and 2.7 ȝM respectively (fig. 3.4a).  
3-oxo-C12-HSL also significantly inhibited IL-4 release in a dose dependent manner 
with an IC50 8.5 µM (fig. 3.4b) in contrast to PQS, which had no significant effect on 
IL-4 production except at 100 µM. 
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Figure 3.3 
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Figure 3.3.  The influence of P. aeruginosa QSSMs and CsA on murine 
splenocyte viability as determined by MTS analysis.  All three compounds had no 
cytotoxic effect on murine splenocytes.  No significant decrease in absorbance was 
noted with any of the test groups.  DMSO and ethanol were used as diluent controls 
for the QSSMs and CsA respectively and did not have any effect on cell viability 
(data not shown).  Cell control represents untreated cells and Bkg (background) 
represents measurement of CTCM alone.  Data represents the mean of independent 
experiments (n = the number of independent experiments); the results of the original 
experiments are individually plotted in A.2.5.   
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Figure 3.4 
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Figure 3.4.  Influence of 3-oxo-C12-HSL and PQS on IFNȖ (a) and IL-4 (b) 
production by ConA stimulated murine splenocytes.  (a) 3-oxo-C12-HSL and 
PQS inhibited IFNȖ release in a dose dependent manner where PQS has an IC50 of 
2.7 µM and 3-oxo-C12-HSL has an IC50 of 3.5 µM.  (b) 3-oxo-C12-HSL inhibited 
IL-4 release in a dose dependent manner with an IC50 of 8.5 µM whereas PQS did 
not significantly inhibit IL-4 release except at 100 µM.  ***P<0.001, **P<0.01 and 
*P<0.05 compared to ConA control (cells treated with only ConA).  Cell control 
represents untreated cells and Bkg (background) represents reading for CTCM.  
Results are the mean of triplicate data.   
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3.3.6. Summary of mouse splenocyte assays 
 
 IC50 
Compounds ConA 
proliferation  
IFNȖ 
production  
IL-4 
production  
ĮCD3 
proliferation  
3-oxo-C12-HSL Inhibition 
6.3±0.4 µM 
Inhibition 
3.5 µM  
Inhibition 
8.5 µM 
Inhibition 
5.7±0.4 µM 
PQS Inhibition 
2.3±0.06 µM 
Inhibition 
2.7 µM 
Inhibits  only 
at 100 ȝM 
Inhibition 
2.3±0.1 µM 
CsA Inhibition   
2.8±0.7 µM 
Not tested Not tested Inhibition       
2.1±0.3 µM 
DMSO No effect No effect No effect No effect 
Ethanol No effect No effect No effect No effect 
 
Table 3.1.  Summary of the effects of QSSMs and CsA on mouse splenocyte 
proliferation and cytokine production.   
 
The proliferation assays indicated that all three compounds inhibited splenocyte 
proliferation.  PQS was the more potent anti-proliferative compound shown by the 
IC50 value of 2.3±0.06 µM compared to 6.3±0.4 µM for 3-oxo-C12-HSL in the 
ConA assay and 2.3±0.1 µM compared to 5.7±0.4 µM in the anti-CD3 proliferation 
assays.  CsA also significantly inhibited ConA and anti-CD3 driven mouse 
splenocytes with IC50 values of 2.8±0.7 µM and 2.1±0.3 µM respectively, similar to 
the IC50 concentrations of PQS.  The MTS assays confirm all three compounds did 
not affect cell viability.  Furthermore, the cytokine assays suggest that even though 
both PQS and 3-oxo-C12-HSL inhibited ConA stimulated splenocyte proliferation, 
they have differential activity with 3-oxo-C12-HSL inhibiting both IFNȖ and IL-4 
release while PQS inhibits IFNȖ production with no significant effect on IL-4 
production.   
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3.4. Discussion 
 
The aim of this chapter was to investigate the effects of 3-oxo-C12-HSL and PQS on 
cell proliferation, viability and cytokine release in mouse splenocyte cells.  
Throughout all the experiments CsA was used as the positive control since its potent 
immunosuppressive properties are similar to that of 3-oxo-C12-HSL, and so that a 
comparable analysis could be made to the potency between these three compounds.  
The concentrations used for the two QSSMs and the incubation time of 48 hr was 
based on previous studies (Chhabra et al., 2003, Hooi et al., 2004), and allowed both 
QSSMs to exert their full effects on the cell types used. 
 
3.4.1. Immunosuppressive effects of 3-oxo-C12-HSL and PQS 
 
The initial experiments determined the comparison between 3-oxo-C12-HSL and 
PQS on BALB/c mice spleen cells, as they were readily available; this allowed for a 
training element and for reproducible, comparative data to be obtained.   
 
The spleen is formed by reticular and lymphatic tissue and is the largest lymph 
organ.  It was the first choice of organ to use in this study due to its cellular material, 
consisting of lymphocytes and macrophages (splenic pulp), red pulp which is part 
suffused with blood and white pulp consisting of areas of lymphatic tissue where 
there are sleeves of lymphocytes and macrophages around the blood vessels.  One of 
the main functions of the spleen is to bring blood into contact with lymphocytes and 
to activate lymphocytes if there is foreign antigen contact.  The richness of immune 
cells,  such as monocytes, leukocytes and macrophages is advantageous to this study. 
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The present results confirm that ConA has the ability to induce mitogenic activity of 
mouse splenocytes in a dose dependent manner (fig. 3.1a).  A typical bell shaped 
course of the ConA dose response curve was obtained representing a proliferative 
response to suboptimal concentration of ConA and a toxic action of ConA at 
supraoptimal concentrations.  The proliferative and suppressive responses of ConA 
has been confirmed by Niks et al. (Niks et al., 1990).  ConA is one of the most 
widely used and well-characterised lectins isolated from Canavalia ensiformis.  
ConA has broad applicability primarily because it recognises a commonly occurring 
sugar structure, Į-linked mannose.  It is a potent mitogen used to stimulate cell 
proliferation in lymphocytes and primary T cells independently of accessory cells 
and activates via the T cell receptor and other cell surface receptors (Powell and 
Leon, 1970, Novogrod.A and Katchals.E, 1971).  ConA has also been shown to 
activate macrophages and neutrophils (Boldt et al., 1975, Cameron et al., 1983) as 
well as stimulate toll-like receptor expression (Sodhi et al., 2007). 
 
Fig. 3.2a. clearly demonstrates that 3-oxo-C12-HSL and PQS, which are in 
hierarchical cascade involved in the regulation of numerous essential P. aeruginosa 
virulence determinants (Passador et al., 1993, Pearson et al., 1994, Diggle et al., 
2003), significantly reduced the ability of splenocytes to respond to ConA (IC50, 
6.3±0.4 µM and 2.3±0.06 µM, respectively).  Although assays involving mitogens do 
not directly correlate with physiological activities of cells, they do provide a first 
indication of the pharmacological activity of test compounds.  It has been shown that 
ConA signals via PTK (Asahi et al., 1993), however, 3-oxo-C12-HSL does not 
inhibit PTK activity (Telford et al., 1998), thus presumably acts at downstream level.  
Further suggestions on the action of 3-oxo-C12-HSL include possible inhibition of 
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interaction with the T cell receptors (TCR) or of autophosphorylation.  It is equally 
conceivable that 3-oxo-C12-HSL acts as, or activates a transcription factor in T cells.   
Optimal activation of human T cells in vivo is ensured by the interaction of specific 
antigen with the T cell receptor (TCR) in the presence of co-stimulatory signals, 
provided for by antigen-presenting cells (APC).   
 
As the frequency of human antigen-specific T cells in PBMCs samples is very low 
and autologous or HLA-match APC are rarely available, stimulation of T cells in 
vitro is often carried out with polyclonal activators such as the lectins PHA or ConA, 
or with the combination of the phorbol ester TPA and calcium ionophore.  Although 
these modes of activation may provide useful information on signalling pathways in 
T cells, they are, from a biological point of view, artificial and not always 
comparable to in vivo stimulation conditions (Yssel et al., 1992, Byun et al., 1994, 
Yang et al., 1995b).  A more physiological relevant mode of activation is stimulation 
of T cells with a combination of a monoclonal antibody (mAb) specific for anti-CD3 
which mimics antigen-mediated TCR/anti-CD3 complex-mediated signalling 
(Reinherz et al., 1982), and a anti-CD28 mAb that provides the required co-
stimulatory signals (Hara et al., 1985, Geppert and Lipsky, 1987, Schwartz, 1990).  
Thus to enhance the biological significance of this study, the effect of QSSMs on 
anti-CD3 driven mouse splenocyte proliferation was examined.   
 
The purified hamster anti-mouse CD3e (CD3İ chain) mAb used reacts with the 
25-kDa İ chain of the T cell receptor-associated CD3 complex, which is expressed 
on thymocytes, mature T-lymphocytes and natural killer T cells.  The cytoplasmic 
domain of anti-CD3 participates in the signal transduction events that activate several 
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cellular biochemical pathways as a result of antigen recognition.  Interestingly, 
anti-CD28 is not required to stimulate IL-2 release and proliferation when using 
murine lymphocytes (Green et al., 1994, Shahinian et al., 1993).  Many studies have 
demonstrated that T cells from CD28-deficient mice are still able to produce immune 
responses to pathogens (Shahinian et al., 1993) and in addition, CD28-deficient 
T cells can be activated in vitro and in vivo, albeit at a lower magnitude than normal 
T cells (Shahinian et al., 1993, Green et al., 1994).   
 
As with ConA, both 3-oxo-C12-HSL and PQS inhibited cell proliferation in a dose 
dependent manner when splenocytes were stimulated to proliferated using 3 ȝg/ml 
anti-CD3.  PQS was a consistently more potent anti-proliferative in this assay with 
an IC50 value of 2.3 ȝM ± 0.1 compared to 5.7±0.4 µM for 3-oxo-C12-HSL 
(fig. 3.2b) similar to that found in the ConA proliferation assay.  In addition, 
[
3
H]-thymidine assays indicate CsA inhibited both ConA and anti-CD3 driven 
splenocyte proliferation with similar potency to PQS  2.8±0.7 µM and 2.1±0.3 µM 
respectively  (fig. 3.2a and b). 
 
A general observation noted that thymidine uptake was lower when splenocytes were 
stimulated with anti-CD3 (between 40000 to 50000 cpm) compared to that of ConA 
(between 55000 to 70000).  The difference in cell count may reflect the specificity of 
anti-CD3 targeting T cells whereas ConA targets a boarder range of receptors. 
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3.4.2. Effects of 3-oxo-C12-HSL and PQS on IFNȖ and IL-4 release from 
mouse splenocytes 
 
To gain further insight into the molecular mechanisms of action of 3-oxo-C12-HSL 
and PQS, the effects of these QSSMs on IFNȖ and IL-4 production on was 
investigated. 
 
The effects of 3-oxo-C12-HSL and PQS on IFNJ and IL-4 production were tested as 
they are markers of T helper 1 (Th1) and T helper 2 (Th2) responses respectively 
(Mosmann et al., 1986, Cherwinski et al., 1987).  Cytokines clearly are important in 
the development of different cytokine-producing Th1 and Th2 cells.  Th1 cells 
produce several characteristic cytokines, most notably IL-12 and IFNȖ, whereas Th2 
cells produce a set of cytokines, most notably IL-4, IL-5 and IL-13.  In turn, IL-2 and 
IFNȖ promote the development of strong cell-mediated immunity, whereas the type 2 
cytokines promote allergic responses effective in eliminating parasites (Kuo and 
Leiden, 1999, Glimcher and Murphy, 2000, Murphy et al., 2000).  Although not 
absolute, one of the most critical elements of determining Th differentiation is the 
cytokine milieu in which the T cell is activated.   
 
Both 3-oxo-C12-HSL and PQS inhibited production of IFNJ in ConA stimulated 
murine leukocytes in a dose dependent manner (fig. 3.4a).  IFNJ production inhibited 
in the presence of 3-oxo-C12-HSL and PQS suggest that it is unlikely that they are 
activating NFțB-dependent pathways in T cells since such activation is associated 
with increased transcription and production of inflammatory mediators such as IFNJ 
(Sica et al., 1992, Sica et al., 1997).  The inhibition of IFNȖ by both QSSMs suggest 
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suppression of T cell activation is via Th1 as IFNȖ is required for the promotion of 
the Th1 linage.  This supports Telford et al.s study in which the authors 
demonstrated reduction of total IL-12 production by LPS-stimulated macrophages, as 
cytokine that directs the generation of a Th1 response via the induction of IFNȖ 
secretion (Telford et al., 1998).  3-oxo-C12-HSL also inhibited IL-4 release while 
PQS had no significant effect on IL-4 production in mouse splenocytes (fig. 3.4b).  
IL-4 is required to stimulate a Th2 response.  The inhibition of IL-4 as well as IFNȖ 
by 3-oxo-C12-HSL suggests this QSSM may suppress T cell response to 
P. aeruginosa infections by inhibiting both Th1 and Th2 activity, or is a less specific 
inhibitor of T cell function.  Ritchie et al. also demonstrated in vitro exposure of 
mouse spleen cells to 3-oxo-C12-HSL had suppressive effects on both IFNȖ and IL-4 
release, however, their in vivo study demonstrated an increase in IFNȖ and IL-4 
production (Ritchie et al., 2003).  This highlights important implications for 
extrapolating in vitro results to models of P. aeruginosa infections. 
 
To conclude, results obtained in this study demonstrates that 3-oxo-C12-HSL and 
PQS exhibit immune suppressive properties in mouse splenocytes, and suggests this 
may be due to suppression of the Th1 pathway  a pathway that is important to the 
clearance of bacteria.  To further understand the effects of P. aeruginosa  quorum 
sensing signalling molecules on human immune cells, this study move on to using 
human peripheral mononuclear cells and pure human T cells isolated from venous 
whole blood, to obtain more biologically relevant data.   
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4. Assessment of the effect 3-oxo-C12-HSL, PQS and CsA on 
hPBMC and pure human T cell proliferation and cytokine 
production 
 
4.1. Introduction 
 
As demonstrated in Chapter 3, 3-oxo-C12-HSL and PQS are immune-suppressive 
with indication that PQS inhibits via the Th1 pathway, while 3-oxo-C12-HSL may 
inhibit both Th1 and Th2 pathways, or is a less specific inhibitor of T cell function.  
The aim of this chapter is to look at the effects of these two QSSMs and CsA on 
more biologically relevant cell types  first on human PBMC and finally on pure 
human T cells.  At each stage, the effect on cell proliferation, viability and cytokine 
release was assessed. 
 
Hooi et al. demonstrated the immune suppressive properties of 3-oxo-C12-HSL and 
PQS on anti-CD3 and anti-CD28 driven human PBMCs.  In addition, it was also 
shown 3-oxo-C12-HSL inhibited TNFĮ release from human PBMCs as also shown 
by Telford et al. in mouse peritoneal macrophages (Telford et al., 1998), and 
inhibited IL-2 production.  In contrast, PQS induced the release of both TNFĮ and 
IL-2 (Hooi et al., 2004), highlighting the differential immune-modulatory activity of 
these two QSSMs.  This differential activity lead the authors to suggest 
3-oxo-C12-HSL may inhibit T cell activity by suppressing upstream of the IL-2 
signalling pathway, while PQS may inhibit downstream of the IL-2 signalling 
pathway, actions reminiscent of the immune-suppressive drugs CsA and rapamycin 
respectively. 
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4.2. Methods 
 
To understand the effects of 3-oxo-C12-HSL and PQS on human PBMC and pure 
T cells, cell proliferation, viability and cytokine production were examined. 
 
x The effects of 3-oxo-C12-HSL and PQS on hPBMC proliferation using 
[
3
H]-thymidine incorporation, viability using MTS-PMS analysis and IL-2 
production using ELISA (chapter 4.2.1). 
x The effects of 3-oxo-C12-HSL and PQS on pure human T cell proliferation 
using [
3
H]-thymidine incorporation and viability using MTS-PMS analysis 
(chapter 4.2.2). 
x The effects of 3-oxo-C12-HSL and PQS on IL-2 production using ELISA and 
IL-2, IL-4, IL-5, IL-10, IFNȖ and TNFĮ production using cytometric bead 
analysis (CBA) in pure T cells (chapter 4.2.3 and section 4.2.4 respectively). 
 
4.2.1. Human Peripheral blood mononuclear cells 
 
4.2.1.1.  hPBMC isolation and stimulation 
 
Blood specimens were obtained with consent from healthy human volunteers age 
ranging from 22 to 45 years.  Human PBMCs were isolated from heparinised 
(100 unit/ml) venous whole blood by buoyant density centrifugation over histopaque 
1077 (Sigma, Poole, UK).  Briefly, blood was diluted to a ratio of 1:1 with CTCM 
and layered gently onto the surface of histopaque 1077 (at a ratio of 1:2 respectively) 
before centrifuging at 450 x g for 20 min at RT.  The upper plasma layer was 
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discarded and using a sterile pipette, the cloudy layer containing the PBMC was 
gently collected and placed in a sterile 20 ml universal tube.  A further 10 ml CTCM 
was added into the PBMC suspension and centrifuged at 600 x g for 10 min before 
repeating the wash.  Finally, the pellet was re-suspended in 1 ml CTCM.  The 
concentration of anti-CD3 and anti-CD28 that induced optimal PBMCs proliferation 
was determined in preliminary dose response experiments with concentration ranging 
0.003 ȝg/ml to 0.4 ȝg/ml and 0.15 ȝg/ml to 20 ȝg/ml respectively.   
 
Cell density was determined using the trypan blue assay and adjusted to 10
6
 cells/ml.  
100 ȝl cell suspension was added per well of 96-well round-bottom tissue culture 
plates.  PBMCs were stimulated with anti-CD3 monoclonal antibody (mAb) 
(0.1 ȝg/ml) and anti-CD28 mAb (5 ȝg/ml), and further stimulated with either 
3-oxo-C12-HSL, PQS and CsA (100 ȝM and subsequent half dilutions).  PBMCs 
were cultured for 24 hr at 37
o
C in 5% CO2.  Control cells were performed, 
stimulating PBMCs with only ĮCD3 and ĮCD28 or resting PBMCs (non-stimulated).  
100 ȝl of cell culture supernatants was removed and stored at -20oC until required for 
cytokine analysis after 24 hr.  Cells were then incubated for a further 24 hr at 37
o
C. 
 
4.2.1.2. Proliferation assay 
 
After 24 hr, cells were pulsed with 10 µl per well (0.25 µCi) 
3
H-thymidine 
(
3
H-LThy; Amersham, UK) and incubated for 24 hr at 37
o
C in 5% CO2.  Finally, 
cultures were harvested on glass-fibre culture (GF/C) plates (Unifilter Filtermate 
Harvester
TM
, Packard Biosciences Ltd, UK), left to dry at 37
o
C for 2 hr, followed by 
the addition of 40 ȝl scintillant (MicroScint-OTM, Packard Biosciences Ltd, UK) to 
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each well.  Incorporated radioactivity was measured in a liquid scintillation ȕ-counter 
(Topcount
TM
, Packard Bioscience Ltd, UK) according to manufacturers instructions.  
Results are expressed as mean counts per minute (cpm) of triplicate wells ± SD 
(Appendix 2) and mean cpm of all individual data ± SE (main chapter).  Statistical 
analysis was performed applying the parametric, ordinary ANOVA test. 
 
4.2.2. Human T cells 
 
4.2.2.1. T cell isolation 
 
hPBMC cells were isolated as described previously (section 4.2.1.1).  10
7
 cells were 
re-suspended in 10 ml CTCM and centrifuged at 600 x g for 10 min.  Pure human 
T cells were then isolated using the negative selection Human Pan T cell Isolation 
Kit II (Miltenyi Biotec Inc., Surrey, UK) with biotin-conjugated monoclonal 
antibodies against CD14, CD16, CD19, CD36, CD56, CD123 and glycophorin A.   
 
Briefly, after centrifugation of PBMC cells, supernatant was removed completely 
and re-suspended in 40 ȝl of degassed T cell isolation buffer (PBS pH 7.2 
supplemented with 0.5% BSA and 2 mM EDTA), 10 ȝl biotin-antibody cocktail was 
added and mixed well by swinging the universal tube from side to side before 
incubating at 4
o
C for 10 min.  A further 30 ȝl of T cell isolation buffer and 20 ȝl 
anti-biotin microbeads was added, mixing well before incubating at 4
o
C for 15 min.  
Cells were then washed with T cell isolation buffer by adding 10-20 times the 
labelling volume and centrifuging at 300 x g for 10 min at 4oC.  The supernatant was 
completely removed before re-suspending in 500 ȝl of T cell isolation buffer.   
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The magnetically labelled non-T cells are depleted by retaining them on a MACs LS 
column (Miltenyi Biotec Inc., Surrey, UK) in the magnetic field of a MACs 
Separator (Miltenyi Biotec Inc., Surrey, UK), while unlabelled T cells pass through 
the column and are collected.  The MACs LS column was placed in the magnetic 
field of a miniMACs separator.  The column was prepared the column by rinsing 
with 3 ml of T cell isolation buffer.  The cell suspension was then pipetted into the 
column, allowing the cells to pass through completely, collecting the enriched T cell 
fraction into a universal tube.  A further 3 ml of T cell isolation buffer was added 
3 times to the column, collecting the entire effluent representing the enriched T cells 
into the same universal tube.  10 ml of CTCM was added to the enriched T cell 
suspension and centrifuged at 600 x g for 10 min, discarding the supernatant and 
re-suspended in 1 ml CTCM.  Cell density was determined using trypan blue assay. 
 
4.2.2.2. Evaluation of T cell purity using flow cytometry 
 
T cells were isolated and their density determined using trypan blue assay.  10
5
 total 
cells in CTCM were centrifuged at 300 x g for 10 min and supernatant removed 
completely before re-suspending into test tubes using 15 ml T cell isolation buffer 
and centrifuging at 600 x g for 10 min.  The supernatant was removed completely 
and cell pellet re-suspended in 1 ml 0.5% formaldehyde in saline and incubating at 
room temperature for 30 min.  The suspension was then centrifuged at 600 x g for 
10 min, discarding the supernatant before washing twice with PBS supplemented 
with 2% (w/v) FCS and 0.1% (w/v) sodium azide (PBA) and centrifuging at 600 x g 
for 10 min.  The supernatant was discarded and pellet re-suspended in the residue.   
Fluorescence-labelled antibody - CD25-PE (phycoerythrin) 5 ȝl/tube was added to 
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detect T cell activation and CD3-ECD (an energy transfer fluorophore consisting of 
Texas red coupled to PE) 5 ȝl/tube was added to detect T cell purity (DAKO, 
Trappes, France) - and incubated for 45 min away from light.  A further 1 ml of PBA 
was added to the T cells and centrifuged at 600 x g for 10 min.  Finally, the treated 
T cells were re-suspended in 0.5 ml PBA and fluorescence was detected using 
fluorescence-activated cell sorter (FACSCalibur; BD Biosciences, UK) and analysed 
using WinMDI program. 
 
4.2.2.3.  T cell stimulation 
 
The concentration of anti-CD3 and anti-CD28 that induced optimal T cell 
proliferation was determined in preliminary dose response experiments with 
concentration ranging 0.003 ȝg/ml to 0.4 ȝg/ml and 0.15 ȝg/ml to 20 ȝg/ml 
respectively.  T cells were isolated and cell density determined using the trypan blue 
assay.  100 ȝl cell suspension at 106 cells/ml in CTCM was added per well of 96-well 
round-bottom tissue culture plates.  3-oxo-C12-HSL, PQS and CsA were tested at 
final concentrations of 100 ȝM and subsequent half dilutions and cells were 
stimulated with 0.1 ȝl/ml anti-CD3 and 5 ȝg/ml anti-CD28.  T cells were cultured for 
24 hr at 37
o
C in 5% CO2.  Control cells were performed, stimulating T cells with 
only anti-CD3 and anti-CD28 or resting T cells (non-stimulated).  After 24 hr, 100 µl 
of cell culture supernatant was removed and stored at -20
o
C for the cytokine assays, 
and cells incubated for a further 24 hr at 37
o
C. 
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4.2.2.4. Proliferation assay 
 
 After 24 hr, cells were pulsed with 10 ȝl 0.25 ȝCi/well [3H]-thymidine (3H-LThy; 
Amersham, UK) and incubated for 24 hr at 37
o
C in 5% CO2.  Finally, cultures were 
harvested on glass-fibre culture (GF/C) plates (Unifilter Filtermate Harvester
TM
, 
Packard Biosciences Ltd, UK), left to dry at 37
o
C for 2 hr, followed by the addition 
of 40 ȝl scintillant (MicroScint-OTM, Packard Biosciences Ltd, UK) to each well.  
Incorporated radioactivity was measured in a liquid scintillation ȕ-counter 
(Topcount
TM
, Packard Bioscience Ltd, UK) according to manufacturers instructions.  
Results are expressed as mean counts per minute (cpm) of triplicate wells ± SD 
(Appendix 2) and mean cpm of all individual data ± SE (main chapter).  .   
 
4.2.2.5. Cytokine determination using Cytometric Bead Array 
 
Flow cytometry is an analysis tool that allows for the discrimination of different 
particles based on size and colour.  Multiplexing is the simultaneous assay of many 
analytes in a single sample.  The BD
TM
 CBA (BD biosciences, Europe) was chosen 
for this assay.  BD
TM
 CBA employs a series of particles with discrete fluorescence 
intensities to simultaneously detect multiple soluble analytes, and when combined 
with flow cytometry, a multiplexed assay is created.  The BD
TM
 CBA Human 
Th1/Th2 Cytokine Kit (BD biosciences, Europe) was used to quantitatively measure 
IL-2, IL-4, IL-5, IL-10, TNF and IFNȖ protein levels in a single sample.  Alterations 
to the protocol were made and were used to supplement the manufacturers protocol. 
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Firstly, the human Th1/Th2 cytokine standards were prepared.  One vial of 
lyophilized human Th1/Th2 cytokine standards was reconstituted with 200 µl of 
assay diluents (provided in kit) to prepare a 10x bulk standard.  The reconstituted 
standard was allowed to equilibrate for 20 min before agitating the vial to mix 
thoroughly.  The 10x bulk standard was aliquoted to 10 ȝl eppendorfs and stored at 
-20
o
C.  12 x 75 mm FACs tubes (BD Biosciences, Europe) were labelled and 
arranged in the following order: Top Standard, 1:2, 1:4, 1:8, 1:16, 1:32, 1:64, 1:128, 
and 1:256.  90 µl of assay diluents was added to the top standard tube while 30 µl of 
assay diluents was added to each of the remaining tube.  10 µl of 10x bulk standard 
was then transferred to the top standard tube and mixed thoroughly by inverting tube.  
Serial dilutions followed by transferring 30 µl from the top standard to the 1:2 
dilution tube and mixed thoroughly before transferring 30 µl from the 1:2 tube to 1:4 
tube and so on to the 1:256 tube mixing thoroughly each time.  The assay diluents 
reagent served as the negative control. 
 
Next, mixed human Th1/Th2 cytokine capture beads were prepared.  The capture 
beads are bottled individually (i.e. each cytokine in a different bottle) and needed to 
be pooled together immediately before use.  The number of assay tubes including 
standards and controls was determined and labelled.  The capture bead suspension 
was vigorously vortexed for a few seconds before use.  3 µl aliquot of each capture 
bead for each assay tube to be analysed was added to a single tube labelled mixed 
capture beads and vortexed to mix thoroughly.  15 µl of the mixed capture beads 
was added to the appropriate assay tubes followed by 15 µl of the human Th1/Th2 
PE detection reagent (included in the kit).  15 µl of the human Th1/Th2 cytokine 
standard dilutions was then added to the control assay tubes while 15 µl of T cell 
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supernatant test samples was added to the test assay tubes.  The assay tubes were 
incubated for 3 hr at room temperature and protected from direct exposure to light 
before washing with 500 ȝl of wash buffer (included in kit) and centrifuged at 
200 x g for 5 min.  The supernatant was carefully aspirated and discarded from each 
assay tube and the bead pellets re-suspended in 300 µl of wash buffer before reading 
on a flow cytometer.  Results were analysed using the BD CBA software (BD 
biosciences, Europe). 
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4.3. Results 
 
4.3.1. Human PBMCs  
 
4.3.1.1. Optimisation of assay condition 
 
The dose response of anti-CD3 and anti-CD28 were initially assessed stimulating 
human PBMC with 0.4 ȝg/ml anti-CD3 and subsequent half dilutions with 20 ȝg/ml 
anti-CD28 and subsequent half dilutions.  Results indicated anti-CD3 and anti-CD28 
stimulated cellular proliferation in a dose dependant manner.  The optimal dose for 
anti-CD3 and anti-CD28 is 0.1 µg/ml and 5 µg/ml respectively (fig. 4.1).  The 
optimal dose of anti-CD3 and anti-CD28 was used to stimulate cell proliferation to 
test the effects of P. aeruginosa QSSMs on hPBMC cells. 
 
4.3.1.2. Effects of QSSMs and CsA on hPBMC proliferation 
 
3-oxo-C12-HSL and PQS inhibited human PBMC proliferation in a dose dependent 
manner when stimulated with 0.1 ȝg/ml anti-CD3 and 5 ȝg/ml anti-CD28 antibodies 
(fig. 4.2).  PQS gave an IC50 value of 3.5±0.34 µM compared to 42.4±4 µM for 
3-oxo-C12-HSL.  CsA also suppressed cell proliferation with an IC50 value of 
5.1±0.35 µM.  DMSO and ethanol were used as diluent controls to the QSSMs and 
CsA respectively and had no significant effect on cell proliferation. 
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4.3.1.3. Effects of QSSMs and CsA on hPBMC viability   
 
PQS and CsA had no significant cytotoxic effect on human PBMC viability 
(fig. 4.3).  Over 97% of cells survived when treated with the selected concentrations 
of PQS, and over 80% of cells survived when treated with the selected 
concentrations of CsA.  Over 97% of cells survived when treated with  12.5 ȝM 
3-oxo-C12-HSL.  83% of cells survived when treated with 25 ȝM 3-oxo-C12-HSL, 
and less than 65% of cells survived when treated with  50 ȝM 3-oxo-C12-HSL. 
 
4.3.1.4. IL-2 production by human PBMC cell cultures stimulated with 
anti-CD3 and anti-CD28 and P. aeruginosa QSSMs or CsA 
 
To determine whether P. aeruginosa QSSMs mediated hPBMC suppression affects 
IL-2 production, the levels of IL-2 in cultures of hPBMC stimulated with anti-CD3 
and anti-CD28 alone or in the presence of QSSMs was assessed by ELISA.  
Anti-CD3 and anti-CD28 stimulation of hPBMCs resulted in increased IL-2 release 
- 1210±125 pg/ml compared to untreated cell control (8.3±1.2 pg/ml)  (fig. 4.4).  
3-oxo-C12-HSL inhibited the release of IL-2 giving an IC50 value of 18±4 µM while 
PQS had no significant effect on Il-2 production.  The presence of IL-2 was also seen 
in the CsA assay giving levels of IL-2 present similar to the anti-CD3/28 control 
(cells treated with anti-CD3 and anti-CD28 only) (fig. 4.4). 
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Figure 4.1 
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Figure 4.1. Stimulatory effect of anti-CD3 and anti-CD28 on human PBMC 
proliferation.  Anti-CD3 and anti-CD28 stimulated cellular proliferation in a dose 
dependent manner with an optimal dose of 0.1 µg/ml and 5 µg/ml respectively.  
1 = 0.003/0.15 ȝg/ml, 2 = 0.006/0.312 ȝg/ml, 3 = 0.012/0.62 ȝg/ml, 4 = 0.025/1.25 
ȝg/ml, 5 = 0.05/2.5 ȝg/ml, 6 = 0.1/5 ȝg/ml, 7 = 0.2/10 ȝg/ml and 8 = 0.4/20 ȝg/ml of 
anti-CD3/28.  Data represents the mean of 4 independent experiments; results of the 
original experiments are individually plotted in A.2.6.   
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Figure 4.2 
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Figure 4.2.  The effect of P. aeruginosa QSSMs and CsA on anti-CD3 and 
anti-CD28 driven hPBMC proliferation.  3-oxo-C12-HSL, PQS and CsA inhibited 
cell proliferation.  DMSO and ethanol were used as diluents controls for the QSSMs 
and CsA respectively and had no effect on cell proliferation.  ***P<0.001, **P<0.01 
and *P<0.05 compared with the anti-CD3/28 control.  Cells control represents 
untreated cells.  Data represents the mean of independent experiments (n = number 
of independent experiments); the results of the original experiments are individually 
plotted in A.2.7.   
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Figure 4.3 
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Figure 4.3.  The effect of P. aeruginosa QSSMs and CsA on hPBMC viability.  
3-oxo-C12-HSL inhibited cell proliferation before cell viability was affected while 
with PQS and CsA, immune suppression was evident in the absence of cytotoxicity.  
**P<0.01 compared to the untreated cell control.  Data represents the mean of 6 
independent experiments; the results of the original experiments are individually 
plotted in A.2.8.   
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Figure 4.4 
Concentrations of compounds (PM)
0.1 1 10 100
R
el
ea
se
 o
f 
IL
-2
 (
p
g
/m
l±
S
E
)
0
200
400
600
800
1000
1200
1400
1600
1800
2000
2200
C
el
ls
an
ti-
C
D
3/
28
B
kg
***
***
*
*
**
*
*
** ** **
**
 
 
Key: 3-oxo-C12-HSL;     , PQS;     , CsA;     ,  
 
Figure 4.4.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-2 
from hPBMC cells determined by ELISA.  3-oxo-C12-HSL inhibited IL-2 release 
whereas PQS had no significant effect on the release of IL-2.  CsA also significantly 
inhibited IL-2 release.  ***P<0.001, **P<0.01, *P<0.05 compared to the 
anti-CD3/28 control (cells treated only with antibodies).  Cell control represents 
untreated cells and Bkg (background) represents readings for CTCM.  Data 
represents the mean of 5 independent experiments; the results of the original 
experiments are individually plotted in A.2.9.   
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4.3.1.5. Summary of human PBMC assays 
 
 IC50 
Compounds Anti-CD3 and anti-CD28 
proliferation  
IL-2 production 
 
3-oxo-C12-HSL Inhibition  
42.4±4 µM 
Inhibition 
18±4 µM 
PQS Inhibition 
3.5±0.34 µM 
No significant effect  
CsA Inhibition  
5.1±0.35 µM 
Inhibits at all concentration 
DMSO No significant effect No significant effect 
Ethanol No significant effect No significant effect 
 
Table 4.1.  Summary of the effects of QSSMs and CsA on hPBMC proliferation 
and cytokine production. 
 
The establishment of reproducible data for the effects of QSSMs on human 
leukocytes in culture is seen.  PQS inhibits proliferation of hPBMC without affecting 
cell viability, while 3-oxo-C12-HSL is also immunosuppressive to PBMCs with an 
immunosuppressive window of 28.5±2.1 µM.  At high concentrations, 
3-oxo-C12-HSL causes cell death.  Cytokine assays confirm the differential activity 
of both QSSMs.  This allowed progression to looking at the effects of these two 
QSSMs on purified T cells. 
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4.3.2. Pure human T cell 
 
4.3.2.1. Evaluation of the purity and activity of isolated human T cells 
 
FACs analysis was used to detect the percentage of pure T cells isolated and their 
state of activation.  Fig. 4.5a shows inactive hPBMC cell mixture, while fig. 4.5b 
indicates 93% of inactive pure T cells were present. 
 
4.3.2.2. Pure human T cell proliferation following stimulation with 
anti-CD3 and anti-CD28 and P. aeruginosa QSSMs or CsA 
 
3-oxo-C12-HSL and PQS inhibited T cell proliferation in a dose dependent manner 
when stimulated to proliferate with 0.1 ȝg/ml anti-CD3 and 5 ȝg/ml anti-CD28 
antibodies (fig. 4.6a).  PQS and 3-oxo-C12-HSL have IC50 values of 3.8±0.15 µM 
and 19±1.62 µM respectively.  The positive control, CsA was also found to inhibit 
proliferation with an IC50 value of 3.2±0.31 µM.   
 
4.3.2.3. Effects of QSSMs and CsA on T cell viability 
 
The cytotoxic effects of these P. aeruginosa QSSMs on human T cells was also 
tested using the MTS assay (fig. 4.6b).  Results indicate PQS and CsA did not affect 
T cell viability at the concentrations and incubation times tested (over 96% and 95% 
cell survival respectively).  In contrast, 3-oxo-C12-HSL did not affect cell viability at 
low concentrations, but caused cell death at high concentrations.  90% of cells 
survived when treated with  12 ȝM 3-oxo-C12-HSL, 85% cells survived when 
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treated with 25 ȝM 3-oxo-C12-HSL, and fewer than 76% of cells survived when 
treated with  50 ȝM 3-oxo-C12-HSL. 
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Figure 4.5 
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Figure 4.5.  Assessment of T cell activation and purity using FACs analysis.  
Total PBMC cells (a) and T cells (b) were isolated and treated with CD25-PE to 
detect cell activation and CD3-ECD to detect T cell purity.  Graph (a) indicates 
human PBMC cell mixture while graph (b) shows the proportion of pure human 
T cells isolated.  hPBMCs and T cells were isolated in their inactive form.  Purified 
T cells were 93% pure. 
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Figure 4.6 
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Figure 4.6. The effect of P. aeruginosa QSSMs and CsA on anti-CD3 and 
anti-CD28 driven pure human T cell proliferation (a) and viability (b).  
(a) 3-oxo-C12-HSL, PQS and CsA inhibited T cell proliferation.  
(b) 3-oxo-C12-HSL inhibited cell proliferation before cell viability was affected 
while with PQS and CsA, immune suppression was evident in the absence of 
cytotoxicity.  DMSO and ethanol were used as diluent controls for the QSSMs and 
CsA respectively and had no effect on cell proliferation nor were they cytotoxic to 
the T cells.  ***P<0.001, **P<0.01 and *P<0.05 compared with the anti-CD3/28 
control (cells treated with anti-CD3 and anti-CD28 only).  Data represents the mean 
of 7 independent experiments for the proliferative assay and 6 independent 
experiments for the viability assay; the results of the original experiments are 
individually plotted in A.2.10 and A.2.11 respectively. 
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4.3.2.4. Cytokine production by pure human T cell cultures 
 
To determine the effect of P. aeruginosa QSSMs mediated T cell suppression on the 
production of IL-2, the levels of IL-2 in cultures of T cells stimulated with anti-CD3 
and anti-CD28 alone or in the presence of 3-oxo-C12-HSL or PQS was assessed by 
ELISA and CBA.  Anti-CD3 and anti-CD28 stimulation of T cells resulted in 
increased production of IL-2  2480±200 pg/ml compared to untreated cell control of 
52±10 pg/ml for the ELISA assay (fig. 4.7a), and this was further confirmed with the 
CBA assays (1925±105 pg/ml compared to the untreated cell control of 41±19 pg/ml, 
fig. 4.7b).  3-oxo-C12-HSL inhibited IL-2 release giving an IC50 value of 
15.7±4.1 µM using the ELISA technique and 28.5±0.5 µM using the CBA kit, while 
PQS significantly enhance IL-2 production above 25 µM for both the ELISA assay 
and CBA assay (fig. 4.7a and b).  CsA also significantly suppressed IL-2 production 
at all the concentrations tested. 
 
The release of IFNȖ and IL-4 was also assessed in T cells treated with the QSSMs 
and CsA by CBA.  3-oxo-C12-HSL appears to inhibit IFNȖ production at 50 ȝM and 
100 ȝM while CsA appears to suppress IFNȖ production in a dose dependent manner 
with an IC50 value of 17 ȝM.  The concentrations of IFNȖ obtained for the PQS 
treated cells exceeded the maximum concentration that could be analysed 
(> 5000 pg/ml) using the CBA kit.  The concentration of IFNȖ detected for the 
anti-CD3/anti-CD28 control also exceeded the maximum concentration therefore 
statistical analysis could not be calculated for this assay (fig. 4.8). 
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3-oxo-C12-HSL also significantly inhibited IL-4 release giving an IC50 value of 
25±5 µM (fig. 4.9) when compared to the anti-CD3 and anti-CD28 control, while 
PQS inhibited IL-4 production only at 3.12 ȝM.  CsA significantly inhibited IL-4 
release at all the concentrations tested (fig. 4.9). 
 
3-oxo-C12-HSL also inhibited the release of IL-5 giving an IC50 of 26±1 µM 
(fig. 4.10) while CsA significantly suppressed IL-5 production in a dose dependent 
manner giving an IC50 value of 1.35±0.05 µM.  PQS had no effect on IL-5 
production.   
 
In addition, 3-oxo-C12-HSL suppressed IL-10 production with an IC50 value of 
36±3 µM, whereas PQS significantly inhibited IL-10 release only at 1.6 ȝM and 
3.12 ȝM.  CsA significantly inhibited IL-10 release with near total inhibition at 
higher concentrations giving an IC50 value of 3.5±0.7 ȝM (fig. 4.11). 
 
Finally, the effect of the QSSMs and CsA on TNFĮ release was assessed by CBA.  
3-oxo-C12-HSL inhibited TNFĮ production as the concentration increased giving an 
IC50 value of 23±7 µM while PQS significantly enhanced the release of TNFĮ at 
concentrations  25 ȝM.  CsA also significantly inhibited TNFĮ release with an IC50 
of 9.7±8.2 µM (fig. 4.12). 
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Figure 4.7. 
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Figure 4.7. The effect of P. aeruginosa QSSMs and CsA on the release of IL-2 
from pure human T cells using the sandwich ELISA technique (a) and CBA 
technique (b).  3-oxo-C12-HSL inhibited IL-2 release while PQS significantly 
enhanced the release of IL-2 shown using both the ELISA and CBA techniques.  
(a) The IC50 value obtained for 3-oxo-C12-HSL was 15.7±4.1 µM, while PQS 
stimulated the release of IL-2 at concentrations above 25 ȝM.  (b) The IC50 obtained 
for 3-oxo-C12-HSL was 28.5±0.5 µM, while PQS stimulated the release of IL-2 at 
concentrations  25 ȝM.  Significantly low levels of IL-2 were also found in T cells 
harvested with cyclosporin A.  ***P<0.001, **P<0.01 and *P<0.05 compared with 
the anti-CD3/28 control (cells treated with anti-CD3 and anti-CD28 only).  Cells 
represent untreated cells and CTCM represents background readings.  Results 
represent the mean of 6 independent experiments for the ELISA assays and 2 
independent experiments for the CBA assays.  The results of the original experiments 
are individually plotted in A.2.12 and A.2.13 respectively. 
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Figure 4.8. 
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Figure 4.8.  The effect of P. aeruginosa QSSMs and CsA on the release of IFNȖ 
from pure human T cells using CBA technique.  The lower concentrations of 
3-oxo-C12-HSL ( 12 µM) and all concentrations of PQS contained a quantity of 
IFNȖ that exceeded the maximum concentration that could be analysed 
(> 5000 pg/ml).  Higher concentrations of 3-oxo-C12-HSL and CsA appear to inhibit 
IFNȖ release in a dose dependent manner.  As the anti-CD3/28 control (cells treated 
with anti-CD3 and anti-CD28 only) reached over the array limit, it was difficult to 
apply meaningful statistical analysis to this set of results.  Cells represent untreated 
cells and CTCM represents background readings.  Data represents the mean of 2 
independent experiments (A.2.14).   
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Figure 4.9. 
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Figure 4.9.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-4 
from pure human T cells using CBA technique.  3-oxo-C12-HSL significantly 
inhibited IL-4 release with an IC50 value of 25±5 µM while PQS had no significant 
effect on the release of IL-4.  CsA significantly inhibited IL-4 release and all 
concentrations tested.  ***P<0.001, *P<0.05 compared with the anti-CD3/28 control 
(cells treated with anti-CD3 and anti-CD28 only).  Cells represent untreated cells and 
CTCM represents background readings.  Data represents the mean of 2 independent 
experiments (A.2.15).   
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Figure 4.10. 
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Figure 4.10.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-5 
from pure human T cells using CBA technique.  3-oxo-C12-HSL significantly 
inhibited IL-5 release with an IC50 value of 26±1 µM whereas PQS had no 
significant effect on the release of IL-5.  CsA inhibited IL-5 release in a dose 
dependent manner giving an IC50 value of 1.35±0.05 µM.  ***P<0.001, **P<0.01 
and *P<0.05 compared with the anti-CD3/28 control (cells treated with anti-CD3 and 
anti-CD28 only).  Cells represent untreated cells and CTCM represents background 
readings.  Data represents the mean of 2 independent experiments (A.2.16).   
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Figure 4.11. 
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Figure 4.11.  The effect of P. aeruginosa QSSMs CsA on the release of IL-10 
from pure human T cells using CBA technique.  3-oxo-C12-HSL significantly 
inhibited IL-10 release at concentrations with an IC50 of 36±3 µM while PQS 
significantly inhibited IL-10 release only at 3.12 µM.  CsA also inhibited the release 
of IL-10 giving an IC50 value of 3.5±0.7 µM.  ***P<0.001, *P<0.05 compared with 
the anti-CD3/28 control (cells treated with anti-CD3 and anti-CD28 only).  Cells 
represent untreated cells and CTCM represents background readings.  Data is 
represents the mean of 2 independent experiments (A.2.17).   
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Figure 4.12. 
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Figure 4.12.  The effect of P. aeruginosa QSSMs and CsA on the release of 
TNFĮ from pure human T cells using CBA technique.  3-oxo-C12-HSL 
significantly inhibited the release of TNFĮ in a dose dependent manner with an IC50 
of 23±7 µM whereas PQS enhanced the release of TNFĮ at concentrations  25 ȝM.  
CsA also inhibited TNFĮ release giving an IC50 value of 9.75±8.2 µM.  ***P<0.001, 
**P<0.01, *P<0.05 compared with the anti-CD3/28 control (cells treated with anti-
CD3 and anti-CD28 only).  Cells represent untreated cells and CTCM represents 
background readings.  Data represents the mean of 2 independent experiments 
(A.2.18).   
Chapter 4                                                                                                                   
 - 115 -
4.3.2.5. Summary of pure T cell assays 
 
 IC50 
Compounds Anti-CD3 and anti-CD28 proliferation  
3-oxo-C12-HSL Inhibition          19±1.62 µM 
PQS Inhibition          3.8±0.15 µM  
CsA Inhibition          3.2±0.31 µM 
DMSO No effect 
Ethanol No effect 
 
Table 4.2.  Summary of the effect of QSSMs and CsA on pure human T cell 
proliferation. 
 
 IC50 
Cytokines PQS              3-oxo-C12-HSL  CsA              
IL-2 (ELISA) Enhanced release  
 25 ȝM 
Inhibition 
15.7±4.1 µM 
Inhibits at all 
concentrations 
IL-2 (CBA) Enhanced release 
 25 ȝM 
Inhibition 
28.5±0.5 µM 
Inhibits at all 
concentrations 
IL-4 (CBA) Inhibition only at 
3.12 ȝM 
Inhibition 
25±5 µM 
Inhibits at all 
concentrations 
IL-5 (CBA) No effect Inhibition 
26±1 µM 
Inhibition 
1.35±0.7 µM 
IL10 (CBA) Inhibition only at 
1.6 ȝM  & 3.12 ȝM
Inhibition 
36±3 µM 
Inhibition 
IC50 = 2.75 
IFNȖ (CBA) Inconclusive Inhibition at high 
concentrations 
Inhibition 
17 ȝM 
TNFĮ (CBA) Enhanced release 
 25 ȝM 
Inhibition 
23±7 µM 
Inhibition 
9.75±8.2 µM 
 
Table 4.3. Summary of the differential effects of 3-oxo-C12-HSL, PQS and CsA 
on Th1/Th2 cytokine release.   
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Both 3-oxo-C12-HSL and PQS inhibited pure T cell proliferation with IC50 values of 
19±1.62 µM and 3.8±0.15 µM respectively.  PQS had suppressed T cell proliferation 
without causing cell death (> 96% cell survival at all PQS concentrations tested) 
while 3-oxo-C12-HSL inhibited proliferation before cell viability was affected 
(< 85% cell survival at  25 µM of 3-oxo-C12-HSL).  CsA also inhibited T cell 
proliferation giving an IC50 of 3.2±0.31 µM  similar to that of PQS. 
 
3-oxo-C12-HSL inhibited all six cytokines tested where the IC50 value obtained for 
IL-2 is similar to that obtained for the proliferation assay (IC50 value of 
19±1.62 µM).  IL-4, IL-5, IL-10 and IFNȖ were also inhibited by 3-oxo-C12-HSL.  
In contrast, PQS had significantly enhanced IL-2 and TNFĮ release but inhibited IL-
4 and IL-10 at low concentrations, had no effect on IL-5.  The positive control, CsA 
also significantly inhibited all six cytokines where IC50 values were obtained for 
IFNȖ, IL-5, IL-10 and TNFĮ.  No IC50 values were obtained for IL-2 and IL-4, as the 
concentrations of these cytokines were similar throughout the CsA concentration 
range. 
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4.4. Discussion 
 
The aim of this chapter was to investigate the effects of 3-oxo-C12-HSL and PQS on 
more biologically relevant cells.  The effects of these two QSSMs on human PBMC 
and pure T cell proliferation, viability and cytokine release was therefore examined.  
Several reports have focused on the immune modulatory effects of these two QSSMs 
on mouse splenocytes and human PBMCs but this is the first time their effects have 
been shown in pure human T cells.  As with the mouse splenocyte experiments 
(chapter 3), CsA was used as the positive control for these human immune cell 
assays.  The concentrations used for the two QSSMs and the incubation time of 48 hr 
was based on previous studies (Chhabra et al., 2003, Hooi et al., 2004), and allowed 
both QSSMs to exert their full effects on the cell types used.  The concentration and 
incubation times of CsA were the same as for the QSSMs so that comparable results 
can be obtained.   
 
4.4.1. Immunosuppressive effects of 3-oxo-C12-HSL and PQS 
 
Human PBMCs and pure T cells were isolated from whole blood donated by healthy 
individuals.  Human PBMCs and pure T cells were stimulated to proliferate and 
release IL-2 using anti-CD3 and anti-CD28.  Engagement of the T cell receptor 
(TCR)/CD3 complex are involved in signal transduction (Clevers et al., 1988), and 
anti-CD28 is particularly potent in enhancing lymphokine production (Thompson et 
al., 1989).  The CD28 receptor is expressed on the surface of most mature T cells; it 
is found on  approximately 95% of CD4
+
 and on 50% CD8
+
 T cells (Damle et al., 
1983).  Studies have shown that co-stimulation of CD3 with CD28 leads to complete 
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activation of T cells and a dramatic up-regulation of IL-2 expression mediated by 
both enhanced transcription and induction of mRNA stabilisation (Fraser et al., 1991, 
Lindsten et al., 1989), confirming the requirement of anti-CD3 and anti-CD28 
monoclonal antibodies for T cell activation in this present research.   
 
In the human immune system, activation of the T lymphocyte upon recognition of 
foreign antigen and presentation of the foreign fragment and MHC class to the TCR 
via APCs, another protein is brought into the receptor complex: the CD4 or CD8 
molecule depending on the type of foreign fragment.  CD4 binds MHC class II 
molecules and therefore participates in the response to antigen by inducer T cells, 
whereas CD8 binds MHC class I molecules, and therefore participates in the 
response to antigen by cytotoxic T cells (Swain, 1983).  These accessory molecules 
are not always essential for antigen responsiveness as past studies have shown 
activation of T cells occurs in the absent of CD4 or CD8 binding (Macdonald et al., 
1982).  Instead, they are thought to facilitate the response of T cells bearing receptors 
with low affinity for the peptide-MHC complex by increasing the avidity of the 
T cell for the APC, by altering the signalling portion of the antigen receptor to 
decrease the occupancy required for signal transduction, or by transmitting a separate 
synergising signal (Eichmann et al., 1987), therefore the addition of these molecules 
were not required for T cells activation in this study. 
 
Both 3-oxo-C12-HSL and PQS, as well as the positive control CsA, suppressed 
human PBMC and pure T cells proliferation (fig. 4.2 and fig. 4.6a respectively).  
PQS was the more potent anti-proliferative compared to 3-oxo-C12-HSL as indicated 
by the IC50 values obtained, 3.4±0.34 µM and 42.4±4 µM respectively for the human 
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PBMC assay and 3.8±0.15 µM and 19±1.62 µM respectively for the pure T cell 
assays.  This supports previous studies demonstrating the immune-suppressive 
properties of these two QSSMs on human PBMCs (Hooi et al., 2004), and this is the 
first time their immune-suppressive properties have been shown in pure human T 
cells.  The immunosuppressive drug CsA gave IC50 values similar to PQS  
5.1±0.35 µM in the human PBMC assays and 3.2±0.31 µM in the pure T cell assay.  
Therefore, even though 3-oxo-C12-HSL appears to exhibit a similar mode of action 
to CsA (Hooi et al., 2004), PQS seems to have a similar potency to CsA.   
 
Previous studies have looked at the effects of CsA on human T cell proliferation.  
Umland et al. noticed that stimulation in the presence or absence of anti-CD28 
resulted in distinctly different responses to CsA.  Almost complete inhibition of 
proliferation was seen with anti-CD3-stimulated T cells in the presence of 
> 100 ng/ml CsA with an IC50 of 10 ng/ml.  In contrast, when T cells were stimulated 
with both anti-CD3 and anti-CD28, there was at least a 10 fold decrease in potency 
of CsA compared with that of T cells stimulated with anti-CD3 alone (Umland et al., 
1999).  Additionally, Nishiyama S et al. reported 10 ng/ml of CsA reduced T cell 
proliferation by 50% compared to anti-CD3 and anti-CD28 stimulated T cells 
without the addition of CsA (Nishiyama et al., 2005).  The decrease in CsA potency 
to anti-CD3 and anti-CD28 stimulated cell proliferation may be due to proliferation 
induced by the CD28 pathway is resistant to CsA (June et al., 1987). 
 
The differences in IC50 values obtained between human PBMCs and pure T cells 
assays, especially seen with 3-oxo-C12-HSL, may reflect the ability of the QSSMs to 
concentrate on targeting the signalling pathways involved in T cell proliferation and 
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the ability to calculate a more precise value because of the purity of the T cells 
isolated (93%, fig. 4.5).   
 
MTS assay data illustrates 3-oxo-C12-HSL suppressed cell proliferation before cell 
viability was affected, whereas PQS and CsA inhibited human PBMC and pure 
T cell proliferation in the absence of cytotoxicity (fig. 4.3 and 4.6b respectively).  
The reduction of cell proliferation was therefore due to an inhibitory effect by the 
QSSMs and not cell death.  In addition, an increase in absorbance was observed 
when cells were treated with high concentrations of PQS.  Since PQS was shown to 
inhibit T cell proliferation, the increase in absorbance was therefore not due to an 
increase in viable cell concentration.  There are several explanations for this.  PQS at 
high concentrations may cause the increase in absorbance itself, therefore, for future 
reference, extra controls should be included in this study, for example, testing the 
absorbance of medium with the different concentrations of PQS to compare with the 
absorbance of cells treated with PQS.  In addition, PQS may have caused in increase 
in metabolism in the cells.  The MTS/PMS assay relies on the CellTiter colourless 
reagent being reduced by viable cells into a coloured compound.  However, if PQS 
caused an increase in cellular metabolism, more of the CellTiter reagent being 
reduced by cells can be seen without an actual increase in the number of viable cells. 
 
4.4.2. Effects of 3-oxo-C12-HSL and PQS on T cell cytokine release 
 
To gain further insight into the molecular mechanisms of action of 3-oxo-C12-HSL 
and PQS, the effects of these QSSMs on cytokine production in T cell proliferation 
was investigated. 
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As one of the hallmarks of T cells activation by engagement of TCR/CD3 complex 
and CD28 is the production and release of IL-2, the levels of IL-2 released from 
anti-CD3 and anti-CD28-stimulated human PBMC and pure T cells in the presence 
of the QSSMs and CsA were tested to further confirm the activation of T cells by 
anti-CD3 and anti-CD28. 
 
Activated T cells induce mRNA for IL-2 and produce IL-2 protein; secreted IL-2 
successfully induces T cell proliferation by binding to the IL-2 receptor present on 
activated T cells (Geppert and Lipsky, 1987, Meuer et al., 1984).  Results indicate 
PQS, in contrast to 3-oxo-C12-HSL, did not inhibit the release of IL-2 in both human 
PBMC and pure human T cells (fig. 4.4 and 4.7 respectively).  Indeed, PQS induced 
a small but significant increase in the release of IL-2 above the anti-CD3 and 
anti-CD28 control stimulations while still inhibiting cell proliferation in the pure 
human T cell assay, suggesting a cytostatic effect and supporting previous suggestion 
that PQS active proximately to the IL-2R or downstream of the IL-2R in the T cell 
signalling pathway.  3-oxo-C12-HSL inhibited the release of IL-2 giving an 
IC50 value of 18±4 µM in the human PBMC assays and 15.7±4.1 µM and 
28.5±0.5 µM in the pure T cell assays using ELISA and CBA analysis respectively, 
supporting the finding that 3-oxo-C12-HSL acts on early T cell events (Ritchie et al., 
2005).  A significant enhancement of IL-2 was not seen in the human PBMC 
compilation graph (fig. 4.4) which may seem to contradict findings by Hooi et al..  
However, a significant increase in IL-2 can be seen in the individual data (A.2.9). 
 
CsA also suppressed IL-2 release in both human PBMC and pure T cell assays.  Past 
studies have demonstrated the inhibitory effect of CsA on IL-2 production.  Landewé 
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et al. showed that 1-100 nM inhibited the production of IL-2 in a concentration-
dependent fashion with an IC50 of approximately 11 nM.  In addition, cloned T cell 
activated with anti-CD3 in the presence o IL-2 and CsA resulted in a concentration 
restoration of proliferative activity to the level of drug-free anti-CD3 induced 
proliferative activity (Landewe et al., 1995).  The reversibility of the CsA-induced 
inhibition of T cell proliferation by IL-2 suggests that inhibition of IL-2 production 
by CsA is responsible for the effect of CsA on T cell proliferation.   
 
Using CBA analysis, 3-oxo-C12-HSL seems to inhibit production of IFNȖ in 
anti-CD3 and anti-CD28 stimulated pure T cells, a cytokine required for the 
promotion of Th1 linage (fig. 4.8), though results were inconclusive for PQS due to 
limitations using the CBA kit.  Nevertheless, inhibition of IFNȖ by 3-oxo-C12-HSL 
does confirm data obtained from mouse splenocyte experiments. In addition, 
3-oxo-C12-HSL also suppressed IL-4 release, a cytokine required to stimulate a Th2 
response, while PQS only inhibited IL-4 production at 3.12 ȝM (fig. 4.9).  The 
inhibition of IFNȖ and IL-4 by 3-oxo-C12-HSL may indicate it is a less specific 
inhibitor of T cells function due to the suppression of both Th1 and Th2 linage, 
compared to PQS which only inhibited IL-4 production at a low concentration and 
was shown to inhibit IFNȖ in mouse splenocytes, suggesting it may suppress T cell 
activation primarily via the Th1 signalling pathway.  CsA also inhibited IFNȖ with 
an IC50 value of 17 ȝM and inhibited IL-4 at the concentrations tested.  Past studies 
have also demonstrated the inhibition of IL-4 and IFNȖ.  Umland et al. showed 
inhibition of IFNȖ and IL-4 by CsA with IC50 concentrations of 40 to 60 ng/ml 
(Umland et al., 1999), however, the concentration of CsA used in their study was 
considerably lower (1-100 ng/ml) than those used in this present study. 
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It was further demonstrated 3-oxo-C12-HSL and CsA suppressed IL-5 production 
with IC50 value of 26±1 µM and 1.35±0.05 µM respectively, while PQS had no effect 
on this cytokine (fig. 4.10).  Inhibition of IL-5, a Th2 cytokine, prevents interaction 
with T lymphocytes to mediate maturation of cytotoxic T cells and further indicates 
the suppression of a Th2 response.  Umland et al. showed that CsA-mediated 
inhibition of IL-5 production by CD4
+
 T cells stimulated with anti-CD3 and anti-
CD28 was biphasic.  CsA concentrations of less than 125 ng/ml, IL-5 levels were 
enhanced above that found in the control cultures.  Concentrations of CsA above 
250 ng/ml were weakly inhibitory (Umland et al., 1999).  The concentrations used in 
this present study were considerably higher ( 0.8 ȝM) and were shown to be 
strongly inhibitory. 
 
In addition, 3-oxo-C12-HSL and PQS both inhibited the release of IL-10 though PQS 
only significantly inhibited this cytokine at 1.6 ȝM and 3.12 ȝM (fig. 4.11).  IL-10 is 
produced in both recently differentiated primary Th1 and Th2 cells, although Th2 
cell produce much higher levels than Th1 cells.  As naïve T cells differentiate to Th1 
and Th2 cells, Th1 cells slowly lose their ability to express IL-10, whereas Th2 cells 
increase IL-10 production and maintain high IL-10 levels.  Furthermore, IL-10 
inhibits Th1 proliferation by suppressing IFNȖ and IL-2 release.  IL-10 also 
stimulates and/or  enhances the proliferation of B cells, thymocytes and mast cells 
(Moore et al., 1993) and enhances the cytotoxic T cell generation (Yang et al., 
1995a).  Inhibition of IL-10 therefore indicates a preference to allow Th1 
proliferation to occur, again suggesting suppression of a Th2 response by 
3-oxo-C12-HSL and to some extent, by PQS.  CsA also suppressed IL-10 release 
with an IC50 of 3.5±0.7 µM.  Rafiq et al. recognized that IL-10 production was 
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strongly, although not completely, blocked by CsA at 400 ng/ml in T cells stimulated 
with anti-CD3 cross-linked on P815/CD80 cells (Rafiq et al., 1998) and is in 
agreement with other published data showing that the immunosuppressive drug CsA 
inhibits IL-10 production in murine T cells in vitro (Tomkins et al., 1995) and in vivo 
(Durez et al., 1993).  Moreover, circulating levels of IL-10 were suppressed by 
treatment with CsA in patients with rheumatoid arthritis (Ferraccioli et al., 1998). 
 
Further differential immune modulatory activity was observed when TNFĮ secretion 
was inhibited by 3-oxo-C12-HSL and CsA yet PQS had a stimulatory effect 
(fig. 4.12).  Previous studies have demonstrated intracheal infection of mice with 
P. aeruginosa leads to up-regulation of TNFĮ mRNA expression and enhanced 
secretion of TNFĮ protein into the alveolar space, and were associated with host 
resistance to infection, suggesting that TNFĮ may represent an important genetically 
regulated early defence signal crucial for the outcome of acute infection with 
P. aeruginosa.  This was further supported by the finding that in vivo depletion of 
TNFĮ markedly impaired the ability of BALB/c mice to control infection with 
P. aeruginosa (Gosselin et al., 1995).  TNFĮ is also known to promote the 
recruitment of neutrophils and macrophages to the site of infection (Kolls et al., 
1993, Vanfurth et al., 1994).  This effect was shown to be associated with the 
capacity of TNFĮ to up-regulate the expression of adhesion molecules on endothelial 
and epithelial cells as well as neutrophils (Mulligan et al., 1993, Tosi et al., 1992), to 
stimulate the secretion of chemotactic factors by epithelial cells and phagocytes 
(Smart and Casale, 1994), or to act directly as a chemoattractant (Ming et al., 1987).  
The ability to inhibit TNFĮ is therefore advantageous to the bacterium.  However, a 
number of reports have also demonstrated that high levels of TNFĮ sustained over a 
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prolonged period may cause severe lung damage, shock, fibrosis and tissue 
dysfunction (Remick, 1993, Kolls et al., 1993, Piguet et al., 1990, Tracey and 
Cerami, 1994). 
  
It is generally accepted that cytokines produced by Th1 cells, particularly IFNȖ, 
activate phagocytic cells.  Th1 cell when activated produce chemokines that assist in 
the recruitment of monocytes, and GM-CSF that induces their differentiation into 
macrophages at the site of infection.  TNFĮ from Th1 cells alters the surface 
properties of endothelial cells to promote the adhesion of monocytes at the site of 
infection.  IFNȖ and TNFĮ are then critical for effective macrophage activation and 
the elimination of the pathogen.  In addition, Th1 cytokines especially, IFNȖ and 
TNFĮ, help the development of B cells and the production of IgG1 and IgG3 
opsonising - which provide the bulk of immunity to most blood borne infectious 
agents - and complement-fixing antibodies (Abbas et al., 1996, Romagnani, 1994).  
In contrast, cytokines produced by Th2 cells provide optimal help for humoral 
immune responses.  Th2 cytokines, especially Il-4 and IL-5 induce IgE production by 
B cells through induction of mast cells and eosinophil differentiation and activation 
and facilitation to IgA synthesis (Abbas et al., 1996, Romagnani, 1994).  Allergic 
reactions are predominantly associated with IgE, where reintroduction of a antigen 
into a previously sensitised individual binds to antigen-specific IgE on mast cells and 
trigger the release of pharmacologically active agents e.g. histamine (Alberts et al., 
1994, Janeway et al., 2001).  On the other hand, IgA is a first line of defence against 
microbes entering through mucosal surfaces (the respiratory, gastrointestinal and 
genitourinary tracts).  This antibody prevents colonisation of mucosal surfaces by 
pathogens and mediates their phagocytosis (Alberts et al., 1994). 
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The cytokine results obtained therefore indicate elimination of both Th1 and Th2 
responses by 3-oxo-C12-HSL and PQS.  The ability to inhibit one or both pathways 
will therefore help promote and sustain bacterial infections. 
 
To conclude, 3-oxo-C12-HSL and PQS are immunosuppressive in that they suppress 
proliferation of T cells and modulate cytokine release, where PQS is significantly 
more potent.  However, while PQS has no cytotoxic effects on T cells, 
3-oxo-C12-HSL inhibited proliferation before cytotoxicity occurred.  These two 
structurally diverse QSSMs can also exert differential modulatory effects on pure 
human T cell response, most noticeably on the cytokines IL-2 and TNFĮ, where 
3-oxo-C12-HSL inhibits and PQS stimulates IL-2 and TNFĮ production.  As T cell 
play an important role in defending the host against P. aeruginosa infections, it is 
important to understand in more detail the mode of action of these two QSSMs at a 
protein and RNA level.   
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5. The effect of P. aeruginosa  PQS on the activation of Erk 1/2  
 
5.1. Introduction 
 
Hooi et al. (2004) has suggested 3-oxo-C12-HSL and PQS possess activities 
reminiscent of CsA and rapamycin on hPBMCs.  It has been well established that 
rapamycin prevents T cell proliferation by blocking IL-2 signalling (Powell et al., 
1998, Brennan et al., 1999).  Rapamycin inhibits the serine-threonine kinase mTOR 
(Brown et al., 1994, Almawi et al., 1999, Gingras et al., 2001) where mTOR is a key 
regulator of translation.  CsA, on the other hand inhibits phosphatase activity of 
calcineurin (Liu et al., 1991) thus inhibiting the translocation of the NFAT family of 
transcription factors important for IL-2 production.  CsA has also recently been 
found to block JNK and p38 signalling pathways (Matsuda and Koyasu, 2000).  The 
potential for 3-oxo-C12-HSL and PQS to become future immunosuppressants due to 
their immune suppressive properties warrants further research into their mode of 
action in the T cell signalling pathway.  In addition, the importance of MAPKs in 
controlling cellular responses to the environment and in regulating gene expression, 
cell growth and apoptosis has made them a priority for research related to many 
human diseases (Kawaguchi et al., 2003, Zhang et al., 2005, Zhu et al., 1999, Zhang 
et al., 1999).   
 
The Erk pathway is a molecular target for drug development supporting the reason to 
test the effects of the QSSMs on this particular signalling pathway.  Smith et al. 
(2001) demonstrated 3-oxo-C12-HSL activated Erks that subsequently induced the 
activation of transcription factor NFțB in bronchial epithelial cells.  The Erk 
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signalling pathway is also an important element in Nerve growth factor (NGF) 
survival.  NGF is a well-characterised neurotrophin essential for development and 
differentiation of both peripheral and central neurones.  NGF also exerts specific 
effects on immune functions and previous studies have given evidence that NGF 
promotes T lymphocyte proliferation (Thorpe and Perezpolo, 1987, Otten et al., 
1989).  The binding of NGF to the TrK receptor tyrosine kinase A (TrKA) causes its 
dimerisation leading to the phosphorylation of the TrKA receptor.  TrK 
phosphorylation induces the activation of three major intracellular signalling 
pathways; the PI3-kinase pathway (resulting in Akt phosphorylation), the Ras 
pathway (resulting in Erk 1/2 phosphorylation), and the phospholipase CȖ pathway 
(Kaplan and Miller, 2000) (fig. 5.1).    Ehrhard et al. (1994) demonstrated expression 
of functional NGF receptors on T cells (Ehrhard et al., 1994), and is consistent with 
data showing that NGF induces a proliferative response in human blood peripheral 
T lymphocytes (Otten et al., 1989) and in rat spleen lymphocytes (Thorpe and 
Perezpolo, 1987), and stimulates expression of IL-2R on cultured human 
lymphocytes (Thorpe et al., 1987).  Taken together, suggest that NGF, in addition to 
its neurotrophic functions, acts as an immunomodulator mediating cross-talk 
between cells of the nervous and the immune systems.  The inhibition of the NGF 
pathway will therefore also be advantageous to P. aeruginosa.   
 
Using this as a starting point, the effect of 3-oxo-C12-HSL and PQS on total and 
phospho-Erk 1/2 in pure T cells were investigated using western blot analysis.  
SDS-PAGE separates proteins based primarily on their molecular masses (Laemmli, 
1970).  SDS is an anionic detergent, meaning that when dissolved its molecules have 
a net negative charge within a wide pH range. A polypeptide chain binds SDS in 
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proportion to its relative molecular mass. The negative charges on SDS denature 
most of the complex structure of proteins, which are strongly attracted toward an 
anode (positively-charged electrode) in an electric field. Protein separation by SDS-
PAGE can be used to estimate relative molecular mass, to determine the relative 
abundance of major proteins in a sample. 
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Figure 5.1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1.  NGF signalling pathway.  NGF is the ligand of TrKA and induces its 
phosphorylation and the subsequent activation of the intracellular signalling 
pathways Erk 1/2 and Akt, which are responsible for neuronal survival as well as 
T cell proliferation (Akassoglou, 2005). 
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5.2. Methods 
 
5.2.1. Immunoblotting 
 
T cells were isolated and cell density determined using the trypan blue assay.   500 ȝl 
of cell suspension was added at a density of 10
6
 cells per well of 48-well tissue 
culture plates (NUNC, Leicestershire, UK).  4 ȝM PQS was added per well after the 
addition of 0.1 ȝg/ml anti-CD3 and 5 ȝg/ml anti-CD28 bringing the final volume up 
to 1ml per well with CTCM.  T cells were incubated for 0, 5, 10, 20, 30, 60, 90 and 
120 min.  Resting control (T cells with no stimulants) was also included in this assay.  
Cells were then collected into eppendorfs and centrifuged for 10 min at 450 x g, 
discarding the supernatant and washing three times with cold phosphate buffered 
saline (PBS, A.3.1), centrifuging at 10 000 x g for 5 min each time.  After removing 
the final supernatant, cells were lysed with RIPA buffer (Sigma, Poole, UK) in the 
presence of protease inhibitors (Sigma, Poole, UK) and 1 µl of phosphatase inhibitor 
I and II (Sigma, Poole, UK) for 30 min on ice.  Cells were then centrifuged at 
12 000 x g for 30 min at 4oC and the supernatant containing the total cellular extracts 
were collected.  Protein concentration was measured using the NanoDrop 
Spectrophotometer (Labtech International, Sussex, UK) at the wavelength OD280.  
The cellular extracts were collected using acetone precipitation.  Briefly, ice cold 
acetone (Fisher Scientific, Leistershire, UK) was added to the total cellular extracts 
in RIPA buffer at the ratio of 4:1 respectively and incubated overnight at -20
o
C, 
followed by centrifugation at full speed 10 000 x g for 15 min, discarding the 
supernatant and re-suspending the pellet in SDS reducing sample buffer (1 M 
Tris-HCL pH 6.8, 50% glycerol, 10% SDS, 1% bromophenol blue and 0.5 ml 2-ME) 
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at a volume used to dilute the protein concentration to 50 ȝg per 20 ȝl.  Proteins were 
then denatured by boiling the sample at 100
o
C for 10 min and electrophoresed on 
SDS-PAGE gel.   
 
12% polyacrylamide (Sigma, Poole, UK) gel was used as resolving gel (29.2% 
acrylamide, 1.5 M Tris-HCl pH 8.8, 10% SDS, 60 µl 10% ammonium persulphate 
and 6 µl TEMED) and 4% was used as stacking gel (29.9% acrylamide, 
0.5 M Tris-HCL pH 6.5, 10% SDS, 50 µl 10% ammonium persulphate and 20 µl 
TEMED).  The Bio-Rad Mini-Gel apparatus was setup by clamping clean back and 
front plates together and placing in casting stand.  After checking if there was any 
leakage with water, the resolving gel was prepared and poured in between the two 
plates overlaying with tert-amyl alcohol and allowing it to polymerize for 30 min.  
Residual alcohol and buffer mix was poured off and the surface of the gel washed 
with dH2O several times draining dH2O completely.  The stacking gel was now 
prepared and 900 ȝl was poured above the resolving gel before introducing a clean 
dry comb at an angle to avoid trapping bubbles and left to polymerize for 10 min.  
The comb was removed from the set gel transferring the gel to an electrode stand and 
placed in a tank, pouring Running Buffer (A.1.5.4) into the tank washing out the well 
with reservoir buffer using a pipette.  20 ȝl of protein sample was loaded into each 
well including a well with 10 ȝl of pre-stained standards with a weight range of 
10-250 kDa (Bio-Rad, Hertfordshire, UK).  The red and black electrical leads in the 
green cover was connected to the matching coloured electrodes of the electrode 
assembly and ran  at 100 V for 90 min until the bromophenol blue dye has migrated 
to the bottom of the gel.   
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When finished, the proteins were transferred from SDS-PAGE gel onto nitrocellulose 
membrane (Towbin et al., 1979) using a Bio-Rad Mini Protean II/III Transfer cell.  
Briefly, a sandwich composed of filter paper-gel-blot (nitrocellulose)-filter paper was 
made and placed in a tank with transfer buffer (A.1.5.5) giving an electric field 
where negatively charged proteins migrate out of gel onto the nitrocellulose blot.  
Transfer was carried out at 30 V overnight.  The blot was removed from the transfer 
apparatus, rinsed with Tris buffered saline (A.1.6.1), and immediately placed into 
blocking buffer (TBS buffer/1% BSA) for 2 hr at 37
o
C then washed three times with 
75 ml TBS supplemented with 0.05% Tween-20 (TBS/T, Sigma, Poole, UK) for 
15 min each with agitation.  Primary antibody (Promega, Southampton, UK) was 
diluted to a ratio of 1:5000 with TBST/0.1% BSA and incubated with the membrane 
at 4
o
C overnight with agitation.  The blot was then washed three times with 75 ml 
TBS/T for 15 min each with agitation before incubating with donkey anti-rabbit IgG 
AP-conjugate (Promega, Southampton, UK) diluted to a ratio of 1:5000 with 
TBST/0.1% BSA for 2 hr at room temperature with agitation.  The membrane was 
washed three times (15 min each wash in 75 ml TBS/T buffer) and rinsed twice for 
1 min each in TBS buffer decanting the solution after each wash.  Chemiluminescent 
detection was used to analyse the gel results on nitrocellulose membrane.  Alkaline 
phosphatase substrate (50 mg/ml 5-bromo-4-chloro-3-indoly phosphate in 70% PMF, 
70 mg/ml nitro blue tetrazolium in 70% PMF and 0.75 M Tris pH 9.6) was used as 
detection, removing excess reagent with distilled water before scanning the blot. 
The blotted membranes were scanned using the Bio-imaging system (Syngene, 
Cambridge, UK).  Activation of Erk 1/2 was determined by normalization of band 
density from the phosphorylated protein with that of the total (phosphorylated and 
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non-phosphorylated) protein for the same sample using GeneTools Image Analysis 
software (Syngene, Cambridge, UK).   
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5.3. Results 
 
The presence of total-Erk 1/2 was detected when cells were treated with 4 µM PQS, 
however, there was no indication of PQS having any effect on the concentration of 
total-Erk 1/2 present (fig. 5.2a and b).  It had been previously suggested that 
P. aeruginosa QSSMs may interfere with the activation of Erk 1/2 and so the effect 
of 4 µM of PQS on phospho-Erk 1/2 was investigated.  Figure 5.3a and b indicates 
the presence of phospho-Erk 1/2 however, no significant changes to their 
concentration was detected within the time scale the T cells were treated. 
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Figure 5.2 
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Figure 5.2.  Detection of inactivated (total)-Erk 1/2 in pure human T cells 
stimulated anti-CD3 and anti-CD28.  Cells were treated with 4 µM PQS and 
incubated for 5-120 min.  Cells represent untreated cells and anti-CD3/28 represents 
cells treated with anti-CD3 and anti-CD28 only  both incubated for 120 min.  Bands 
were compared to pre-stained protein ladder (MWM) to confirm the location of total-
Erk (a).  It was confirmed there were no significant changes in total-Erk quantity 
compared to the stimulated control using GeneTools image analysis software (b). 
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Figure 5.3 
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Figure 5.3.  Detection of activated (phospho)-Erk 1/2 in pure human T cells 
stimulated with anti-CD3 and anti-CD28.  Cells were treated with 4 µM PQS and 
incubated for 5-120 min.  Cells represent untreated cells and anti-CD3/28 represents 
cells treated with anti-CD3 and anti-CD28 only  both incubated for 120 min.  Bands 
were compared to pre-stained protein ladder (MWM) to confirm the location of total-
Erk (a).  It was confirmed there were no significant changes in phospho-Erk present 
compared to the stimulated control using GeneTools image analysis software (b). 
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5.4. Discussion 
 
Figure 4.2b shows a constant density of total Erk 1/2 is present throughout T cells 
stimulated to proliferate with anti-CD3 and anti-CD28 and further treated with 4 µM 
PQS.  Figure 4.3 indicates the presence of phospho-Erk 1/2 in pure human T cells 
stimulated to proliferate using anti-CD3 and anti-CD28 and again treated with 4 µM 
PQS.  However, it was expected a decrease in phospho-Erk 1/2 to coincide with the 
inhibition of T cell proliferation.  Reasons why this did not occur may be that the 
activation and progression of the T cell signalling pathway is so fast when the T cells 
were treated with PQS after the addition of anti-CD3 and anti-CD28, the signalling 
pathway may already have occurred.  Previous studies have shown the presence of 
phosphor-Erk 1/2 in anti-CD3 and anti-CD28 stimulated human T cells within 1 min 
from stimulation, with strong activation within 10 min and a decreased presence of 
phospho-Erk 1/2 within 30 min using western blot analysis (Zaffran et al., 2001).  
Therefore, future research in repeating this study may need to add the PQS in first 
before the addition of anti-CD3 and anti-CD28 to activate T cell proliferation.  This 
is biologically relevant as infection by P. aeruginosa occurs before the immune 
system is activated. 
 
Future studies on the effect of QSSMs on Erk1/2 activation may benefit from using 
the ELISA technique to obtain a more quantitative analysis.  The use of U0126, 
which is capable of directly inhibiting activated MEK1 and preventing endogenously 
active MEK 1/2 from phosphorylating and activating Erk 1/2 (Favata et al., 1998, 
DeSilva et al., 1998), represents a good negative control to this study. 
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Unpublished data from the immune modulation group at the University of 
Nottingham used FastKinase
TM
 profiling to assess the effects of 3-oxo-C12-HSL and 
PQS on T cell kinase activity.  Results suggested 3-oxo-C12-HSL is not a kinase 
inhibitor while PQS significantly inhibited TrKA and Erk 1 activity.  This suggests 
P. aeruginosa is able to inhibit additional pathways that may aid the hosts immune 
system to defend against an infection, allowing the bacteria to maintain the infection. 
 
To conclude, even though results here were inconclusive, this Ras pathway remains 
to be an important factor involved in the pathogenesis of P. aeruginosa, and where 
further research is essential. 
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6. Gene array analysis of the differential effects of QSSMs and CsA 
on  RNA expression 
 
6.1. Introduction 
 
The previous chapters have focussed on looking at the effects of 3-oxo-C12-HSL and 
PQS on T cells.  It was established that these two QSSMs suppress T cell 
proliferation and further cytokine and kinase analysis was performed to try to 
establish their mode of action.  The aim of this chapter was to further explore 
possible targets of these QSSMs using gene array analysis. 
 
Genome-wide monitoring of gene expression using DNA microarrays represents one 
of the latest break-through in experimental molecular biology and provides 
unprecedented opportunity to explore changes in cell signalling when faced with 
bacterial infections by providing a comprehensive survey of a cells transcriptional 
landscape.   
 
Using microarray analysis will help elucidate the pathways and entities responsible 
for the immune-modulatory effects of QSSMs and clarify molecular receptors 
involved in the process. 
 
The concentrations of 3-oxo-C12-HSL and PQS used in this analysis were the IC50 
concentrations extracted from the pure T cell proliferation assays. 
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6.2. Methods 
 
Initially, after extraction to total RNA from QSSM-treated T cells, the Ambion 
Amino Allyl MessageAmp
TM
 aRNA amplification kit was used following the 
protocol for two rounds of amplification to allow for dye incorporation and 
microarray analysis (section 5.2.2.).  However, after several attempts to amplify the 
RNA to the appropriate concentration were unsuccessful, an alternative method was 
used for RNA amplification and dye incorporation  Agilents Low RNA Input 
Linear Amplification Kit (section 5.2.3.). 
 
6.2.1. T cell stimulation, total RNA extraction and evaluation 
 
T cells were isolated and cell density determined.  500 ȝl of cell suspension was 
added at a density of 10
6
 cells per well of a 48-well tissue culture plates using 
CTCM.  Cells were stabilised by incubating for 24 hr at 37
o
C in 5% CO2.  19 ȝM 
3-oxo-C12-HSL, 4 ȝM PQS and 3 ȝM CsA were tested with 0.1 ȝg/ml anti-CD3 and 
5 ȝg/ml anti-CD28 bringing the final volume up to 1 ml per well with CTCM.  
Stimulated control samples (T cells stimulated with anti-CD3 and anti-CD28) and 
resting control samples (no stimulation) were included in this assay.  The culture was 
incubated for 8 hr followed by suspending the stimulated T cells in RNAlater RNA 
Stabilization Reagent (Qiagen, Valencia, CA, USA).  RNAlater Stabilization 
Reagent represents a novel technology for RNA protection by rapidly permeating 
tissues and single cells to stabilize and protect cellular RNA in situ.  Briefly, cell 
suspensions were collected into eppendorfs and centrifuged at 300 x g for 5 min.  
Supernatants were removed completely and pellets washed by re-suspending in 
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500 ȝl PBS and spinning at 300 x g for 5 min.  Supernatants were removed 
completely and pellet re-suspended thoroughly in 100 ȝl PBS before further adding 
500 ȝl RNAlater. 
 
RNeasy protect mini kit (Qiagen, Valencia, CA, USA) was used to isolate total RNA.  
This technology combines the selective binding properties of a silica-gel-based 
membrane with the speed of microspin technology.  Briefly, the cell suspension was 
centrifuged at 3000 x g for 10 min and supernatant removed completely.  The cell 
pellet was thoroughly re-suspended by flicking the eppendorfs.  To lyse the cells, 
350 ȝl of RLT buffer (containing 10 ȝl 2-ME per ml of  RLT buffer) was added per 
tube and mixed via vortexing followed by the addition of 350 ȝl 70% ethanol (30% 
DEPC water (Ambion Ltd, Europe), 70% ethanol (Sigma, Poole, UK)) per tube 
before mixing via pipetting.  The lysed cell mixture was then pipetted into an 
RNeasy mini column placed in a 2 ml collection tube.  Samples were centrifuged at 
8000 x g for 15 s, discarding the flow-through after and re-using the collection tube.  
The next step is the removal of contaminating genomic DNA to ensure that the 
specific PCR products are derived only from cDNA, and to avoid competition 
between the cDNA and genomic DNA during PCR reactions.  Residual DNA was 
removed using the RNase-Free DNase I set (Qiagen, Valencia, CA, USA).  DNase I 
stock solution was prepared by dissolving the solid DNase I (1500 Kunitz units) in 
550 ȝl RNase-free water and mixed gently by inverting the tube.  10 ȝl of this DNase 
I stock solution was then added to 70 ȝl RDD buffer and mixed gently by inverting 
the tube before pipetting directly onto the RNeasy silica-gel membrane and incubated 
for 15 min at RT.  After incubation, the column was washed with 350 ȝl RW1 buffer 
and spinning for 15 s at 8000 x g.  The column was then transferred to a new 2 ml 
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collection tube before pipetting 500 ȝl RPE buffer onto the RNeasy column and 
centrifuging for 15 s at 8000 x g.  The flow through was discarded before adding a 
second 500 ȝl RPE buffer onto the column and centrifuging for 2 min at 8000 x g to 
dry the membrane.  To further remove any buffer residue the column was transferred 
to a new 2 ml collection tube and centrifuged at 10 000 x g for 1 min.  To elute, the 
RNeasy column was transferred to a new 1.5 ml collection tube before adding 40 ȝl 
RNase-free water added directly onto the silica-gel membrane and centrifuging for 1 
min at 8000 x g.  To obtain a higher total RNA concentration, the eluate was 
collected and pipetted onto the silica-gel membrane again and centrifuged for a 
further 1 min at 8000 x g. 
 
The samples were placed on ice and the RNA concentration was determined by 
NanoDrop® ND-1000 UV-Vis spectrophotometer (Labtech. International, Sussex, 
UK).  RNase-free water was used as a blank control before pipetting 1.5 ȝl of the 
RNA elute onto the pedestal and measuring the concentration.  RNA samples with 
A260/A280 ratio of 1.9  2.1 and A260/A230 ratio of 1.8  2.1 was further checked for its 
quality using an Agilent 2100 bioanalyzer analysis system (Agilent Technologies, 
Cheshire, UK).  RNA samples chosen for further work had two well-defined 18S and 
28S ribosomal RNA peak with an RNA integrity >8.  If needed, the RNA samples 
were further concentrated using the RNeasy minElute Cleanup Kit (Qiagen, 
Valencia, CA, USA).  This cleanup procedure allows purification and concentration 
of RNA from minimal elution volumes.  RNA samples were adjusted to 100 µl with 
RNase-free water before adding 350 µl Buffer RLT and 250 µl 100% ethanol 
(Sigma, Poole, UK) mixing thoroughly each time via pipetting.  700 µl RNA mix 
was pipetted into an RNeasy MinElute Spin column in 2 ml collection tube and 
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centrifuged for 15 s at 8000 x g before transferring the column to a new 2 ml 
collection tube.  500 µl Buffer RPE was added to the column and centrifuged for 15 s 
at 8000 x g discarding the flow through and reusing the collection tube.  500 µl of 
80 % ethanol was added to the column then centrifuged for 2 min at 8000 x g to dry 
before transferring to a new 2 ml collection tube and centrifuging for a further 5 min 
at 10 000 x g leaving the spin column cap open.  The flow through and collection 
tube were discarded and column transferred to a new 1.5 ml collection tube.  To 
elute, 14 µl RNase-free water was added directly onto the centre of the membrane 
and centrifuged for 1 min at maximum speed resulting in a 12 µl volume eluate of 
RNA in RNase-free water.  RNA concentration was determined using the NanoDrop 
spectrophotometer before diluting the RNA to a concentration of 500 ng in a volume 
of 8 µl RNase-free water.   
 
6.2.2. RNA amplification and Dye incorporation 
 
The Ambion Amino Allyl MessageAmp
TM
 II aRNA Amplification kit (Ambion Ltd, 
Europe) was used.  The two round amplification protocol was followed.  All reagents 
were provided in the kit unless otherwise stated.  To thoroughly mix the RNA and 
additional reagents added, a method of pipetting 3 times, flicking the tube four times 
and centrifuging briefly to settle the RNA was used unless otherwise stated. 
 
Reverse transcription to synthesise first strand DNA 
 
Briefly, 10 µl of total RNA (1000 ng as recommended for two rounds of 
amplification) in high quality water (Fisher Scientific Ltd, UK) was placed into a 
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non-stick, sterile, RNase-free 0.5 ml tube (Ambion Ltd, Europe) along with 1 µl of 
T7 Oligo (dT) primer.  Nuclease-free water was used to bring the final concentration 
up to 12 µl before vortexing briefly then centrifuging to collect the mixture at the 
bottom of the tube.  0.5 µl of control RNA spikes (Ambion Ltd, Europe) was then 
added to every 100 ng of RNA and incubated for 10 min at 70
o
C in a thermal cycler.  
After 10 min, the samples were briefly centrifuged and placed on ice while the 
reverse transcription master mix (A.1.8.1) was prepared at room temperature in a 
nuclease-free tube.  8 µl of the reverse transcription master mix was then added to 
each RNA sample, mixed thoroughly, and centrifuged briefly before incubating at 
42
o
C for 2 hr in an air incubator.  After 2 hr, the samples were briefly centrifuged 
and placed on ice, immediately proceeding to second strand cDNA synthesis. 
 
Second strand cDNA synthesis 
 
The second strand master mix (A.1.8.2) was prepared on ice in a nuclease-free tube 
and mixed well by gently vortexing and centrifuging.  80 µl of the second strand 
master mix was added to each RNA sample and mixed thoroughly, centrifuging 
briefly, and then incubated for 2 hr at 16
o
C in a thermal cycler.  After 2 hr, the 
samples were placed on ice. 
 
cDNA purification  
 
250 µl of cDNA binding buffer (cDNA binding buffer and 100% ethanol) was added 
to each sample and mixed thoroughly followed by a quick spin.  The mixture was 
then passed through a cDNA filter cartridge in a wash tube, and centrifuged for 
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1 min at 10 000 x g discarding the flow-through and replacing the cDNA filter 
cartridge in the wash tube.  500 µl of wash buffer was then applied to each cDNA 
filter cartridge and centrifuged for 1 min at 10 000 x g, discarding the flow-through 
before spinning the cDNA filter cartridge for an additional minute.  The filter 
cartridge was then transferred to a cDNA elution tube.  9 µl of pre-heated 
nuclease-free water (55
o
C) was added to the centre of the filter then left at room 
temperature for 2 min before centrifuging for 2 min at 10 000 x g.  The cDNA was 
eluted with a second 9 µl of pre-heated nuclease-free water, leaving the 
double-stranded cDNA in 14 µl of eluate. 
 
 
In vitro transcription to synthesise biotin-labelled aRNA 
 
The IVT master mix (A.1.8.3) was assembled at room temperature in a nuclease-free 
tube, mixed well via vortexing, and briefly centrifuged.  26 µl of this master mix was 
added to each sample mixing thoroughly before incubating at 37
o
C for 14 hr in a 
hybridization oven.  After 14 hr, the reactions were stopped by adding 60 µl of 
nuclease-free water to each aRNA sample to bring the final concentration up to 
100 µl. 
 
aRNA purification using the Ambion amplification kit 
 
This is required to remove unincorporated aaUTP and Tris from IVT reactions that 
would otherwise compete with the aRNA for de coupling; it also removes enzymes, 
salts, and other unincorporated nucleotides.  350 µl of aRNA binding buffer was 
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added to each sample before further adding 250 µl of ACS grade 100% ethanol 
(Sigma, Poole, UK) to each sample, mixing each sample by pipetting three times.  
Each sample was then pipetted onto the centre of the filter in the aRNA filter 
cartridge placed inside a collection tube and centrifuged for 1 min at 10 000 x g.  The 
flow-through was discarded and the aRNA filter cartridge was placed back into the 
collection tube.  650 µl of wash buffer was then applied to each aRNA filter cartridge 
and centrifuged for 1 min at 10 000 x g before discarding the flow-through and 
spinning for a further minute.  The filter cartridges were then transferred to a fresh 
aRNA collection tube.  To the centre of the filter, 100 µl of pre-heated nuclease-free 
water (55
o
C) was added and left at room temperature for 2 min before centrifuging 
for 2 min at 10 000 x g.  The concentration of RNA was assessed using a nanodrop 
spectrophotometer before moving onto the second round of amplification. 
  
Second round amplification 
 
2 µg of purified aRNA was added to a sterile RNase-free microfuge tube (Ambion 
Ltd, Europe) along with 2 µl of second round primers, bringing the volume up to 
12 µl with nuclease-free water.  The samples were vortexed briefly and centrifuged 
before incubating for 10 min at 70
o
C in a thermal cycler.  After 10 min, the samples 
were centrifuged briefly and placed on ice before preparing the reverse transcription 
master mix for second round amplifications (A.1.8.1) at room temperature.  8 µl of 
this master mix was added to each sample, mixing thoroughly and centrifuging 
briefly before incubating for 2 hr at 42
o
C in a thermal cycler.  After 2 hr, 1 µl of 
RNase H was added to each sample, mixing thoroughly and centrifuging briefly, then 
incubated for 30 min at 37
o
C in a thermal cycler.   
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Synthesis of second strand cDNA (second round) 
 
After incubation, 5 µl of T7 Oligo(dT) primer was added to each sample vortexing to 
mix well and centrifuging briefly to collect the sample at the bottom of the tube.  The 
samples were incubated for 10 min at 70
o
C in a thermal cycler and then placed on ice 
while preparing the second strand master mix for second round amplification 
(A.1.8.4).  74 µl of this master mix was added to each sample and mixed thoroughly 
before centrifuging briefly and incubating for 2 hr at 16
o
C in a thermal cycler.  After 
2 hr, the samples were placed on ice before moving onto cDNA purification, in vitro 
transcription to synthesise biotin-labelled aRNA and aRNA purification.   
 
aRNA: dye coupling reaction 
 
Once the aRNA concentration was determined, 5-20 ȝg aRNA was vacuum dried 
making sure not to over dry.  In the meantime, 11 ȝl of 100% DMSO (Sigma, Poole, 
UK) was added to each tube of Cy3 and Cy5 reactive dyes (Amersham Biosciences, 
UK) and vortexed to mix.  The dried aRNA was then resuspended in 9 ȝl of coupling 
buffer and vortexed gently.  11 ȝl of prepared dye was then added to each RNA 
sample, again vortexing gently to mix before incubating for 30 min at room 
temperature away from light.  4.5 ȝl of 4 M hydroxylamine was then added to each 
sample vortexing to mix and incubating for 15 min at room temperature away from 
light.  5.5 ȝl nuclease-free water was then added to each sample bring the final 
concentration up to 30 ȝl. 
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Dye labelled aRNA purification 
 
105 ȝl aRNA binding buffer was added to each sample followed by 75 ȝl of 100% 
ethanol and mixed by pipetting up and down three times.  Each sample was then 
pipetted into a labelled aRNA filter cartridge in a collection tube and centrifuged for 
1 min at 10 000 x g.  The flow-through was discarded and the filter replaced in the 
collection tube.  500 ȝl of wash buffer was then added into the filter and centrifuged 
for 1 min at 10 000 x g, again discarding the flow-through before spinning the filter 
for an additional minute.  The labelled aRNA filter was then transferred to a labelled 
aRNA elution tube.  10 ȝl of pre-heated nuclease-free water (55oC) was then added 
to the centre of the filter and left at room temperature for 2 min before centrifuging 
for 2 min at 10 000 x g.  An additional 10 ȝl of pre-heated nuclease-free water was 
added to the centre of the filter and left for 2 min at room temperature before 
centrifuging for 2 min at 10 000 x g bringing the labelled aRNA volume to 20 ȝl 
with nuclease-free water. 
 
6.2.3. Alternative method used for RNA amplification and dye 
incorporation 
 
Agilents Low RNA Input Linear Amplification kit (Agilent Technologies, Cheshire, 
UK) was used to amplify and label the total RNA obtained when amplification was 
unsuccessful using the Ambion kit.  This Agilents amplification kit generates 
fluorescent complimentary RNA (cRNA).   
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Briefly, to synthesise cDNA from total RNA, 500 ng of total RNA in a volume of 
8 ȝl in RNase-free water was added to a 0.2 ml PCR tube with 1.2 ȝl of T7 promotor 
primer and 2.5 ȝl of two-colour spike-in mix.  The tubes were placed in a thermo 
cycler and incubated for 10 min at 65
o
C to denature the template and anneal the 
primer, then cooled at 4
o
C.  Immediately before use, the cDNA master mix was 
prepared by mixing 4 ȝl 5x first strand buffer, 2 ȝl 0.1 M DTT, 1 ȝl 10mM dNTP 
mix, 1 ȝl MMLV-RT and 0.5 ȝl RNase OUT then transferred to the RNA mix, 
pipetting up and down to mix before incubating in the thermo cycler at 40
o
C for 2 hr 
then 65
o
C for 15 min to inactivate the MMLV-RT and finally cooled at 4
o
C.  The 
samples were then spun down briefly to drive the contents to the bottom of the tube. 
 
The next step is in vitro transcription and incorporation of cyanine 3-CTP (cy3) and 
cyanine 5-CTP (cy5) (Agilent Technologies, Cheshire, UK).  Briefly, the 
transcription master mix was prepared by mixing 15.3 ȝl nuclease-free water, 20 ȝl 
4x transcription buffer, 6 ȝl 0.1 M DTT, 8 ȝl NTP mix, 64 ȝl 50 % PEG, 0.5 ȝl 
RNase OUT, 0.6 ȝl Inorganic pyrophosphatase, 0.8 ȝl T7 RNA polymerase, 2.4 ȝl 
cy3 and 2.4 ȝl cy5 together.  To each sample tube, 60 ȝl of the transcription master 
mix was added and gently mixed via pipetting before incubated in a thermal cycler 
for 2 hr at 40
o
C then cooled at 4
o
C. 
 
Purification of Amplified RNA 
 
Qiagens RNeasy mini spin columns (Qiagen, Valencia, CA, USA) were used to 
purify the amplified cRNA samples.  Unincorporated dye-labelled nucleotide in the 
hybridization buffer solution significantly increased background fluorescence on the 
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microarray.  All centrifugations used in this protocol were carried out at 4
o
C to 
obtain higher yields.  20 ȝl of nuclease-free water was added to the cRNA sample to 
obtain a total volume of 100 ȝl.  To this, 350 ȝl of Buffer RLT was added and mixed 
well before adding 250 ȝl of 100% ethanol mixing well via pipetting.  700 ȝl of this 
cRNA sample was transferred to an RNeasy mini column in a 2 ml collection tube 
and centrifuged at 10 000 x g for 30 s discarding the flow through and collection tube 
after.  The column was then transferred to a new 2 ml collection tube before adding 
500 ȝl of Buffer RPE to the column and centrifuging at 10 000 x g for 60 s.  The 
flow-through was discarded and an additional 500 ȝl of Buffer RPE was added to the 
column and again spun at 10 000 x g for 60 s.  To elute the now cleaned cRNA 
sample, the column was transferred to a new 1.5 ml collection tube before adding 
30 ȝl RNase-free water directly onto the filter membrane and waiting 60 s prior to 
centrifuging for 30 s at 10 000 x g.  The RNeasy column was discarded and the 
cRNA sample retained in 30 ȝl of RNase-free water. 
 
6.2.4. Quantitating cRNA products 
 
cRNA was quantitated using a ND-1000 spectrophotometer (Labtech International, 
Sussex, UK) to minimise the amount of sample consumed by the measurement.  The 
microarray tab was used to scan the appropriate wavelengths.  1.5 ȝl of nuclease-free 
water was used to blank the nanodrop instrument then 1.5 ȝl of amplified cRNA was 
used for analysis.  The concentration of cRNA was calculated by using the following 
formula: 
  Conc. of cRNA (ȝg/ȝl) = OD260 x 10 x 40 ȝg/ml)/100 
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The reaction is multiplied by 10 because the path length of analysis is 1mm.  To 
calculate the specific activity of cRNA the following formula was used: 
  Specific Activity = pmol dye per ȝl/ conc. of cRNA (ȝg/ȝl) 
Specific activity from reactions starting with 500ng of input RNA was between 
10-15 pmol/ȝg.  Any cRNAs with specific activities less than 8 pmol/ȝg were not 
used as microarray targets. 
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6.3. Results 
 
6.3.1. Assessment of RNA quantity using a nanodrop spectrophotometer 
 
After initial isolation of total RNA from pure human T cells under control and testing 
conditions, RNA concentration was assessed using nanodrop spectrophotometry.  
Concentrations ranged from 190 to 250 ng/µl (data not shown).  To increase the 
RNA concentration to the amount required for PCR and dye incorporation 
(500 ng/µl), the RNA isolated for each condition was pulled together and further 
purified and concentrated using the RNeasy minElute Cleanup Kit.  Final 
concentrations obtained for each testing and control conditions were adjusted to 
500 ng/µl (data not shown). 
 
6.3.2. Assessment of RNA quality using Agilent 2100 Bioanalyzer 
 
The quality of RNA obtained was assessed using the bioanalyzer.  Results indicate 
good quality RNA was isolated with no degradation to each sample isolated.  RNA 
integrity number (RIN) ranged from 8 to 10 (fig. 6.1 and 6.2). 
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18S 
28S 
Figure 6.1 
 
 
Figure 6.1.  Gel image from bioanalyzer showing the 18S and 28S RNA bands.  
The first lane (L) represents the reference ladder, lane (1) pooled stimulated control, 
lane (2) individual stimulated control, (3) resting control, (4) 3-oxo-C12-HSL-treated 
RNA, (5) PQS-treated RNA, (6) CsA-treated RNA, lanes 7 to 11 are repeats of lanes 
2 to 6.   
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Figure 6.2 
 
 
a b
c d
e f
F
lu
o
re
sc
en
ce
 
Time (seconds) 
Chapter 6                                                                                                                  
 - 158 -
Figure 6.2.  Electropherogram summaries of the RNAs isolated from each test 
sample.  Graph (a) shows the ladder reference, (b) stimulated control i.e. cells treated 
only with anti-CD3 and anti-CD28, (c) resting control i.e. untreated cells, (d) cells 
stimulated with 24 µM 3-oxo-C12-HSL, (e) cells stimulated with 4 µM PQS and 
(f) cells stimulated with 3 µM CsA.  Intact total RNA was isolated.  The peaks at 
40 s and 45 s represents 18S and 28S RNA respectively. 
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6.3.3. Summary of Microarray work 
 
After isolation of good quality RNA for pure T cells, amplification of the RNA to the 
required concentration was not successful and so the intention to perform gene array 
analysis was not wholly successful on this occasion.  However, in parallel to this 
study, gene array analysis performed to detect differential gene expression levels of 
stimulated T cells treated with PQS was completed by more experienced experts at 
Mars Inc.  Their findings will be further detailed in the discussion. 
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6.4. Discussion 
 
Intact total RNA was obtained in the concentration required.  The Ambion 
amplification kit was initially used following the protocol for two rounds of 
amplification.  The starting concentration used was 100 ng/ml as recommended by 
Ambion Ltd.  However, after performing the PCR process, the concentration of RNA 
never reached the appropriate concentration of 5 µg required for the dye coupling 
reaction.  After repeating the amplification process several times with no success 
using the Ambion reagents provided in the kit, and performing repeat checks on the 
RNA integrity using the bioanalyzer, advice was given to research into a second 
amplification kit.  The Agilents Low RNA Input Linear Amplification kit (Agilent 
Technologies, Cheshire, UK) was recommended.  After comparing both the Ambion 
and Agilent protocol, it was acknowledged that the Agilent low RNA input Linear 
amplification kit was optimized to generate fluorescent complimentary RNA (cRNA) 
for use with Agilents oligonucleotide microarrays, where as the Ambion Allyl 
MessageAmp II aRNA (anti-sense RNA) Amplification Kit was not specifically 
made for Agilent microarrays use.   
 
In hindsight, it may have been more appropriate to use the Agilent kit as the 
microarray facilities that would have been used is from Agilent Technologies.  The 
concentration of aRNA required for the dye coupling reaction for the Ambion kit was 
also extremely high compared with the Agilent kit (5000 ng and 50 ng respectively).  
This lead to question the reason why the Ambion kit required such high 
concentrations of aRNA for the dye coupling reactions.  Explanations for this could 
be that the efficiency of labelling is better with the Agilent kit compared with the 
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Ambion kit where it may have been limited to how much dye can be bound to the 
aRNA samples. 
 
The Immune Modulation group at the University of Nottingham, where this present 
study was performed work in collaboration with Mars Inc.  In parallel to this 
microarray study, members of this research group also sent samples of stimulated 
T cells treated with PQS and T cells only stimulated to proliferate for external 
microarray analysis, to experienced experts at Mars Inc.  These findings are 
summarised in table 6.1 and table 6.2, showing changes in gene expression relating 
to immune function.   
 
It was observed that the activation of T cells by anti-CD3 and anti-CD28 increased 
gene expression of cytotoxic T-lymphocyte associated protein 4 (CTLA4, a member 
of the immunoglobulin superfamily and encodes a protein which transmits an 
inhibitory signal to T cells), IFNȖ (a hallmark cytokine for Th1 cells), and IL-2 
receptor alpha (IL-2RĮ, associated with constituting the high affinity IL-2 receptor) 
by ten fold.  The increase in IL-2RĮ is an important factor as T cell activation is 
associated with IL-2 production.  An increase in the IL-7 receptor gene was also 
detected, important for proliferation during certain stages of T cell survival, 
development and homeostasis.   
 
When T cells were stimulated with anti-CD3 and anti-CD28 in the presence of PQS, 
the microarray results indicated a 1.6 fold decrease in IL-12B (Table 6.2).  This gene 
encodes a subunit of IL-12, a cytokine that acts on T and natural killer cells, as well 
as being responsible for IFNȖ biosynthesis and the positive regulation of activated 
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T cell proliferation.  This cytokine is expressed by activated macrophages that serve 
as an essential inducer of Th1 cells development.  This cytokine has been found to be 
important for sustaining a sufficient number of memory/effector Th1 cells to mediate 
long-term protection to an intracellular pathogen.  A decrease in IL-12B may 
therefore indicate PQS influences T cell function by suppressing Th1 response due to 
the inhibition of IFNȖ biosynthesis and suppressing the positive regulation of 
activated T cell proliferation this gene has.  Despite this, the introduction of PQS to 
T cells will still initiate an increase in genes responsible for launching an immune 
response (Table 6.2), most noticeably CD7 antigen (p41) which encodes a 
transmembrane protein found on thymocytes and mature T cells and plays an 
essential role in T cell interactions, and IFNĮ-inducible protein (clone IFI-6-16) 
which helps launch immune responses to pest, pathogen or parasites.   
 
In conclusion, although unsuccessful in performing the microarray analysis myself, 
collaboration with Mars Inc. has allowed me to gain insight into the effects PQS may 
have on gene expression.  PQS has shown to inhibit IL-12B suggesting suppression 
of Th1 response and furthering our understanding of immune modulation by PQS. 
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Table 6.1.  Differential gene expression levels of stimulated T cells.  Summary of 
changes in gene activation that are involved in immune response. 
 
10 Fold Change Increase 
Description Biological Process 
Cytotoxic T-lymphocyte-associated 
protein 4 
Immune response 
Interferon, gamma Immune response 
Interleukin 2 receptor, alpha Regulation of cell cycle, apoptosis 
Nedd4 family interacting protein 2 Positive regulation of NF-kappaB cascade 
Suppressor of cytokine signalling 3 Regulation of intracellular signalling cascade, 
JAK-STAT cascade, negative regulation of 
signal transduction 
 
8 Fold Change Increase 
Description Biological Process 
TNF superfamily, member 2 Regulation of transcription, apoptosis, anti-
anti-apoptosis 
 
6 Fold Change Increase 
Description Biological Process 
IL-7 receptor Immune response, cell surface receptor linked 
signal transduction 
 
6 Fold Change Decrease 
Description Biological Process 
C-type lectin domain family 4, 
member A 
Immune response, cell surface receptor linked 
signal transduction 
CDC28 protein kinase regulatory 
subunit 2 
Cell proliferation 
S100 calcium binding protein A12 
(calgranulin C) 
Defence response to bacteria 
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Table 6.2.  Differential gene expression levels of stimulated T cells treated with 
PQS.  Summary of changes in gene activation that are involved in immune response. 
 
1.6 Fold Change Increase 
Description Biological Process 
2,5-oligoadenylate synthetase 1, 
40/46 kDa 
Immune response, response to virus 
IFN, Į-inducible protein (clone IFI-
15K) 
Immune response, cell-cell signalling 
IFN, Į-inducible protein (clone IFI-
6-16) 
Immune response, response to pest, pathogen 
or parasite 
Myxovirus (influenza virus) 
resistance 1, IFN-inducible protein 
p78 (mouse) 
Immune response, response to virus 
Myxovirus (influenza virus) 
resistance 2 (mouse) 
Immune response, response to virus 
 
1.6 Fold Change Decrease 
Description Biological Process 
IL-12B Antimicrobial humoral response, T-helper cell 
differentiation, IFNȖ biosynthesis, positive 
regulation of activated T cell proliferation 
 
1.5 Fold Change Increase 
Description Biological Process 
2,5-oligoadenylate synthetase 2, 
69/71 kDa 
Immune response 
CD7 antigen (p41) Cellular defence response, T cell activation 
RPA interacting protein Immune response 
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7. General Discussion 
 
P. aeruginosa is an opportunistic pathogen of immunocompromised patients 
indicating that it is often vulnerable to the human immune system.  Quorum sensing 
(QS) is a mechanism whereby bacteria are able to sense the environment and, as a 
population, regulate the expression of various genes, including those important for 
the virulence of the organism, and are involved in elevated antibiotic tolerance of 
biofilms as well as elevated tolerance to activity of the innate immune system.  
Therefore, the bacteria in a joint effort are able to subvert the host defences and 
cause infections.  In P. aeruginosa, QS regulates expression of numerous virulence 
genes that are thought to be important for the pathogenesis of the organism.   
 
Recent progress in QS research has demonstrated that Pseudomonas  QSSMs are not 
only important in the regulation of bacterial virulence genes but also interact with 
eukaryotic cells and modulate immune responses (Dimango et al., 1995, Telford et 
al., 1998, Saleh et al., 1999), thus the QS signalling system represent highly 
attractive targets for the development of novel therapeutics.  Given the detection of 
functional P. aeruginosa QSSMs in sputum and biopsy material from patients with 
cystic fibrosis (Singh et al., 2000, Collier et al., 2002, Favre-Bonte et al., 2002, 
Middleton et al., 2002, Chambers et al., 2005), their role in biofilm establishment 
and maintenance, and their implication of driving the disease process associated with 
infection (Wu et al., 2000, Donabedian, 2003, Bjarnsholt et al., 2005a), it was of 
interest to assess the immune modulatory capability of these QSSMs. 
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Early research has already indicated 3-oxo-C12-HSL, but not C4-HSL or 
3-oxo-C6-HSL, suppresses IL-12 and TNF-Į secretion by bacterial 
lipopolysaccharide (LPS)-stimulated macrophages (Telford et al., 1998), and more 
recently, Smith et al. (2002) reported 3-oxo-C12-HSL induces cyclooxygenase-2 and 
prostaglandin E2 production in lung fibroblasts suggesting a pivotal role for 
3-oxo-C12-HSL in inflammation.  Presently, Miyairi et al. (2006) demonstrated that 
specific antibodies to 3-oxo-C12-HSL play a protective role in acute pulmonary 
P. aeruginosa infections, and that the bacterial QS system, especially autoinducer 
molecules, to be a novel candidate for vaccine development against P. aeruginosa 
infection (Miyairi et al., 2006).  Previous studies suggest T cells play an important 
role in defending the host against the attack of P. aeruginosa, for example, 
Stevenson et al. have shown BALB/c mice are resistant to the establishment of 
chronic pulmonary P. aeruginosa infections and mount significantly enhanced T cell 
response to the mitogen ConA (Stevenson et al., 1995).  Suppression of T cell 
activity is therefore likely to be advantageous to P. aeruginosa and warrants further 
research into how P. aeruginosa manipulates human T cell function. 
 
Differential immune-modulatory activity of P. aeruginosa QSSMs has been 
previously described (Pritchard et al., 2003, Hooi et al., 2004) citing the ability to 
promote bacterial communication while suppressing the immune system.  Hooi et al. 
(2004) demonstrated that the two structurally diverse QSSMs, 3-oxo-C12-HSL and 
PQS, could exert differential modulatory effects on mammalian immune responses 
more specifically peripheral blood mononuclear cells (PBMCs) in vitro.  Differential 
immune-modulatory activity was observed when TNF-Į secretion was assessed in 
assays where LPS were used to drive TNF-Į secretion from hPBMC, with 
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3-oxo-C12-HSL (suppressive) and PQS (stimulatory) exhibiting contrasting effects 
(Hooi et al., 2004).  The same effects was also demonstrated with IL-2 release from 
ĮCD3 and ĮCD28 driven hPBMCs (Hooi et al., 2004).  It has been reported that the 
in vitro effects of 3-oxo-C12-HSL and PQS on lymphocytes are suppressive, 
including inhibition of proliferation (Chhabra et al., 2003, Hooi et al., 2004) and 
cytokine production (Telford et al., 1998, Smith et al., 2001, Ritchie et al., 2003).  
So with this knowledge, this study focused on the immunomodulatory effects of 
3-oxo-C12-HSL and PQS on increasingly pure T cell populations (chapter 3), as 
T cells have been shown to be important to immunity against P. aeruginosa 
(Stevenson et al., 1995).  This present study has confirmed the immunosuppressive 
properties of 3-oxo-C12-HSL and PQS in mouse splenocytes and hPBMCs, and has 
shown for the first time their inhibitory effect on pure human T cells.  CsA, as the 
positive control, has potent immunosuppressive properties with potency similar to 
PQS in pure T cells (chapter 3 and 4). 
 
Very recently Bredenbruch et al. (2006) provided novel insight into the molecular 
mechanisms underlying PQS signalling and demonstrates that well documented 
effects of PQS signalling can at least in part be traced back to its activity as an iron 
chelator (Bredenbruch et al., 2006).  As a consequence of its iron-chelating activity, 
the transcriptional profile of PAO1 in response to PQS reflects an iron starvation 
response, accompanied by the up-regulation of genes required for iron acquisition, 
some of which was shown to be regulated by QS (Bredenbruch et al., 2006).  
Bredenbruch et al. (2006) also demonstrated rhl QS system was activated under 
iron-limiting conditions thus affects rhl QS system indirectly as a result of iron 
depletion.  Finding that PQS influences the P. aeruginosa iron haemostasis is an 
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important step in the understanding of complex bacterial interactions and endorses 
the growing evidence that cell-to-cell signalling mediated by QS system can also be 
strongly affected by environmental factors other than cell density.  Moreover, the 
PQS precursor 4-hydroxy-alkyl-quinoline has recently been described to exhibit 
iron-chelating activities although it is not confirmed using synthesized compound 
(Royt et al., 2001).  The consequences of PQS as a potent iron-chelator means when 
added to growth medium, PQS depletes iron from the medium so that the bacteria 
experience iron deprivation and react with an increased expression of iron acquisition 
systems, PQS production and rhl expression.  This questions the extent to which PQS 
as an iron chelator may affect T cell response to this compound, whether this may be 
accountable for the high potency obtained for PQS compared to 3-oxo-C12-HSL.  
Further work is therefore required to assess the extent PQS iron chelating property 
affects cell culture growth, if any. 
 
Although unable to speculate the clinical relevance of the inhibitory effects of the 
two QSSMs, it is possible to hypothesise that 3-oxo-C12-HSL and PQS may, in the 
future, be relevant in providing alternative immunosuppressive agents either in 
conjunction with or in place of present immunosuppressants such as CsA, FK506 and 
rapamycin.  CsA was originally isolated from cultures of the fungus Tolypocladium 
inflatum, while rapamycin is a natural product derived from a soil micro-organism 
Streptomyces hygroscopicus.  CsA, FK506 and rapamycin have not only 
revolutionised the field of organ transplantation but have also been used as a 
molecular tools for dissecting intracellular signal transduction pathways involved in 
T cell activation (Schreiber, 1991, Schreiber, 1992).  Even though this present study 
illustrates the potency of CsA to be higher than 3-oxo-C12-HSL and PQS, the side 
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effects of CsA therapy are the greatest limitation to wider use of this drug, 
particularly in autoimmune diseases where prolonged administration may be 
anticipated.  In general, the toxicity of CsA can be divided into two groups; (a) side 
effects associated with inhibition of immune responsiveness and, therefore, shared 
with other non-specific immunosuppressive agents; and (b) toxicities in other organ 
systems that are unique to this class of compounds.  The latter category is the more 
clinically troublesome, with renal dysfunction the most frequent serious complication 
of CsA therapy (Kahan, 1989).   
 
Other immunosuppressive drugs such as FK-506 and rapamycin are also limited in 
use due to undesirable side effects.  FK-506, although chemically unrelated to CsA 
affect a similar subset of calcium-associated signalling events involved in the 
regulation of lymphokine gene expression, activation-driven T cell death and 
exocytosis.  The most common acute side effects reported mirror those observed with 
CsA; neurologic (headache, insomnia, tremors, paresthesias, lethargy); 
gastrointestinal (nausea, vomiting, diarrhoea); renal (increase in blood urea nitrogen 
and creatinine); and diabetes (Kahan, 1989, Shapiro et al., 1990).  However, in 
general, renal dysfunction appears to be less severe with FK-506 than with CsA, and 
the frequency with which patients treated with FK-506 receive anti-hypertensive 
medication is significantly less than that of CsA-treated patients.   
 
Rapamycin has structural similarity with FK-506 but suppresses T cell activation at a 
different level, mainly through inhibition of proliferation induced by growth 
promoting lymphokine, with molecular targets including RAF T1/FRAP proteins in 
mammalian cells associated with cell cycle progression through G1 phase (Chiu et 
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al., 1994, Sabatini et al., 1994, Almawi et al., 1999, Gingras et al., 2001).  Its main 
advantage is that it appears to lack significant nephrotoxicity, where lymphocele, 
hypercholesterolemia, hypertriglyceridaemia, peripheral oedema, leukopenia and 
thrombocytopenia are the most common adverse effects identified in clinical studies.  
However, as consequence of its inability to interfere with early events after T cell 
activation, rapamycin is a less effective inhibitor of cytokine synthesis than CsA and 
FK-506.  The benefits of present immunosuppressants are therefore limited by their 
side effects and so alternative drugs are constantly being pursued.  The similar 
effects of 3-oxo-C12-HSL and PQS to CsA and rapamycin makes them potential 
targets for alternative drugs and so requires a more in depth study to their mode of 
action. 
 
The potent immunosuppressive properties of CsA are reflected by its ability to block 
the transcription of cytokine genes in activated T cell, including those of IL-2 and 
IL-4 (Kronke et al., 1984, Herold et al., 1986, Granelli-Piperno, 1988).  Previous 
reports have suggested 3-oxo-C12-HSL and CsA have similar immunosuppressive 
properties (Hooi et al., 2004), so to further understand the molecular mechanisms of 
action of the two QSSMs, the effects of 3-oxo-C12-HSL and PQS on cytokine 
production in pure T cells was investigated (chapter 4).   
 
Cytokines are proteins that play an integral role in the human immune response.  The 
functions of these proteins are diverse and include roles in normal T cell-mediated 
immunity, the inflammatory response, cancer, auto immunity, and allergy (Borish 
and Rosenwasser, 1996).  Therefore, various pathologic conditions will be 
accompanied by changes in cytokine levels.  The cytokines measured include 
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Th1-cell cytokines (IFNȖ and TNFȕ), Th2-cell cytokines (IL-4 and IL-5), 
lymphocyte cytokines (TNFĮ and IL-10), and a cytokine produced by both Th1 and 
Th2 cells (IL-2) (Borish and Rosenwasser, 1996). 
 
Activation of T cells through the TCR is followed by a cascade of intracellular 
signalling events, culminating in the transition from the G0 to G1 phase of the cell 
cycle and the induction of cytokine gene expression leading to secretion of IL-2 and 
surface experiments of the IL-2 receptor (IL-2R).  The interaction of IL-2 with the 
IL-2R initiates a second phosphorylation cascade and sequential wave of gene 
expression that drives the S phase followed by clonal expansion (Smith, 1988, 
Crabtree, 1989).     
 
This present study demonstrated that 3-oxo-C12-HSL inhibited both T cell 
proliferation and IL-2 production supporting the finding that 3-oxo-C12-HSL acts on 
early T cell events (Ritchie et al., 2005).  In contrast, PQS inhibited T cell 
proliferation while enhancing IL-2 release indicating a cytostatic effect and 
supporting previous suggestions that PQS acts proximally to the IL-2R or 
downstream of the IL-2R in the T cell signalling pathway.  These activities are 
reminiscent of cyclosporin A and rapamycin respectively.  CsA and rapamycin are 
microbial products with potent immunosuppressive properties that result primarily 
from a selective inhibition of T lymphocyte activation, where CsA prevents the 
transcription of early T cell activation genes (Kronke et al., 1984) and rapamycin 
inhibits proliferation in response to growth factors such as IL-2 (Hatfield et al., 1992, 
Quesniaux et al., 1994).  CsA and rapamycin have become useful probes in 
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understanding lymphocyte signal transduction and in uncovering the 
patho-physiologic processes involved in certain clinical situations. 
 
In addition, the inhibition of IFNȖ by both QSSMs suggests the suppression of T cell 
activation is via Th1 as IFNȖ is required for Th1 activation.  Furthermore, 
3-oxo-C12-HSL also inhibited IL-4 release while PQS inhibited IL-4 release only at 
3.12 ȝM.  The inhibition of IL-4 release by 3-oxo-C12-HSL may indicate that this 
QSSM may also inhibit T cell function by inhibition of Th2, as IL-4 is required to 
stimulate Th2 activity.  Telford et al. (1998) reported that 3-oxo-C12-HSL inhibits 
the production of IL-12 from activated monocytes.  Since IL-12 is a potent stimulator 
of T cells to produce IFNJ, it was hypothesised that its inhibition by 3-oxo-C12-HSL 
would lead to a decrease in T cells with the Th1 phenotype and therefore induces a 
Th2 phenotype.   
 
In contrast, Smith et al. (2002) suggested that 3-oxo-C12-HSL directly interacts with 
T cells to produce IFNJ in the absence of IL-12 production, therefore proposed that 
3-oxo-C12-HSL is able to modulate the immune response during P. aeruginosa 
infections by stimulating the inflammatory Th1 phenotype not Th2 response.  
However, the two studies are not totally contradictory as the effects observed by 
Smith et al. (2002) tended to work with high doses of up to 100 µM compared to the 
low doses (<10 µM) used by Telford et al. (1998).  In addition, high doses of 
3-oxo-C12-HSL (similar to the concentrations used by Smith et al. (2002) have been 
confirmed to cause apoptosis in eukaryotic cells (Pritchard et al., 2003, Tateda et al., 
2003), thus questioning the validity of experiments conducted at high doses of 
3-oxo-C12-HSL.   
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Further studies by Ritchie et al. (2005) analysed the effects of 3-oxo-C12-HSL on 
primary and secondary stimulation of CD4 T cells strongly rather than selectively 
inhibits the development of either Th1 or Th2 cells, 3-oxo-C12-HSL inhibits the 
development of all effector CD4 T cells.  However, a possible explanation for the 
reports of preferential effects of 3-oxo-C12-HSL on either Th1 (Smith et al., 2002) 
or Th2 (Telford et al., 1998) responses can be explained from two pieces of data.  
Firstly, observations that in secondary stimulation, IFNȖ production appears to be 
more sensitive to 3-oxo-C12-HSL than does IL-4, this means that in secondary 
responses, a preferential development of Th2 responses could occur, and 
3-oxo-C12-HSL treatment could favour a Th2-like bias for a long-term response.  
Secondly, the fact that the affinity of the antigen-TCR interaction modulates the 
outcome of 3-oxo-C12-HSL inhibition means that the overall effect of 
3-oxo-C12-HSL on a response could depend on the affinity of the antigen in question 
for the relevant TCR. 
 
Additionally, microarray analysis indicated a decrease in the gene IL-12B when 
T cells were treated with PQS.  As mentioned in chapter 5, this gene is responsible 
for the biosynthesis of IFNȖ that serve as an essential inducer of Th1 cells 
development.  A decrease of the gene IL-12B therefore indicates PQS may suppress 
Th1 response, confirming results obtained from cytokine analysis. 
 
To further understand the immune-modulation of these QSSMs, possible molecular 
targets of 3-oxo-C12-HSL and PQS within the T cell/IL-2 signalling pathway was 
considered.  Smith et al. (2001) demonstrated a specific signal pathway that was 
stimulated by 3-oxo-C12-HSL in bronchial epithelial cells.  3-oxo-C12-HSL 
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activated extracellular signal regulated kinases (Erks) that subsequently induced the 
activation of the transcription factor NFțB.  This activation of NFțB was essential 
for maximal production of IL-8 with 3-oxo-C12-HSL stimulation (Smith et al., 
2001). 
 
The broad range of effects of 3-oxo-C12-HSL on different types of mammalian cells, 
combined with the range of immunomodulatory effects reported for 3-oxo-C12-HSL, 
suggest that it is most probably acting either through a specific target that is 
ubiquitous to many cell types, such as NFțB or an NFțB-dependent pathway, or that 
3-oxo-C12-HSL is in fact interacting with a range of different targets. 
 
With respect to the hypothesis that 3-oxo-C12-HSL and PQS affect different IL-2 
pathways, this study aimed to observe whether the Erk pathway is directly inhibited 
by the QSSMs.  Results in this study were inconclusive to the effects both QSSMs 
may have on Erk 1/2 activity (chapter 5), however, 3-oxo-C12-HSL has already been 
implicated in the NFțB pathway where it has been shown to activate NFțB and 
AP-2 resulting in production of IL-8 (Smith et al., 2001).  Smith et al. (2001) also 
demonstrated 3-oxo-C12-HSL is able to specifically up-regulate both Erk1 and 2 in 
the cytoplasm of 16HBE cells.  Research within the immune-modulation group at the 
University of Nottingham has also indicated PQS inhibits TrKA activity leading to 
subsequent suppression in Erk 1 production (unpublished data).   
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7.1. Future Work 
 
Additional molecular targets of these two QSSMs that warrant future research are 
peroxysomes proliferator activated receptors (PPARs).  PPARs are members of the 
hormone receptor superfamily which are ligand-activated transcription factors 
regulating gene expression.  3-oxo-C12-HSL as a possible PPARȖ agonist is 
currently under investigation.  PPARȖ has been shown to play a role in the 
differentiation and activation of monocytes and the regulation of inflammatory 
activities (Tontonoz et al., 1998, Ricote et al., 1999), and expression and function of 
PPARȖ in T lymphocytes were recently demonstrated (Clark et al., 2000).  Clark et 
al. (2000) demonstrated 15 d-PGJ2 (a ligand of PPARȖ) mediated significant 
inhibitions of the anti-CD3 antibody-stimulated proliferative responses of freshly 
isolated T cell enriched splenocytes (Clark et al., 2000) .  Yang et al. (2000) reported 
PPARȖ is expressed in human peripheral blood T cells and demonstrated that the 
activated PPARȖ physical associates with the transcription factor nuclear factor of 
activated T cells (NFAT) thus blocking its DNA binding and transcriptional 
activation of the IL-2 promoter.  The activation and function of NFAT are known to 
be absolute requirements of IL-2 transcription (Yang et al., 2000).  The inhibitory 
effect on pure T cells and IL-2 by 3-oxo-C12-HSL may be in part due to its effect as 
a PPARȖ agonist.   
 
It may also be of interest to research into any effect 3-oxo-C12-HSL and PQS may 
have on Tregs.  Previous research have shown rapamycin enhances the relative levels 
of CD4
+
CD25
+
 Tregs in the spleen and thymi of mice while most T cell subsets were 
decreased (Qu et al., 2007).  In contrast, CsA did not abrogate, but reduced the 
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function of allostimulated Treg cells in vitro (Zeiser et al., 2006).  Since 3-oxo-C12-
HSL and PQS have been compared to immunosuppressive agents, their effect, if any, 
on Tregs may help advance our understanding on the way these QSSMs work. 
 
Future study on the synergistic effects of 3-oxo-C12-HSL and PQS on T cell 
activation and proliferation is also of importance.  Whether the combined effect of 
these two QSSMs is greater or indifferent or even differ to what we know, will 
contribute to the further understanding of the mechanisms of actions of 3-oxo-C12-
HSL and PQS. 
 
Continual research into the effects of 3-oxo-C12-HSL and PQS at an RNA level 
using microarray technology will also be important.  Insight into the RNAs 
activated/changed will provide a useful tool in the future if these two QSSMs are to 
be considered for possible use as an immunosuppressant as it will provide detailed 
analysis of what pathways and proteins are affected by these QSSMs. 
 
Very recently, work has been carried out to discover the molecular receptor for 
3-oxo-C12-HSL using affinity chromatography.  Actin and profilin were found to 
bind to [
3
H]3-oxo-C12-HSL, and S100A8 (calgranulin A) and S100A9 (calgranulin 
B) was presented as a possible receptor for 3-oxo-C12-HSL.  The continuation of 
this work especially on T cells is important for better understanding of the mode of 
action for this QSSM. 
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7.2. Conclusion 
 
Bacterial communication via quorum sensing is an important component in the 
production of virulence factors, antibiotic sensitivity, and biofilm development.  
P. aeruginosa possesses one to the best studied model of quorum sensing which may 
contribute to the ability of P. aeruginosa to initiate infection and to persist in a host. 
 
This present study clearly advances our knowledge of potential molecular 
interactions at the P. aeruginosa host/pathogen interface by demonstrating for the 
first time that the two structurally diverse QSSMs, 3-oxo-C12-HSL and PQS, can 
exert differential modulatory effects on pure human T cells: 
 
x Both QSSMs inhibit pure human T cell proliferation with PQS being the 
more potent anti-proliferative. 
x 3-oxo-C12-HSL inhibits IL-2 release while PQS significantly enhanced the 
production of IL-2 while suppressing pure T cell proliferation. 
x Both QSSMs inhibited the release of IFNȖ in mouse splenocytes 
x 3-oxo-C12-HSL inhibited the release of IL-4 though not as potent as 
inhibiting the release of IFNȖ, while PQS had no significant effect on the 
production of IL-4. 
x 3-oxo-C12-HSL inhibits TNFĮ release while PQS significantly enhanced the 
release of this cytokine. 
 
CsA, FK506 and rapamycin have found widespread use in the clinic as 
immunosuppressive drugs.  Their potential in treating immune disorders other than 
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graft rejection, however, is limited in large by their side effects including 
nephrotoxicity and neurotoxicity (Hong and Kahan, 2000).  Despite recent 
developments of new immunosuppressants, there remains an unmet need for less 
toxic and more widely applicable immunosuppressive agents.  While it in 
inappropriate to speculate the full clinical significance of these findings until 
bioavailability can be determined, the innate bioactivity of these chemically defined 
QSSMs is clear; these activities may yet be harnessed to treat immunological 
diseases, in the same way present immunosuppressive drugs have been exploited. 
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Appendix 1  Buffers and Reagent Properties 
 
A.1.1.  Cell Culture 
 
A.1.1.2.  Complete medium 
 
RPMI 1640        475 ml 
Fetal calf serum (FCS) heat inactivated    25 ml 
L-glutamine (200 mM)      5 ml 
Penicillin/Streptomycin (10,000 units/ml : 10mg/ml)  5 ml 
2-ME         2 ȝl 
 
A.1.1.3.  0.5 M EDTA 
 
EDTA         84.05 g 
dH2O         500 ml 
 
A.1.1.4.  Red cell lysis buffer (pH 7.3) 
 
Ammonium chloride       144 mM 
Tris base        17 mM 
Titrate with concentrated HCl to pH 7.2 and filter sterilise 
 
A.1.2.  T cell isolation  
 
A.1.2.2.  2 M EDTA stock solution 
 
EDTA         0.684 mg 
dH2O         100 ml 
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A.1.2.3.  T cell isolation buffer 
 
PBS         100 ml 
BSA         0.5 g 
2 M EDTA        0.1 ml 
 
A.1.3.  FACs analysis 
 
A.1.3.1.  Phosphate buffered saline (PBS) solution (10 L) 
 
Sodium chloride        80 g 
Dibasic sodium phosphate       11.6 g 
Potassium dihydrogen phosphate      2 g 
Potassium chloride (KCl)      2 g 
 Adjust to pH 7.0 and make up to 10 L with dH2O 
 
A.1.3.2.  PBA 
 
BSA          30 g 
0.02% sodium azide       0.02 g 
Adjust to 100 ml with PBS   
    
A.1.4.  ELISA   
 
A.1.4.1.  Binding solution 
 
Dibasic sodium phosphate       35.49 g 
dH2O         500ml  
Adjusted to pH 9 with 0.1 M sodium dihydrogen phosphate  
 
A.1.4.2.  0.1 M Sodium dihydrogen phosphate 
 
Sodium dihydrogen phosphate     34.50 g 
dH2O         500 ml 
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A.1.4.3.  PBS/Tween-20 
 
Tween-20        0.5 ml 
PBS         1 L 
 
A.1.4.4.  Blocking buffer 
 
1% BSA 
PBS 
 
A.1.4.5.  Blocking buffer/Tween-20 
 
Tween-20        0.5 ml 
Blocking buffer       1 L 
 
A.1.4.6.  0.05 M Phosphate-citrate buffer (pH 5) 
 
Solution I:  
Dibasic sodium phosphate      28.39 g 
dH2O         1 L 
  
 Solution II:  
Citric acid monohydrate       10.51 g 
 Sodium phosphate        14.20 g 
 Adjust to pH 5 with solution I 
 Adjust to 1 L with dH2O 
 
A.1.4.7.  TMB solution 
 
3,3,5,5,-tetramthylbenzidine (TMB)     1 Tablet 
DMSO         1 ml 
0.05 M Phosphate-citrated buffer (pH 5)    9 ml 
30% Hydrogen peroxide      2 µl 
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A.1.4.8.  0.05 M Phosphate-citrate buffer (pH 5) 
Phosphate-citrate buffer      1 Tablet 
dH2O         100ml 
  
A.1.4.9.  30% Hydrogen peroxide 
 
Hydrogen peroxide       30 ml 
dH2O         100 ml 
 
A.1.5. SDS-PAGE (Sodium dodecyl sulphate  polyacrylamide gel 
electrophoresis) 
 
A.1.5.1.  12% Resolving gel 
 
Acrylamide/bis-acrylamide (29.2% : 0.8% w/v)   4.8 ml 
1.5 M Tris-HCL (pH 8.8)      3 ml 
10% SDS (Sodium dodecyl sulphate)    120 ȝl 
dH2O (Distilled water)       4.08 ml 
Ammonium persulphate (10%)     60 ȝl 
TEMED (N,N,NmN-tetramethylene-ethylenediamine)  6 ȝl 
 
A.1.5.2.  4% Stacking gel 
 
Acrylamide/bis-acrylamide (29.2% : 0.8% w/v)   660 ȝl 
0.5 M Tris-HCL (pH 6.5)      1.25 ml 
10% SDS        50 ȝl 
dH2O         3.04 ml 
Ammonium persulphate (10%)     50 ȝl 
TEMED (N,N,NmN-tetramethylene-ethylenediamine)  20 ȝl 
 
A.1.5.3.  Reducing sample buffer (10ml)  
1 M Tris-HCL (pH 6.8)      0.6 ml 
50% Glycerol        5 ml 
10% SDS        2 ml 
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2-ME         0.5 ml 
1% Bromophenol blue      1 ml 
dH2O         0.9 ml 
 
A.1.5.4.  Running buffer (10 L) 
 
Tris base        30 g 
Glycine        144 g 
SDS         10 g 
Make up to 10 L with dH2O 
 
A.1.5.5.  Transfer buffer (1 L) 
 
Tris base        3.63 g 
Glycine        14.4 g 
20 % Methanol (v/v)       200 ml 
0.038 % SDS         0.37 g 
Make up to 1 L with dH2O 
 
A.1.6.  Western Blotting 
 
A.1.6.1.  1 x TBS (1 L) 
 
NaCl         87.66 g 
Tris          12.11 g 
pH 8.0 
Make up to 1L with dH2O 
 
A.1.6.2.  TBS/0.05% Tween-20 
 
1 x TBS        500 ml 
Tween-20        250 ȝl 
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A.1.6.3.  Blocking Buffer 
 
Bovine serum albumin (BSA)     0.3 g 
1 x TBS        30 ml 
 
A.1.6.4.  Primary and Secondary antibody buffer 
 
BSA         0.03 g 
1 x TBS        30 ml 
 
A.1.6.5.  0.75M Tris pH 9.6 
 
Tris base        45.41 g 
Make up to 500ml with dH2O 
 
A.1.6.6.  Alkaline phosphatase substrate 
 
5-bromo-4-chloro-3-indolyl phosphate (50 mg/ml in PMF)  33 ȝl 
Nitro blue tetrazolium (70 mg/ml) in 70% PMF)   44 ȝl 
Made up to 20 ml 0.75 M Tris pH 9.6 
 
A.1.7.  Isolation of total RNA 
 
A.1.7.1.  70% Ethanol (100ml) 
 
Ethanol        70 ml 
RNase-free water       30 ml 
 
A.1.8.  RNA isolation and dye incorporation 
 
A.1.8.1.  Reverse transcription master mix (for 1 sample) 
 
10x First strand buffer      2 ȝl 
dNTP mix        4 ȝl 
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RNase inhibitor       1 ȝl 
ArrayScript        1 ȝl 
 
A.1.8.2.  Second strand master mix (for 1 sample) 
 
Nuclease free water       63 ȝl 
10x Second strand buffer      10 ȝl 
dNTP mix        4 ȝl 
DNA polymerase       2 ȝl 
RNase H        1 ȝl 
   
A.1.8.3.  IVT master mix for 2 rounds of amplification (for 1 sample) 
 
ATP, CTP, GTP mix (50mM)     12 ȝl 
UTP solution (50mM)      6 ȝl 
T7 10x reaction buffer      4 ȝl 
T7 enzyme mix       4 ȝl 
 
A.1.8.4.  Second strand master mix for second round amplification 
 
Nuclease free water       58 ȝl 
10x second strand buffer      10 ȝl 
dNTP mix         4 ȝl 
DNA polymerase       2 ȝl 
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Appendix 2  Results of individual experiments 
 
A.2.1. Stimulatory effect of ConA on murine splenocytes (BALB/c mice). 1 ȝg/ml 
ConA gives optimal cell proliferation.   
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A.2.2. Stimulatory effect of anti-CD3 on murine splenocytes (BALB/c mice).  
3 ȝg/ml anti-CD3 gives optimal cell proliferation.  
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A.2.3.  The effect of P. aeruginosa QSSMs and CsA on ConA driven splenocyte 
proliferation.  ***P<0.001, **P<0.01, *P<0.05 compared with the ConA control.  
Cells represent untreated cells and Bkg (background) represent readings for CTCM.   
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A.2.4.  The effect of P. aeruginosa QSSMs and CsA on anti-CD3 driven 
splenocyte proliferation.  ***P<0.001, **P<0.01, *P<0.05 compared with the 
anti-CD3 control.  Cells represent untreated cells and Bkg (background) represents 
measurement for CTCM. 
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A.2.5.  The effect of P. aeruginosa QSSMs and CsA on murine splenocyte 
viability.  Cell control represents untreated cells and Bkg (background) represents 
measurement of CTCM. 
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A.2.6.  The dose response of anti-CD3 and anti-CD28 on human PBMC 
proliferation.  The concentration of anti-CD3 and antiCD28 that gives optima 
proliferation is 0.1 ȝg/ml and 5 ȝg/ml respectively.  1 = 0.003/0.15. 2 = 0.006/0.312, 
3 = 0.012/0.62, 4 = 0.025/1.25, 5 = 0.05/2.5, 6= 0.1/5, 7 = 0.2/10, 8 = 0.4/20 ȝg/ml 
of anti-CD3 and anti-CD28 respectively. 
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A.2.7.  The effect of P. aeruginosa QSSMs and CsA on anti-CD3 and anti-CD28 
driven human PBMC proliferation.  ***P<0.001, **P<0.01, *P<0.05 compared 
with the anti-CD3 and anti-CD28 control.  Cells represent untreated cells and Bkg 
(background ) is measurements for CTCM. 
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A.2.8.  The effect of P. aeruginosa QSSMs and CsA on human PBMC viability.  
*P<0.05 compared to the cell control (untreated cells).  Bkg (background) represents 
measurement of CTCM. 
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A.2.9.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-2 from 
human PBMCs.  ***P<0.001, **P<0.01, *P<0.05 compared to the anti-CD3 and 
anti-CD28 control.  'Cells' represents untreated cells and 'Bkg' (background) 
represents the measurements for CTCM. 
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A.2.10.  The effect of P. aeruginosa QSSMs and CsA on anti-CD3 and anti-
CD28 driven pure T cell proliferation.  ***P<0.001, **P<0.01, *P<0.05 compared 
with the anti-CD3 and anti-CD28 control.  Cells represents untreated cells and Bkg 
(background) represents the measurements for CTCM. 
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A.2.11.  The effect of P. aeruginosa QSSMs and CsA on pure T cell viability.  
*P<0.05 compared with the cell control (untreated cells).  Bkg (background) 
represents measurements of CTCM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
*
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
*
*
  Appendix 2  
 - 259 -
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
*
*
*
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
1.2
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
1.2
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
  Appendix 2  
 - 260 -
 
 
 
 
 
 
 
 
 
Concentrations of compounds (PM)
0.1 1 10 100
A
b
so
rb
an
ce
 a
t 
4
9
2
 n
m
±
S
D
0.0
0.2
0.4
0.6
0.8
1.0
3-oxo-C12-HSL
PQS
CsA
C
el
ls
B
kg
**
  Appendix 2  
 - 261 -
A.2.12.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-2 from 
pure T cells using the standard sandwich ELISA technique.  ***P<0.001, 
**P<0.01, *P<0.05 compared with the anti-Cd3 and anti-CD28 control.  Cell 
represents untreated cells and Bkg (background) is the measurement for CTCM. 
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A.2.13.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-2 from 
pure T cells using cytometric bead analysis.  ***P<0.001, **P<0.01, *P<0.05 
compared with the anti-CD3 and anti-CD28 control.  Cells represents untreated cells 
and Bkg (background) is the measurement of CTCM. 
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A.2.14.  The effect of P. aeruginosa QSSMs and CsA on the release of IFNȖ from 
pure T cells using cytometric bead analysis.  Anti-CD3 and anti-CD28 control 
represents cells treated with only these two antibodies.  Cells represents untreated 
cells and Bkg (background) is the measurement of CTCM. 
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A.2.15.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-4 from 
pure T cells using cytometric bead analysis.  ***P<0.001, **P<0.01, *P<0.05 
compared with the anti-CD3 and anti-CD28 control.  Cells represents untreated cells 
and Bkg (background) is the measurement of CTCM. 
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A.2.16.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-5 from 
pure T cells using cytometric bead analysis.  ***P<0.001, **P<0.01, *P<0.05 
compared with the anti-CD3 and anti-CD28 control.  Cells represents untreated cells 
and Bkg (background) is the measurement of CTCM. 
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A.2.17.  The effect of P. aeruginosa QSSMs and CsA on the release of IL-10 
from pure T cells using cytometric bead analysis.  ***P<0.001, *P<0.05 
compared with the anti-CD3 and anti-CD28 control.  Cells represents untreated cells 
and Bkg (background) is the measurement of CTCM. 
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A.2.18.  The effect of P. aeruginosa QSSMs and CsA on the release of TNFĮ 
from pure T cells using cytometric bead analysis.  ***P<0.001, **P<0.01, 
*P<0.05 compared with the anti-CD3 and anti-CD28 control.  Cells represents 
untreated cells and Bkg (background) is the measurement of CTCM. 
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